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ABSTRACT 
 
Mental retardation (MR) is estimated to affect ~2-3% of the general population and may result 
from genetic causes and/or environmental causes. X-linked mental retardation (XLMR) is a 
heterogeneous group of disorders with a broad range of phenotypes and can be classified into 
syndromic XLMR (S-XLMR) and nonsyndromic XLMR (NS-XLMR) types. A number of X-linked 
genes have been identified that are associated with the different forms of XLMR. 
 
In an attempt to refine the diagnostic service to patients with XLMR, the Division of Human 
Genetics, Molecular Laboratory at the National Health Laboratory Service (NHLS) has 
investigated a number of associated X-linked genes. The main objective of this project was to 
investigate three genes, FMR2, XNP and ARX, associated with NS-XLMR and their contribution 
to XLMR in the South African (SA) population of MR males. Patients from different ethnic 
groups, referred to the Division of Human Genetics for fragile X MR syndrome that tested 
negative for the FMR1 expansion mutation were investigated for mutations in these genes. In 
addition, a cohort of Black institutionalized males was also investigated.  
 
The FMR2 expansion mutation responsible for fragile X E syndrome was not identified in 1194 
FMR1 expansion negative MR male patients. FMR2 allele distribution analysis showed that a 
GCC repeat size of 15 was common in the MR cohort, accounting for 42% of alleles identified. 
From a total of 210 FMR1 expansion negative MR male subjects screened for mutations in a 
hotspot region (exons 7, 8 and 9) of the XNP gene, none was found to have a mutation in this 
region. Two patients from a cohort of 868 FMR1 expansion negative MR males were found to 
have a mutation in the ARX gene – one patient tested positive for the common 24 bp duplication 
mutation and a second patient appeared to have a deletion in the region amplified. These 
results indicate that the FMR2, XNP and ARX genes do not contribute significantly to MR in the 
SA population. As a result of this study, routine DNA testing for the FMR2 expansion, mutation 
screening in the hotspot region of the XNP gene and screening for the common 24 bp 
duplication mutation in the ARX gene in FMR1 expansion negative MR male subjects will not be 
implemented. 
 
A retrospective analysis was also done on 1862 probands referred to the Molecular Genetics 
Diagnostic service from 1992 to 2009 for fragile X MR syndrome testing. The FMR1 full 
expansion mutation was detected in 6.2% of probands, higher than reported worldwide figures.  
FMR1 allele distribution analysis in a cohort of 1184 FMR1 expansion negative MR males 
showed that 29 CGG repeats was the most frequent repeat size observed, accounting for 
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32.6% of all alleles in the cohort.  The analysis of FMR1 alleles in MR males shows a similar 
distribution between different ethnic groups and compares well with other reported studies. This 
study reinforces the presence of fragile X MR syndrome in the SA Black population. 
 
Molecular investigations were also undertaken on 3 patients clinically suspected to have X-
linked -thalassaemia mental retardation syndrome (ATR-X) and extended family members. 
Mutations were identified in each of the patients – two patients were found to have a novel 
mutation in the XNP gene and the third patient had a common XNP mutation. As a result, carrier 
testing and prenatal diagnosis was made possible in these families. 
 
A large family positive for the FMR1 expansion causing fragile X A MR syndrome was 
investigated. As an incidental finding, 2 females were found to be compound heterozygotes for 
2 FMR1 alleles. Extended family members were tested and their FMR1 status was determined. 
Haplotype analysis was used to track the high-risk X chromosome in the family. As a result of 
this investigation, females at risk for premature ovarian failure and fragile X tremor ataxia 
syndrome have been identified. 
 
The approach to testing genes implicated in NS-XLMR has to be refined to allow for a cheaper 
and more efficient alternative. The use of newer techniques such as CGH microarray and MLPA 
has allowed for better detection of mutations. Delineating the causes of MR and their molecular 
and cellular consequences will assist families but also provide insight into the mechanisms that 
are required for the normal development of cognitive functions in humans. 
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CHAPTER ONE 
1 INTRODUCTION 
Mental retardation (MR) or developmental delay is said to be one of the most common human 
disorders and is a serious social and medical problem. It has an estimated prevalence of 2-3% 
in developed countries (Penrose, 1938; Toniolo, 2000) and is reported to be the most common 
reason for referral to genetic clinics (Leonard and Wen, 2002).  
 
There is large interest in identifying the causes of MR. It can impose a costly and lifelong burden 
on the public health sector. Establishing the cause in an individual with MR improves clinical 
management and facilitates genetic counselling for the family. 
 
MR is reported to have a genetic cause in 25-30% of cases and is observed more frequently in 
males than females, with an affected ratio of 1.3:1 (Leonard and Wen, 2002). This indicated that 
defects on the X-chromosome are an important factor in the etiology of MR. X-linked mental 
retardation (XLMR) represents ~10-15% of all MR in males (Ropers, 2008) and from 
epidemiological studies a prevalence figure of 1 in every 600 males is estimated (Herbst and 
Miller, 1980). 
 
XLMR is historically classified into syndromic XLMR (S-XLMR) and nonsyndromic (also referred 
to as non-specific) XLMR (NS-XLMR) forms (Kerr, Turner, Mulley et al., 1991), although this 
distinction has become less clear since mutations in a single gene have been associated with 
both forms. The FMR1 gene responsible for fragile X MR syndrome is the most common 
inherited form of MR, accounting for at least 25% of XLMR (Fishburn, Turner, Daniel et al., 
1983; Ropers 2006). As the FMR1 gene is implicated in other disorders, for the purpose of this 
dissertation, fragile X syndrome resulting in MR from an expansion in the FMR1 gene is referred 
to as fragile X MR syndrome. Fragile X E syndrome due to an expansion in the FMR2 gene is 
referred to as FRAXE syndrome. 
  
Initial research focussed on delineating the molecular causes of fragile X MR syndrome, while 
the search for other XLMR genes was relatively slow. The field of XLMR has gained interest and 
developed rapidly, facilitated by the cloning of the human genome. Significant breakthroughs in 
identifying genes and the molecular and cellular mechanisms underlying XLMR have been 
made in the past 10-15 years through the establishment of large collaborations between clinical 
and molecular research teams such as the European XLMR consortium (EuroMRX website, 
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2009), the Greenwood Genetics Centre in the U.S.A (GGC website, 2009) and The Genetics of 
Learning Disability study in the UK (IGOLD website, 2009). To date, >90 XLMR genes have 
been identified (Gecz, Shoubridge and Corbett, 2009). Delineating the causes of XLMR and 
their molecular and cellular consequences will provide insight into the mechanisms that are 
required for the normal development of cognitive functions in humans. 
 
The study of XLMR genes has been of particular interest to the Division of Human Genetics, 
Molecular Genetics Laboratory at the National Health Laboratory Service (NHLS). This was 
brought about by the escalating number of genes being involved in XLMR and the increasing 
number of patients with unexplained MR. The focus has been concentrated mainly on 
developing and/or refining screening methods with a view to offering them as diagnostic tests in 
the Division. Previous studies on fragile X MR syndrome had been undertaken in the Division by 
Goldman (1997). In 2000 a study undertaken by myself, in collaboration with scientists from the 
Greenwood Genetic Centre showed that a dodecamer duplication in the HOPA gene was not 
associated with MR in South African populations (Friez, Essop, Krause et al., 2000).   
 
This study investigated additional genes associated with XLMR. It was undertaken as part of a 
worldwide effort to elucidate genes implicated in XLMR and focussed particularly on the South 
African population and the contribution of 3 NS-XLMR genes, FMR2, XNP and ARX. When this 
study was initiated, the Division of Human Genetics, Molecular Genetics Laboratory at the 
National Health Laboratory Service (NHLS) had considered and proposed investigating 
additional X-linked loci/genes such as MECP2 and/or other XLMR genes if indicated. As the 
study progressed many of the XLMR genes discovered were found not to contribute significantly 
to XLMR. As a result additional XLMR genes were not investigated as part of this study. Further, 
the current methods are generally too expensive or too unreliable to justify mutation screening 
of all known XLMR genes in diagnostic testing. It must be noted that this study was started in 
2001 and has spanned many years of changing knowledge and technology. The general feeling 
at the time was that mutations in a few genes would contribute to a large amount of NS-XLMR 
cases. The approach taken in this study was to screen mutation hotspots as a first target for 
screening for causes of MR in patients. However through the subsequent years, many genes 
have been identified with few common mutations, none of which has been reported to contribute 
substantially to NS-XLMR. Presently such a study would not be performed using the approach 
taken. Newer technologies have allowed for rapid screening methods at affordable costs. 
 
This study also undertook a retrospective analysis of fragile X MR syndrome referrals to the 
Molecular Genetics Diagnostic Laboratory, NHLS over a 17 year period (1992 to 2009). It 
extends the PhD study of Goldman (1997) in which the frequency of fragile X MR syndrome was 
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assessed and allele distributions were determined in the South African population by 
investigating a larger cohort of families. 
 
Family studies for X-linked -thalassaemia mental retardation syndrome (ATR-X) and fragile X 
MR syndrome were also undertaken. Molecular investigations were undertaken on three 
patients with ATR-X and their extended family members. The causative mutation was identified 
and carrier and prenatal testing was performed. As an incidental finding during a routine 
investigation for the FMR1 expansion, an interesting result was found. Two siblings were found 
to have two expanded FMR1 alleles in the intermediate and premutation range respectively. 
The segregation of this expansion in the family was examined using haplotype analysis. As this 
is the first South African report of females with 2 expanded FMR1 alleles and the fifth family 
reported thus far in the world, it has been presented in this dissertation.  
 
As there are many facets to this study, each of the genes investigated has been discussed in a 
separate chapter. Chapter 1 provides an introduction and review of the current literature on MR 
and a review on each of the genes investigated in this project, viz., FMR1, FMR2, XNP and 
ARX. Chapter 2 outlines the subjects tested and provides an in-depth overview on the methods 
and materials used. The results obtained for each of the NS-XLMR genes investigated and a 
discussion of these results is presented in Chapters 3 and 4. Chapters 5 and 6 describe the 
results on the family studies undertaken for ATR-X syndrome and fragile X MR syndrome. It 
was decided to present results and discussion for each component of the study in order to try to 
ensure continuity. Chapter 7 presents a final combined discussion and conclusion on all the 
genes investigated in this study. 
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1.1 MENTAL RETARDATION 
1.1.1 Features of MR 
The American Association on Mental Retardation defines mental retardation (MR) as “…a 
disability characterized by significant limitations both in intellectual functioning (criterion 1) and 
in adaptive behavior (criterion 2) as expressed in conceptual, social, and practical adaptive 
skills. This disability originates before the age of 18 (criterion 3).” (AAMR website, 2007). 
 
Intellectual functioning varies in severity and is classified on the basis of Intelligence Quotient 
(IQ) scores. The different classes of MR vary in IQ and the criteria set by the International 
Statistical Classification of Diseases (ICD-10), coordinated by the World Heath Organization 
(WHO, 1980) are summarized in Table 1.1 . 
 
 
Table 1.1 IQ scores relative to the degree of severity of MR according to ICD-10 criteria. 
 
 
The above classes are usually simplified into 2 groups: severe MR (IQ<50) and mild MR (IQ 50-
70). Mild forms are thought to be more frequent with an estimated prevalence of 2-3% and 
severe MR with an incidence of 0,5-1% (Raymond, 2006; Ropers, 2006). 
 
 
1.1.2 Aetiology of MR 
The causes of MR are diverse and include teratogenic and environmental factors, perinatal 
asphyxia, genetic causes or a combination of genetic and acquired/environmental factors. 
Although environmental and teratogenic factors play a role in the occurrence and severity of the 
disease and are reported to occur in 5-13% of cases, genetic factors have a significant impact, 
with 25-30% of cases thought to be genetic. Less than 50% of MR cases have a known primary 
cause (Curry, Stevenson, Aughton et al., 1997). 
 
 
DEGREE OF MENTAL RETARDATION INTELLIGENCE QUOTIENT (IQ) 
Borderline 70-85 
Mild 50-70 
Moderate 35-50 
Severe 20-35 
Profound <20 
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1.1.2.1 Genetic causes 
Chromosome abnormalities (microscopic/submicroscopic, interstitial/subtelomeric) are the most 
common known causes of MR, occurring in 20% of unexplained MR cases (de Vries, Pfundt, 
Leisink et al., 2005). The use of newer and powerful technologies such as multiple-ligand-probe 
amplification (MLPA) and genome wide array based Comparative Genomic Hybridisation (CGH) 
using tiling path DNA microarrays that detect copy number alterations/variations (CNVs) have a 
more extensive coverage of the genome and have allowed the detection rates to increase. In 
patients with dysmorphic features and congenital anomalies, 5-7% are reported to have 
subtelomeric microdeletions or microduplications (Frints, Froyen, Marynen et al., 2002). In 
syndromic patients, CGH enables detection of genomic copy number changes in 16% of 
patients (Stankiewicz and Beaudet, 2007). Recently the diagnostic yield of clinically significant 
CNVs was reported to be 9.1% (Koolen, Pfundt, De Leeuw et al., 2009). 
 
It is estimated that ~50% of severe cases of MR have a genetic cause (Prieto Garcia, 1998). X-
linked mental retardation (discussed in Section 1.2) represents 10-15% of all MR (Ropers, 
2008) and from epidemiological studies a prevalence figure of 1 in every 600 males is estimated 
(Herbst and Miller, 1980; Chiurazzi, Schwartz, Gecz et al., 2008).  
 
MR resulting from genes on autosomes has also been described. While there has been 
significant progress made in identifying X-linked genes, genetic knowledge on autosomal 
inheritance remains largely unknown due to its extreme genetic heterogeneity. To date five 
genes have been implicated in causing autosomal recessive mental retardation (ARMR). 
These are PRSS12 (neurotrypsin; MIM606709, 4q26), CRBN (cereblon, MIM 609262, 3p26) 
and CC2D1A (MIM 610055, 19p13), GRIK2 (glytamate receptor 6, MIM 138244, 6q16) and 
TUSC3 (8p22) (Molinari, Rio, Meskenaite et al., 2002; Higgins, Pucilowska, Lombardi et al., 
2004; Basel-Vanagaite, Attia, Yahav et al., 2006; Motazacker, Rost, Hucho et al., 2007; Basel-
Vanagaite, 2008; Garshasbi, Hadavi, Habibi et al., 2008). The five genes are reported to 
contribute a small percentage to the total ARMR cases. In addition, 10 new loci have recently 
been mapped, indicating extreme genetic heterogeneity (Basel-Vanagaite, 2007). 
 
The difficulty in ascertaining large families has made the identification of autosomal dominant 
genes difficult. A possible reason could be that MR results in lower reproductive fitness which 
makes it difficult to identify families for linkage analysis. Recently, Hamdan, Gauthier, 
Spiegelman et al. (2009) reported on the SYNGAP1 gene, which encodes a ras GTPase 
activating protein critical for cognition and synapse function, as a cause of autosomal dominant 
nonsyndromic mental retardation. They reported on de-novo mutations being present in 
  Chapter 1. Introduction 
6 
approximately 3% of their patient cohort with nonsyndromic mental retardation. Figure 1.1 
illustrates the main genetic etiologies of MR. 
 
 
 
  
Figure 1.1 Main genetic etiologies of MR  
(Basel-Vanagaite, 2008) 
 
 
 
1.1.2.2 Environmental causes 
The causes of MR differ for each country, with the socioeconomic status of that country having 
a major influence. In developing countries, poverty and environmental conditions are the major 
factors responsible for MR. The causes can be divided into biomedical (biologic processes, e.g. 
genetic disorders, infection or nutrition), social (social and family interaction such as child 
stimulation and adult responsiveness), behavioural (harmful behaviours, such as maternal 
substance abuse), and educational risk factors (availability of family and educational support 
that promote mental development and increases in adaptive skills) that interact during the life of 
an individual and/or across generations from parent to child (Curry et al., 1997). 
 
  
Genetic MR 
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Autosomal 
recessive 
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aberrations 
  Chapter 1. Introduction 
7 
1.1.3 MR in South Africa 
The prevalence of MR and its epidemiology in developing countries is not well established. 
Limited information is available for developing countries since most of the research has focused 
on developed countries.  It is estimated that the developing nations have ~70 to 110 million 
children with MR (Shah, 1991; Roeleveld, Zielhuis and Gabreels, 1997). 
 
The most common cause of MR in South Africa (SA) is fetal alcohol syndrome (FAS). In fact, 
SA has the highest rate of FAS in the world. In comparison with the USA rate of 0.05 to 2.0 per 
1000 births (May and Gossage, 2001), SA has a rate of 46 to 89 cases per 1000 births reported 
in the Western Cape Province, a rate of epidemic proportions (May, Brooke, Gossage et al., 
2000; Viljoen, Gossage, Brooke et al., 2005; May, Gossage, Marais et al., 2007). 
  
Other studies have been conducted to investigate the prevalence of MR in rural and urban 
populations in South Africa. These are presented below. 
 
The prevalence of severe MR among Coloured children under 18 years in the Cape Town 
suburb of Athlone (urban residential area) was studied (Power, 1977). The author found the 
administrative (number of severely retarded children known to social, medical or educational 
agencies serving the surveyed population) prevalence was 2.62-3.36/1000, a figure lower than 
that for Europe and North America but comparable to other reported figures (Friedlander and 
Power, 1982). The authors found that in the Heideveld area of Cape Town (including Heideveld, 
Vanguard, Surrey and Welcome Estates), the prevalence of severe MR among children less 
than 18 years of age was 2.5/1000. The prevalence of profound MR was calculated to be 0.4% 
and 4% for mild to moderate MR, under 19 years of age on the Witwatersrand (Cartwright, Van 
Rijlaarsdam, Wagner et al., 1988). 
 
A study was also conducted on Black South African children with developmental disabilities at a 
neurodevelopmental clinic at Baragwanath Hospital, Soweto in Johannesburg (Rubin and 
Davis, 1986). Their study found that 4% of the etiological diagnoses were prenatal genetic 
causes, defined as including “children with chromosomal (e.g., Down syndrome), 
nonchromosomal syndromes of multiple congenital anomalies, and proven cases of congenital 
infections”. 
 
The aetiology of moderate and severe learning disability in preschool children in Cape Town 
was determined (Molteno and Lachman, 1996). In 45% the disability was prenatal in origin, in 
17% perinatal, in 9% postnatal and in ~29% it was idiopathic. 
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In 1981 the first South African cases of XLMR were described in which 11 males in 4 families 
were investigated by cytogenetic studies and were found to have a marker X chromosome (fra 
(X) (q27)) (Venter, Gericke, Dawson et al., 1981). 
 
The prevalence and types of intellectual disabilities in a rural Black population in South African 
children aged 2-9 years was investigated in 2002 by Christianson, Zwane, Manga et al. (2002). 
The ratio of males to females with intellectual disorders was 3:2. The prevalence of severe 
intellectual disability was found to be 0.64/1000 and mild disability 29.1/1000. Aetiology for MR 
was determined and 20.6% were found to be due to congenital causes, 6.3% acquired and 
undetermined in 73.1%. The observed prevalence of intellectual disabilities (35.6/1000) 
compared well with that found by Molteno, Roux, Nelson et al. (1990) in Cape Town and with 
the prevalence figure of 30/1000 presented by WHO for developing countries (WHO, 1985b). 
 
 
1.2 X-LINKED MENTAL RETARDATION (XLMR) 
Since there is an excess of males affected with MR compared to females, with approximately 
30% more males affected than females, the search for disease-associated genes has 
predominantly been focussed on the X chromosome (Turner, Turner and Collins, 1970; Lehrke, 
1974; Raymond and Tarpey, 2006). In XLMR families, the most common form of XLMR, fragile 
X MR syndrome (discussed in Section 1.3) accounts for 25% of the mutations (Fishburn et al., 
1983, reviewed in Ropers, 2006). 
 
XLMR has been classified into syndromic XLMR (S-XLMR) and non-syndromic or nonspecific 
XLMR (NS-XLMR) (Kerr et al., 1991). NS-XLMR refers to a heterogeneous group of disorders in 
which cognitive impairment is usually the only consistent clinical feature seen while S-XLMR 
refers to a form where MR is associated with other recognizable clinical signs (Gecz and Mulley, 
2000). The distinction between these two types appears to be blurred as in some cases the 
same genes have been identified in both S-XLMR and NS-XLMR (Table 1.3) and also the same 
gene in different S-XLMR conditions. 
 
The identification of XLMR genes has been an international collaborative effort, involving 
several groups working in the fields of XLMR, e.g. European XLMR consortium (EuroMRX 
website, 2009), founded in 1995, comprising Paris, France; Leuven, Belgium; Nijmegen, The 
Netherlands; Tours, France; Berlin; the Australian associated collaborative group and the Italian 
XLMR groups of Pavia and Siena (Frints et al., 2002). The Greenwood Genetics Centre in the 
U.S.A (GGC website, 2009) and the GOLD study group (IGOLD website, 2009) in Cambridge 
have also contributed to the identification of XLMR genes. 
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Significant progress has been made, especially in the last 13 years in finding and characterizing 
genes for XLMR. More than 215 different XLMR disorders have been described, including 149 
S-XLMR forms and 66 NS-XLMR forms. To date, >90 XLMR genes have been identified (S-
XLMR and NS-XLMR) with detected mutations (Ropers, 2006; Chiurazzi et al., 2008). Table 1.2 
gives an updated count of XLMR conditions. 
 
 
Table 1.2 Count of XLMR conditions by clinical presentation: syndromes, neuromuscular 
conditions and NS-XLMR conditions. 
 TOTAL MAPPED CLONED 
S-XLMR 
     X-linked syndromes 
     Neuromuscular disorders 
149 
98 
51 
47 
31 
16 
66 
38 
28 
NS-XLMR conditions 66 50 16 
TOTAL XLMR CONDITIONS @  8 SEPT 2009 215 97 82 
A detailed list of all the conditions/syndromes can be found on the XLMR website, 2009 
X-linked syndromes refer to X-linked syndromes with MR and multiple congenital anomalies. 
Neuromuscular disorders refer to disorders characterized by neurological symptoms such as epilepsy, 
spastic paraplegia, ataxia, etc. 
 
Given the extensive heterogeneity of NS-XLMR, different strategies have been used for 
identifying new genes. These include linkage analysis, associations with fragile sites, e.g. 
FRAXA and FRAXE, breakpoint mapping and cloning in MR patients with balanced X 
chromosomal rearrangements, characterization of X-chromosome microdeletions at a molecular 
level and candidate gene strategies by screening for mutations in regions of the X-chromosome 
involved in neuronal development and function (Ropers and Hamel, 2005; Chiurazzi et al., 
2008). 
 
1.2.1 Non-syndromic or non-specific X-linked mental retardation (NS-XLMR) 
NS-XLMR is characterized by the lack of distinctive phenotypic features and clinical variability in 
the degree of MR within families (Chelly, 1999). NS-XLMR appears to be twice as common as 
S-XLMR (reviewed in Ropers, 2006). The incidence of NS-XLMR has been estimated to be 
1.8/1000 or 1 in 600 males (Herbst, 1980; Kerr et al., 1991). 
 
Each NS-XLMR family was initially represented by a single pedigree and the gene segregating 
in each family was given a distinctive label, MRX by the Human Genome Gene Nomenclature 
Committee (HUGO website, 2009). If a minimum lod score of +2 was shown between the MR 
locus and one or more X chromosome markers in that family, the family was assigned a unique 
number, MRX1, MRX2, MRX3,… (Mulley, Kerr, Stevenson et al., 1992). The first MRX family 
(MRX1) was characterized in 1988 (Suthers, Turner and Mulley, 1988) and the associated gene 
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was localized. The first NS-XLMR disorder cloned was Fragile X E mild mental retardation 
syndrome (FRAXE) (discussed in Section 1.4) (Sutherland and Baker, 1992; Flynn, Hirst, Knight 
et al., 1993). 
 
Target regions have been identified on the X chromosome where mutations are clustered. Most 
of these are on proximal Xp and the Xp11 region (Ropers, Hoeltzenbein, Kalscheuer et al., 
2003). To date, 38 of the >90 XLMR genes have been implicated in NS-XLMR. Each of these 
genes (except fragile X MR syndrome, MECP2 and ARX) accounts for 0.2-0.5% of XLMR cases 
(Gecz et al. 2009; XLMR website, 2009). Table 1.3 lists the 38 genes that have been implicated 
in NS-XLMR and the frequency of genes commonly associated with NS-XLMR. Table 1.4 lists 
the genes involved in both NS-XLMR and S-XLMR. Figure 1.2 shows an ideogram of the NS-
XLMR genes on the X chromosome with their chromosomal locations. 
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Table 1.3 NS-XLMR genes identified to date (n=38) 
GENES THAT CAUSE NS-XLMR 
OMIM PROTEIN NAME LOCUS 
GENE 
SYMBOL 
REFERENCE 
MUTATION 
FREQ IN 
NS-XLMR 
309548 AFF2 protein Xq28 FMR2 Gecz et al. 1996  
300142 p21 Act. Kinase 3 Xq23 PAK3 Allen et al. 1998 1-2% 
300104 RABGDIA Xq28 GDI1 D‟adamo et al. 1998 <1% 
*300206 
IL1 receptor accessory 
protein-like 1 
Xp21.2 IL1RAPL1 Carrie et al. 1999 1-2% 
*300267 -PIX Xq26.3 ARHGEF6 Kutsche et al. 2000 Rare/very rare 
*300096 Tetraspanin Xp11.4 TM4SF2 Zemni et al. 2000  
*300157 fatty acid-CoA ligase 4 Xq23 
FACL4 
(ACSL4) 
Meloni et al. 2002 <1% 
300034 Angiotensin rec. 2 Xq23 AGTR2 Vervoort et al. 2002 Rare/very rare 
314995 zinc-finger protein 41 Xp11.3 ZNF41 Shoichet et al. 2003  
*300336 neuroligin 3 Xq13 NLGN3 Jamain et al. 2003  
*300427 neuroligin 4 Xp22.3 NLGN4 Laumonnier et al. 2004  
*314998 zinc-finger protein 81 Xp11.23 ZNF81 Kleefstra et al. 2004  
300189 Discs, large homolog 3 Xq13.1 DLG3 Tarpey et al. 2004 1-2% 
*300499 FtsJ homolog 1 Xp11.23 FTSJ1 Freude et al. 2004 1-2% 
*300579 Shroom family member 4 Xp11.2 SHROOM4 Hagens et al. 2006  
300573 
zinc-finger family member 
674 
Xp11.3 ZNF674 Lugtenberg et al. 2006  
*312173 Ribosomal protein L10 Xq28 RPL10 Klauck et al. 2006  
*300304 Cullin 4B Xq23 CUL4B 
Tarpey et al. 2007a 
Zou et al. 2007 
 
*300576 
zinc finger, DHHC-type 
containing 9 
Xq13.3 ZDHHC9 Raymond et al. 2007  
*300553 
Bromodomain and WD 
repeat domain-containing 
3 
Xq21.1 BRWD3 Field, M. et al. 2007  
*300298 
UPF3 regulator of 
nonsense transcripts 
homolog B 
Xq24 UPF3B Tarpey et al. 2007b  
*305915 
Glutamate receptor, 
ionotrophic, AMPA3 
Xq25 GRIA3 Wu et al. 2007  
*300231 
Solute carrier family 9 
(sodium-hydrogen 
exchanger) 
Xq26.3 SLC9A6 Gilfillan et al. 2008  
*300697 
HECT, UBA- and WWE-
domain-containing1 
Xp11.22 HUWE1 Froyen et al. 2008  
*300715 Magnesium transporter 1 Xq13.1-q13.2 MAGT1 Molinari et al. 2008  
*314990 Zink finger protein 711 Xq21.1-q21.3 ZNF711 Chiurazzi et al. 2008 0.3% 
*300172 
Calcium/calmodulin-
dependent serine protein 
kinase 
Xp11.4 CASK 
Chiurazzi et al. 2008 
 
*313475 Synatophysin 
Xp11.23-
p11.22 
SYP Tarpey et al. 2009 0.3% 
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Table 1.4 Genes that cause NS-XLMR and S-XLMR 
 
*  Gene with known sequence 
#  Phenotype description, molecular basis known 
No symbol before an entry number - generally indicates a description of a phenotype for which the 
mendelian basis, although suspected, has not been clearly established or that the separateness of this 
phenotype from that in another entry is unclear 
 
(Modified from Ropers, 2006; Gecz et al, 2009; XLMR website, 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENES THAT CAUSE NS-XLMR AND S-XLMR (OR NEUROMUSCULAR FORMS) 
*300075 Coffin-Lowry  Xp22.1 
RSK2 
(RPS6KA3) 
Merienne et al. 1999 <1% 
*300005 Rett Xq28 MECP2 Couvert et al. 2001 Rare/very rare 
*300036 
Creatine transporter 
deficiency 
Xq28 SLC6A8 Salomons et al. (2001) >2% 
305400 Aarskog-Scott Xp11.22 FGD1 Lebel et al. 2002  
*300382 West, infantile spasms Xp22.1 ARX 
Stromme et al. 2002; 
Bienvenu et al. 2002 
>5% 
*300463 
Sutherland-
Haan/MRXS3 
Xp11.23 PQBP1 Kalscheuer et al. 2003 Rare/very rare 
*300127 Cerebellar ataxia Xq12 OPHN1 Billuart et al. 1998  
*300032 ATR-X Xq13.3 ATRX (XNP) Gibbons et al. 1995a  
*314690 JARID1C-related XLMR  Xp11.22 
JARID1C / 
SMCX 
Jensen et al. 2005 >2% 
#300630 
Adaptor-related protein 
complex 1 
Xp22.2-p21.2 AP1S2 Tarpey et al. 2006  
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Figure 1.2 Ideogram of the X-chromosome showing the genes implicated in NS-XLMR and S-
XLMR. 
 
The 38 genes implicated in NS-XLMR are shown on the left hand side, with arrows indicating position of 
genes. Genes with high contribution to NS-XLMR are highlighted in bold. The numbers in brackets indicate 
either the MRX family number or the number of unrelated families with mutations in this gene. The 52 genes 
on the right hand side are implicated in S-XLMR. The vertical lines shown on the right represent linkage 
intervals on the X chromosome in MRX families (numbers indicate the MRX family) with lod score >2. Genes 
involved in S-XLMR and NS-XLMR are shown by an asterisk near the gene. The horizontal boxes indicate 
regions with frequent deletions (green) and duplications (blue) (Gecz et al, 2009). The genes investigated in 
this study are indicated by red boxes. 
FMR2 
(FRAXE) 
ARX 
XNP / 
ATR-X 
FMR1 
(FRAXA) 
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It is noteworthy that mutations in the ARX gene have been reported in almost 10% of the 81 
large MRX (NS-XLMR) families; far more frequent than mutations in other NS-XLMR genes. 
Ropers (2006) mentions that the frequency of mutations in the ARX gene was much lower (0% 
to 5%) in smaller families. Mutations in 5 other genes, JARID1C, SLC6A8, MECP2, IL1RAPL1 
and PQBP1 have each been found to account for ~1% of NS-XLMR genes (reviewed in Ropers, 
2006). 
 
Mutations in the MECP2 (methyl-CpG-binding protein 2) gene are known to cause Rett 
syndrome, the most common cause of MR in females. It was proposed that mutations in 
MECP2 gene might account for ~2% of males with MR of unknown cause (Couvert, Bienvenu, 
Aquaviva et al., 2001). The authors suggested that the frequency of MECP2 mutations was 
comparable to that of fragile X MR syndrome. Subsequent studies (Yntema, Kleefstra, 
Oudakker et al., 2002a; Bourdon, Philippe, Martin et al., 2003; Ylisaukko-Oja, Rehnstrom, 
Vanhala et al., 2005) have shown that MECP2 mutations do not represent a major cause of NS-
XLMR and are far rarer than initially thought and the contribution of MECP2 has probably been 
overestimated. Recently, Villard (2007) in his review reports that MR caused by MECP2 
mutations is not rare in male patients. An estimated frequency of 1.3-1.7% in males with 
moderate or severe MR is reported, while the incidence of fragile X MR syndrome is reported to 
be 2.8% in the same population. Caution should be taken with analysis and interpretation of 
MECP2 sequence variants as the pathogenicity of these is questionable. Many non-pathogenic 
variants were identified in MECP2 and the gene has a high rate of de novo mutations. Also, 
testing males who are negative for the FMR1 expansion is not a useful criterion to select a 
population for MECP2 mutation screening (Villard, 2007). 
 
It is hoped that elucidating the function of the XLMR proteins will provide insight into brain 
function. The genes responsible for NS-XLMR are a heterogeneous group and their precise role 
and function is unknown. XLMR genes that were identified initially were involved in the 
RhoGTpase pathway as signalling molecules (GD1, PAK3, ARHGEF6) or associated with 
chromatin remodelling (RPS6KA3, ATRX). Genes identified more recently have been involved 
in synaptic vesicle formation (SYN1, SLC6A8, NLGN4 and DLG3) or are novel transcription 
factors (ZNF41, 81 and 674)  (Raymond and Tarpey, 2006).  
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1.2.2 Syndromic X-linked mental retardation (S-XLMR) 
In S-XLMR MR is usually a secondary feature and forms part of a complex syndrome with 
additional neurological, behavioural, metabolic or somatic abnormalities accompanying MR that 
define a syndrome (Gedeon, Donnelly, Mulley et al., 1996). Furthermore, S-XLMR can be 
subdivided into four categories, namely: malformation syndromes, neuromuscular disorders, 
metabolic disorders and dominant conditions (where males die before birth and females are 
affected). There have been an increasing number of S-XLMR genes cloned (Figure 1.2) due to 
the fact that most genes on the X chromosome are haploid in males and mapping genes on this 
chromosome is relatively simpler (Chelly, 1999). This task has been made easier by the 
availability of the annotated human genome sequence.  
 
 
 
 
1.3 FRAGILE X A MR SYNDROME (FRAXA) 
Fragile X MR syndrome (OMIM#300624, OMIM website, 2009), also known as the Martin-Bell 
syndrome, was the first XLMR described. It is the most common inherited cause of MR 
(Hagerman, 1996) accounting for 2-2.5% of MR in males and ~25% of all XLMR (reviewed in 
Ropers, 2006).  A relationship between rare fragile sites and MR was proposed many years 
ago. In 1969, Lubs described a fragile site on the X chromosome in MR males (discussed in 
Section 1.3.5). The FRAXA fragile site at Xq27.3 is associated with fragile X MR syndrome 
(Sutherland, Mulley and Richards, 1993). 
 
1.3.1 Structure and function of FMR1 gene and protein FMRP 
The gene consists of 17 exons and is 38 kb long (Eichler, Richards, Gibbs et al., 1993). It 
encodes an mRNA of ~3.9 kb composed of a ~0.2 kb 5‟ untranslated region, a 1.9 kb coding 
region, and a 1.8 kb 5‟ untranslated region (Bardoni, Schenck and Mandel, 2001). The cause of 
MR in fragile X MR syndrome is due to the absence of the FMR1 gene product, fragile X mental 
retardation protein (FMRP) (Pieretti, Zhang, Fu et al., 1991). 
 
FMRP was shown to have properties of an RNA-binding protein as it contains two K-homology 
(KH) domains and an RGG box, found in various RNA-binding proteins (Siomi, Siomi, 
Nussbaum et al., 1993; Siomi, Choi, Siomi, et al., 1994) and to associate with translating 
polyribosomes, in particular the 60S subunit (Khandjian, Corbin, Woerly et al., 1996).  
 
  Chapter 1. Introduction 
16 
FMRP was shown to have a cytoplasmic localization and has been detected in almost every 
tissue, with highest levels observed in neurons (Devys, Lutz, Rouyer, et al., 1993), human fetal 
brain (Abitbol, Menini, Delezoide et al., 1993), testes (Bachner, Steinbach, Wohrle et al., 1993), 
oesophagus, lung and kidney (Khandjian, 1999). FMRP was shown to function as a 
nucleocytoplasmic shuttling protein that binds to specific mRNas that are involved in dendrite 
development or synapse function (Weiler and Greenough, 1999). There is evidence that FMRP 
mediates translational silencing of mRNAs through interaction with microRNAs and the RNA-
induced silencing complex (RISC) (Jin, Zarnescu, Ceman et al., 2004; Plante and Provost, 
2006). Research in this field has been extensive since it helps in understanding the fundamental 
aspects of neuronal function (Ropers and Hamel, 2005). The FMR1 gene is thought to have a 
function during germ cell proliferation in both males and females (reviewed in Brouwer, 
Willemsen and Oostra, 2009b). 
 
1.3.2 Molecular basis of fragile X MR syndrome 
Fragile X MR syndrome is an X-linked condition. The majority (>99%) of fragile X MR syndrome 
results from the expansion of a CGG (or CCG) triplet repeat in the 5'-untranslated region (UTR) 
of exon 1 of the Fragile X Mental Retardation-1 gene (FMR1) (OMIM#309550, OMIM website, 
2009) at Xq27.3 resulting in gene methylation and silencing (Kremer, Pritchard, Lynch et al., 
1991; Verkerk, Pieretti, Sutcliffe et al., 1991). Fragile X MR syndrome was the first known 
trinucleotide repeat disorder (TRD) described. TRDs have been implicated in the pathogenesis 
of more than 20 neurological disorders (reviewed in Brouwer, Willemsen and Oostra, 2009a).  
 
TRDs are repeat regions which are heritable unstable elements that behave differently from 
static mutations. Their mutation mechanism is dynamic as the repeats become unstable once it 
exceeds a certain threshold length and undergo an increase in copy number in successive 
generations (Oberle, Rousseau, Heitz et al., 1991). The resulting phenotype is usually based on 
the length of the repeat. To date, nine polyglutamine diseases resulting from the expansion of a 
CTG repeat are known: Huntington disease, spinal and bulbar muscular atrophy, dentatorubral-
pallidoluysian atrophy and six forms of spinocerebellar ataxia (Katsuno, Banno, Suzuki et al., 
2008). The repeat sequences, location within the genes, ranges of normal and disease-causing 
repeat lengths and the clinical outcomes differ in the different TRDs (Gatchel and Zoghbi, 
2005). 
 
The pathogenic mechanisms underlying TRDs result in gain-of-function and loss-of-function. 
The timing of the expansion is still under debate, although some attempts have been made to 
gain insight into this and different models have been proposed (reviewed in Brouwer et al., 
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2009a). There has been much speculation as to the mechanism of repeat instability at the 
molecular level. The mechanism is complex arising through multiple processes (Pearson, Nichol 
Edamura, and Cleary, et al., 2005). One proposed mechanism suggested is slippage of the 
replication fork during replication (Kunkel, 1993; Richards and Sutherland, 1994). Proteins 
involved in lagging strand synthesis, coordination between synthesis of the leading and the 
lagging strand and restarting of the replication fork play a role in the stability of the microsatellite 
repeats (reviewed in Mirkin, 2007; reviewed in Brouwer et al., 2009a). 
 
Fragile X MR syndrome shows anticipation, i.e. increased severity and earlier onset in 
successive generations (Fu, Kuhl, Pizzuti et al., 1991; Oberle et al., 1991). The length of the 
repeat correlates with the severity of the syndrome (Oberle et al.,1991; Sutherland, Haan, 
Kremer, et al., 1991b; Yu, Pritchard, Kremer et al., 1991). Figure 1.3 illustrates the range of 
CGG repeats in the FMR1 gene. 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Range of FMR1 CGG repeats 
 
 
 
1.3.2.1 FMR1 normal (N) alleles 
The normal number of repeats is polymorphic and varies from 5 to 40 CGG repeats in the FMR1 
gene (GeneReviews website, 2009). These alleles are stably transmitted without any increase 
or decrease in repeat number. The most common alleles described in different populations 
range between 28 and 30 repeats and over 98% of all normal alleles are below 46 repeats 
(Reiss, Kazazian, Krebs et al., 1994). The CGG repeat is interrupted by AGG repeats, which are 
thought to provide stability to the CGG repeat through the influence of RNA structures (Eichler, 
Holden, Popovich et al., 1994; reviewed in Brouwer et al., 2009b) 
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1.3.2.2 FMR1 intermediate (I) / gray zone alleles 
Intermediate alleles are reported to range from 41-58 CGG repeats (GeneReviews website, 
2009). The clinical significance of carrying an allele in this intermediate size range is unclear. 
There is an increased risk of expansion compared to normal alleles, but expansion into the full 
mutation range is very rare (Morris, Morton, Collins et al., 1995). Alleles above 45 CGG repeats 
are reported to be more unstable upon transmission than alleles below 45 CGG repeats 
(reviewed in Brouwer et al., 2009b). 
 
 
1.3.2.3 FMR1 premutation (PM) alleles 
Premutation carriers have small expansions of 59 to 200 repeats which are not associated with 
MR (GeneReviews website, 2009).  These repeats are unstable (Oberle et al., 1991; Yu et al., 
1991) and prone to expand as they pass from one generation to the next. Carrier males have 
normal, non-carrier sons, but they transmit the CGG repeat unchanged to their daughters, who 
are all normal, but then obligate carriers of fragile X MR syndrome. The risk of expansion into a 
full mutation depends on the PM size. The smallest repeat known to expand to a full mutation in 
a single generation was 59 repeats (Nolin, Brown, Glicksman et al., 2003). This makes the 
diagnosis of female carriers essential since they are at risk of having offspring affected with 
fragile X MR syndrome. This illustrates the exclusive maternal inheritance pattern, i.e. the PM 
expands to a full mutation only when it is transmitted by a female (Fu et al., 1991; Sutherland et 
al., 1991).  
 
Most PM carriers do not present with a clinical phenotype. However, there have been reports of 
some PM carriers with mild learning disabilities, developmental delay, obsessive thinking, 
ADHD, autism and some cases reported to present with MR, social phobia or anxiety disorder 
(reviewed in Brouwer et al., 2009b).  
 
It is now well established that males with a PM in the FMR1 gene have an increased risk for 
developing Fragile X tremor ataxia syndrome (FXTAS) (OMIM#300623, OMIM website, 2009), a 
progressive neurodegenerative disorder which is clinically distinct from fragile X MR syndrome 
(OMIM#300624, OMIM website, 2009). Patients with FXTAS generally present with cerebellar 
gait ataxia and intention tremor but may develop other neurological symptoms (Hagerman and 
Hagerman, 2004; Jacquemont, Farzin, Hall, et al., 2004). The length of the CGG repeat is 
thought to influence the severity of the disorder. Female PM carriers are less likely to develop 
FXTAS and present with a less severe phenotype compared to males with a PM most probably 
due to the presence of a normal FMR1 allele. X-inactivation patterns appear to influence the 
severity of the clinical outcome of FXTAS in females (reviewed in Brouwer et al., 2009b). PM 
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carriers are reported to have increased FMR1 mRNA levels in leucocytes with FMRP levels 
decreasing with increasing CGG repeat length (Tassone, Hagerman, Taylor et al., 2000). A 
toxic RNA gain-of-function mechanism has thus been proposed for the pathogenesis of FXTAS, 
similar to that proposed for another TRD, myotonic dystrophy (DM) (reviewed in Brouwer et al., 
2009b).  
 
Females with a PM have a 20% risk of developing premature ovarian failure (POF: cessation of 
menstruation at or before 40 years of age), or more accurately termed, primary ovarian 
insufficiency (POI), as the range of clinical presentation has broadened since it was first 
described (OMIM#311360, OMIM website, 2009), compared to 1% in the general population 
(Sherman, 2000; reviewed in Brouwer et al., 2009b). There is some speculation that RNA-
mediated toxicity may also be a cause of POF (reviewed in Brouwer et al., 2009b). 
 
 
1.3.2.4 FMR1 disease-associated / full mutation (FM) alleles 
Affected individuals have over 200 copies of the CGG repeat (full mutation); up to as many as 
2000 CGG repeats (Fu et al., 1991; Kremer et al. 1991; Verkerk et al., 1991). A FM is 
associated with hypermethylation of an upstream gene promoter region (CpG island), and 
silencing of FMR1 gene transcription and thus FMRP is not produced (Oberle et al., 1991; 
Pieretti et al., 1991). Approximately 1% of mutations include missense mutations, full and partial 
deletions (Mila, Castellvi-Bel, Sanchez et al., 1996b; reviewed in Garber, Visootsak and Warren, 
2008). The absence of the FMRP in neurons is the cause of MR seen in fragile X MR patients 
(reviewed in Brouwer et al., 2009b). 
 
 
1.3.3 Clinical features of fragile X MR syndrome 
The physical features can be very subtle and therefore difficult to recognize. Clinically, fragile X 
MR syndrome in males and females can be recognized by intellectual, physical and behavioural 
features, which include developmental delay, long narrow face, large prominent forehead and 
chin, protruding ears, macro-orchidism in males (large testes), hyperactivity, hand flapping, 
attention deficit and autism (Hagerman, Amiri and Cronister, 1991).  The phenotypic expression 
of the syndrome is very variable and MR is the most consistent feature. It is considered a “soft” 
S-XLMR syndrome. A phenotypic screening checklist for fragile X MR syndrome was proposed 
by Maes, Fryns, Ghesquiere et al. (2000) to be used in men of any age who have 
developmental delay of unknown cause (reviewed in Garber et al., 2008).  
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1.3.4 Frequency of fragile X MR syndrome 
It is reported that 1 in 4000 males and 1 in 8000 females are affected with fragile X MR 
syndrome (Fishburn et al., 1983; Sherman, 1996; Turner, Webb, Wake et al., 1996; Crawford, 
Meadows, Newman et al., 1999; Biancalana, Beldjord, Taillandier et al., 2004; Ropers, 2006). 
The condition is present in almost all ethnic groups. The first White South African case was 
described by Venter and Gericke (1980). A study undertaken in this laboratory (Division of 
Human Genetics, NHLS, Johannesburg) by Goldman, Krause and Jenkins et al. (1997) showed 
that the condition occurs in the Black population at a frequency comparable to that in the White 
population and that it was under-diagnosed in the past. 
 
 
1.3.5 Cytogenetic analysis of FRAXA and other fragile sites 
Fragile X MR syndrome is associated with a fragile site, FRAXA at Xq27.3 (Sutherland, Mulley 
and Richards, 1993). A fragile site appears cytogenetically as a non-staining gap or break on a 
chromosome, a chromatid gap, or, less frequently, as a break in metaphase chromosome 
spreads as shown in Figure 1.4  (Sutherland, 1979; Knight, Flannery, Hirst et al., 1993). These 
sites are usually induced through culture in a folate deficient medium. Rare fragile sites are 
characterized by CGG repeat expansion and silencing of any associated gene due to 
methylation. Four fragile sites have been described at Xq27-28, viz. FRAXA, FRAXE, FRAXD 
and FRAXF. Seven folate sensitive fragile sites (FRA10A, FRA11B, FRA12A, FRA16A, FRAXA, 
FRAXE and FRAXF) have been molecularly characterized and involve the expansion of 
CCG/CGG trinucleotide repeats (Lukusa and Fryns, 2008).  
 
 
 
 
Figure 1.4 An X chromosome showing the FRAXA fragile site responsible for fragile X MR 
syndrome. 
 
 
centromere 
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The FRAXE site is situated 600 kb distal to the FRAXA site at Xq28 (Sutherland and Baker, 
1992; Flynn et al., 1993). FRAXD (proximal to FRAXA at Xq27) (Hecht and Bixenman, 1990) 
and FRAXF (distal to FRAXE at Xq28) (Hirst, Barnicoat, Flynn et al., 1993; Parrish, Oostra, 
Verkerk et al., 1994; Ritchie, Knight, Hirst et al., 1994) are other rare folate-sensitive sites. 
 
Cytogenetic analysis will detect males and females affected with fragile X MR syndrome, but it 
fails to identify carriers (Jacobs, 1991; Rousseau, Heitz, Biancalana et al., 1991). Also, since 
other fragile sites like FRAXD, FRAXF with no pathogenic association and the more common 
FRAXA site cannot be distinguished from each other, cytogenetic analysis can be misleading. 
Routine karyotyping is still recommended in males referred for fragile X MR syndrome testing to 
exclude any other chromosomal abnormalities. 
 
1.3.6 Fragile X MR syndrome founder haplotypes 
Studies have indicated that fragile X chromosomes are in linkage disequilibrium with a small 
subset of flanking DXS548-FRAXAC1-FRAXAC2 microsatellite marker haplotypes (Zhou, Tang, 
Law et al., 2006). Two of the polymorphic AC repeats, DXS548 (150 kb from the CGG repeat on 
the centromeric side (Riggins, Sherman, Oostra et al., 1992) and FRAXAC2 (10 kb from the 
CGG repeat on the telomeric side) (Richards, Holman, Kozman et al., 1991) have been 
described as useful markers, together with the CGG repeat (Goldman, 1997). Figure 1.5 shows 
the location of these markers relative to the FMR1 gene. 
 
 
 
 
 
 
Figure 1.5 Microsatellite markers in and around the FMR1 gene locus on Xq27.3. 
Green boxes represent FMR1 exons. The red box indicates the FMR1 CGG repeat (not to scale) (modified 
from Zhou et al., 2006).  
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1.4 FRAGILE X E SYNDROME (FRAXE) 
This study investigated the contribution of the FMR2 gene to NS-XLMR in the South African 
population. This gene is discussed in detail below as well as its role in NS-XLMR.  
 
 
1.4.1 Structure and function of FMR2 gene and protein 
The FMR2 gene at the FRAXE locus at Xq28 was cloned by Knight, Voelckel, Hirst et al. (1994). 
FMR2 is a large gene, 500 kb in size and composed of 22 exons, which show a complex pattern 
of alternative splicing (Gecz, Bielby, Sutherland et al., 1997a; Gecz, Oostra, Hockey et al., 
1997b; Gecz and Mulley, 1999). The FMR2 gene encodes a protein of 1311 amino acids with a 
major 8.75 kb transcript in placenta, fibroblasts adult and brain and a longer 13.7 kb isoform in 
fetal brain (Gecz and Mulley, 1999; Gecz, 2000). Gecz, Gedeon, Sutherland et al. (1996) 
showed that loss of FMR2 expression was correlated with FMR2 expansion. 
 
The precise function of FMR2 is unknown, especially its function in processes underlying its 
association with mild MR (Gecz, 2000). Studies performed in yeast and mammalian cells show 
that FMR2 is a nuclear protein, with strong transcriptional activation and that it might serve as a 
downstream effector of Ras/mitogen activated protein (MAP) kinase signalling pathways 
(Hillman and Gecz, 2001). Recent findings show that FMR2 is an RNA binding protein 
implicated in regulating splicing as it co-localizes with the splicing factor SC35 in nuclear 
speckles, a region where splicing factors are concentrated, assembled and modified. This is 
accomplished through its interaction with G-quartet RNA, an exonic splicing enhancer (Bensaid, 
Melko, Bechara et al., 2009). 
 
The mouse fmr-2 shows 88% amino acid identity to the human FMR2 protein (Chakrabarti, 
Bristulf, Foss et al., 1998), which could help in understanding the function of the protein. Studies 
on fmr-2 knockout mice indicate no phenotypic or pathologic abnormalities; however, 
behavioural studies display impairment in conditioned fear and enhanced long term potentiation 
(LTP), suggesting a role for FMR2 in regulating synaptic plasticity and memory formation 
(Nelson, Gu, Yamagat et al., 1999; Gu and Nelson, 2003). 
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1.4.2 Molecular basis of FRAXE syndrome 
The presence of a fragile site localised at Xq28 is associated with FRAXE syndrome (FRAXE) 
(OMIM+309548, OMIM website, 2009), a mild form of NS-XLMR (Sutherland and Baker, 1992; 
Flynn et al., 1993; Mulley, Yu, Loesch et al., 1995). Similar to FRAXA, a CpG island is found 
near the FRAXE site. A gene, FMR2 (fragile X mental retardation gene 2), was found 
associated with the FRAXE CpG island and shown to be an unstable expansion of a GCC (or 
GGC) triplet repeat, which is hypermethylated in individuals with the expanded allele (Gecz et 
al., 1996; Gu, Shen, Gibbs et al., 1996). This in turn suppresses FMR2 transcription and leads 
to absence of the FMR2 protein (Knight et al., 1993). A phenotype of MR is not always expected 
from an expansion in the FMR2 gene since it is incompletely penetrant (Gecz and Mulley, 
2000). Sometimes, a microdeletion of the FMR2 gene leads to a truncated FMR2 protein (Gecz 
et al., 1996; Gu et al., 1996; Gecz et al., 1997b). There have been cases reported of males in 
large families who were cytogenetically positive, fully methylated, in some cases not expressing 
FMR2, but mentally normal. It was suggested that the normal phenotype in these individuals 
might be the result of clinical variability of the disease and of the effect of other genes on the 
phenotype or of mosaicism and different methylation states in neuronal tissues (Toniolo and D 
Adamo, 2000). 
 
Unlike fragile X MR syndrome, the GCC repeat of FMR2 can either expand or contract and is 
similarly unstable when transmitted through the female germ line (Knight et al., 1993). The 
FMR2 repeat is a pure repeat with no unique interspersed sequences, like the AGG triplets in 
FMR1, which are thought to provide stability to the CGG repeat (Eichler et al., 1994; Zhong, Ju, 
Curley et al., 1996). The range of repeats in the FMR2 gene is shown in Figure 1.6. 
 
 
 
 
 
 
 
 
Figure 1.6 Range of FMR2 GCC repeats in the FMR2 gene. 
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1.4.2.1 FMR2 normal (N) alleles 
The GCC (or GGC) repeat is polymorphic in the normal population. Normal individuals have 6 to 
25 GCC repeats (Knight et al., 1993). 
 
 
1.4.2.2 FMR2 intermediate (I) / gray zone alleles 
Intermediate/gray alleles usually range from 26 to 59 GCC repeats. Intermediate-sized 
expansions are similar to FMR1 premutations in that they are unmethylated on the active X 
chromosome and may be unstable upon transmission to offspring (Knight et al., 1994). 
 
 
1.4.2.3 FMR2 premutation (PM) alleles 
Premutation alleles range from 60 to 200 GCC repeats. The border between normal alleles and 
premutation alleles is still poorly defined, because the FMR2 expansion mutation is so rare.  
 
 
1.4.2.4 FMR2 disease-associated / full mutation (FM) alleles 
Affected individuals have more than 200 GCC copies and the FMR2 gene is not transcribed due 
to methylation of the CpG island (Knight et al., 1993). Gecz (2000) cautions not to overlook 
other causative mutations such as deletions, insertions and point mutations other than the GCC 
repeat expansion mutation, which can be expected in the FMR2 gene, as is the case for FMR1 
(Gedeon, Baker, Robinson et al., 1992; De Boulle, Verkerk, Reyniers et al. 1993). However, 
screening for any other mutations, especially on a large scale is inefficient and costly.  
 
1.4.3 Clinical spectrum of FRAXE syndrome 
There has been a spectrum of clinical phenotypes associated with FRAXE syndrome. The 
disorder is unique among XLMR phenotypes due to its very mild to borderline nature 
(50<IQ<85). The phenotype associated with the FMR2 expansion is usually considered as mild 
or moderate MR, with incomplete penetrance. The characteristic feature of the phenotype is 
learning difficulties, often a consequence of communication problems (speech delay, poor 
writing skills) and overactivity (reviewed in Gecz, 2000). However, genotype/phenotype relations 
have been less characterized.  
 
In addition to the FRAXE/FMR2 contribution to the aetiology of MR, other phenotypes, some 
unrelated to MR, were speculated to be linked to the FMR2 gene. These include mild attention 
deficit hyperactivity disorder (ADHD) (Abrams, Doheny, Mazzocco et al., 1997), premature 
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ovarian failure (Murray, Webb, Grimley et al., 1998) and autism (Holden, Wing, Chalifoux et al., 
1996b; Longshore, Tarlton, Schwartz  et al., 1997). Fmr-2 knockout mice were shown to display 
a condition similar to human MR, with impaired learning and memory performance and a 
hippocampal increased long-term potentiation (Gu, Mcilwain, Weeber et al., 2002).  
 
Wang, Gu, Ferguson, et al. (2003) reported on the FMR2 expansion in one male patient with 
obsessive-compulsive disorder, a chronic psychiatric disease. A family member with a 
phenotype of speech impairment also had the FMR2 expansion (630-1200 copies). The co-
segregation of the full mutation with the apparent neurologic disorders in the same family 
provides support that FRAXE syndrome is possibly a genetic neurologic condition. 
 
No evidence for an increased risk of POF, FXTAS and additional diseases in FMR2 mutation 
carriers was shown in a recent study (Spath, Petersen, Kremer et al., 2007). However, a study 
undertaken by Sofola, Jin, Botas et al. (2007) showed that that the GCC premutation length 
repeat leads to an RNA-mediated neurodegenerative phenotype in a Drosophila model. 
 
 
1.4.4 Frequency of FRAXE syndrome 
FRAXE syndrome appears to be much rarer than fragile X MR syndrome, but this may be due in 
part to ascertainment bias for more severe MR than that associated with FMR2 mutations 
(Biancalana, Taine, Bouix et al., 1996). FRAXE syndrome has an estimated incidence of at 
least 1/50 000-1/100 000 males, and more than 50 families are known worldwide (reviewed in 
Gecz, 2000). As it is not screened for routinely, the number of affected families is expected to 
be an underestimate. 
 
 
1.4.5 FRAXE founder haplotypes 
A study by Limprasert, Zhong, Currie et al. (1999) demonstrated possible founder effects for 
FMR2 alleles as there are for FMR1 alleles (Richards, Holman, Friend et al., 1992), when they 
found haplotype associations between FMR2 triplet repeats and two (DXS8091 and DXS1691) 
of the five microsatellite markers examined.  
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1.5 XNP AND ITS ASSOCIATION WITH XLMR 
The third XLMR gene that was investigated in this study is the XNP gene. Interest in this gene 
was prompted by a study undertaken by Villard, Bonino, Abidi et al. (1999a) in which screening 
for XNP mutations in MR males with a typical facial appearance was suggested. Mutations in 
this gene were shown not only to be involved in S-XLMR, such as X-linked -thalassaemia 
mental retardation syndrome (ATR-X), but also in NS-XLMR (Gibbons, Picketts, Villard et al., 
1995a; Villard, Lossi, Cardoso et al., 1997). This gene is discussed in detail below as well as its 
role in NS-XLMR, ATR-X syndrome and other syndromes. 
 
1.5.1 XNP gene 
The XNP (X-linked nucleoprotein) gene, also called XH2 (X-linked helicase-2) or ATR-X gene 
(OMIM*300032, OMIM website, 2009) (hereafter referred to as XNP), is located at Xq13.3 
(Gibbons et al., 1995a). The gene was isolated in 1994 by Gecz, Pollard, Consalez et al. 
(1994). Villard et al. (1997) identified and sequenced the intron/exon boundaries of the XNP 
gene. The gene contains 36 exons and spans about 300 kb of genomic DNA although there is 
some uncertainty whether exon 7 is functional, and contains a 4 kb open reading frame (ORF) 
(Picketts, Higgs, Bachoo et al., 1996). 
 
1.5.2 XNP protein 
The XNP gene encodes a predicted protein of 2,492 amino acids (Villard et al., 1997). 
Expression analysis found that XNP encodes at least 2 alternatively spliced mRNA transcripts of 
~10.5 kb (NM_000489.3 and NM_138270.2) that give rise to slightly different proteins of 265 
and 280 kDA, respectively (NP_000480.2 and NP_612114.1). One of these transcripts is 
expressed predominantly in embryonic tissues (Gibbons, Bachoo, Picketts et al., 1997). A 
further transcript of ~7 kb represents an isoform that truncates just after intron 11, giving rise to 
ATRXt, a truncated protein isoform, which is conserved between mouse and man (Garrick, 
Samara, Mcdowell et al., 2004). 
 
The N-terminal segment has a high degree of conservation between human and mouse (97 of 
98 amino acids) and the central and C-terminal regions show 94% conservation (Picketts, 
Tastan, Higgs et al., 1998). The closest known non-mammalian relative of the XNP protein is 
xnp-1, a Caenorhabditis elegans (nematode) gene (Villard, Fontes and Ewbank, 1999b). 
 
At the N-terminal of the protein (see Figure 1.7) there is a zinc finger domain (also called the 
ADD domain or ATRX DNMT3-DNMT3L domain) which is related to sequences seen in the 
  Chapter 1. Introduction 
27 
DNA methyltransferase 3 (DNMT3) family of de novo DNA methyltransferases (Gibbons, 2006). 
It is thought to be involved in regulating transcription (Aasland, Gibson and Stewart et al., 1995). 
The central portion of the protein contains motifs that identify XNP as a novel member of the 
sucrose-nonfermenting 2 (SNF2) subgroup of ATPase/DNA helicases. This is a superfamily of 
proteins that are involved in various regulatory functions, ranging from DNA recombination and 
repair to control of transcription and mitotic chromosome segregation (Gibbons, Mcdowell, 
Raman et al., 2000). It is believed that their function is to facilitate these processes by 
remodelling chromatin. The function of the protein is unknown but the fact that α-globin 
expression is perturbed in patients with XNP mutations suggests that it may play a role in 
epigenetic regulation of globin gene expression (Gibbons, 2006). 
 
Cardoso, Lutz, Mignon, et al. (2000) showed altered or absent XNP expression in cells of 
affected ATR-X patients with mutations of the zinc finger domain. Although many different types 
of mutations have been identified, no specific genotype-phenotype correlation appears to exist, 
suggesting that irrespective of mutation type, gene alteration leads to a loss of function. 
Recently XNP was shown to interact with MECP2, a gene responsible for Rett syndrome and 
XLMR (Nan, Hou, Maclean et al., 2007). The authors suggested that the disruption of the 
MECP2-ATRX interaction causes a pathologic change that contributes to MR. 
 
 
Figure 1.7 (a) ATR-X protein structure illustrating position of the N-terminal cysteine-rich domain 
and the C-terminal helicase-like domain.  
Disease-associated missense mutations are shown by circles. (b) A magnification of the ADD or zinc 
finger domain, illustrating the locations of mutations and secondary structural elements (N-terminal 
GATA-like zinc finger, PHD (plant homeodomain) finger and a long C-terminal extension). The orange 
vertical bars represent the conserved cysteine residues (Argentaro, Yang, Chapman et al., 2007). 
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1.5.3 XNP mutations in NS-XLMR 
Guerrini, Shanahan, Carrozzo et al. (2000) proposed that mutations in the XNP gene should be 
considered as a cause of mild MR in male patients that lack specific diagnostic features, e.g. 
facial dysmorphism. This shows the expanding phenotype of XNP mutations-mild to moderate 
MR patients WITHOUT facial dysmorphism should be screened for XNP mutations. 
 
As mutations in the XNP gene are reported to lead to a severe MR phenotype, screening for 
XNP mutations in MR males who have a negative family history was suggested (Villard et al., 
1999a) and this led the authors to propose large screening of additional patients. The authors 
reported mutation analysis of the XNP gene using direct sequencing of the 300 bp zinc finger 
coding region, spanning exons 7, 8, and 9. They concluded that this method was suitable for 
screening individuals in this population. 
 
Mutations are found predominantly in the two protein motifs, the helicase and zinc finger (ADD) 
domains. The majority of XNP mutations identified (~50-60%) for ATR-X cases and related 
syndromes are clustered in a „hot spot‟ region, which is found in the zinc finger (ADD) domain of 
the gene (Villard et al., 1997; reviewed in Gibbons, 2006). This is a 300 bp region, encoded by 
exons 7, 8, and the beginning of exon 9 in the XNP gene, suggesting that this is a functionally 
important region. The remaining mutations have been found in the helicase domain, which 
extends over 3 kb at the C-terminus (COOH) of the protein (Villard et al., 1999a). 
 
1.5.4 XNP mutations in S-XLMR 
Mutations in XNP are associated with several XLMR syndromes, the best known being ATR-X 
syndrome (Gibbons et al., 1995a). The types of mutations found include, deletions, insertions, 
missense, nonsense, and splice mutations. Missense mutations are more frequent than 
frameshift and nonsense mutations (HGMD website, 2009). Twenty percent have the common 
c.736C>T (p.R246C) mutation. Mutations lead to decreased XNP activity (Gibbons and Higgs, 
2000). 
 
Mutations in XNP have been reported in families affected with Juberg-Marsidi syndrome (MIM 
309590) (Villard, Gecz, Mattei et al., 1996a), Carpenter-Waziri syndrome (Abidi, Schwartz, 
Carpenter et al., 1999), XLMR with spastic paraplegia (R1742K mutation) (Lossi, Millan, Villard 
et al., 1999), Holmes-Gang syndrome (Stevenson, Abidi, Schwartz et al., 2000), Smith-
Fineman-Myers syndrome (Villard, Fontes, Ades et al., 2000) (MIM309580), Chudley-Lowry 
syndrome (Abidi, Cardoso, Lossi et al., 2005) and MR phenotypes without ATH (Villard, 
Lacombe and Fontes, 1996b; Villard, Toutain, Lossi et al., 1996c). Mutations in XNP have also 
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been described in other, less well-characterized XLMR syndromes. Despite the clinical variation 
seen with XNP mutations, all male patients have a severe MR associated with microcephaly 
and facial dysmorphism. It suggests that this gene may be involved in the development of facial 
morphogenesis (Cardoso et al., 2000). It is unclear if these patients have distinct phenotypes or 
are part of the spectrum of ATR-X syndrome (Stevenson et al., 2000). Mutations in different 
regions of the gene have an influence on the phenotype. Mutations in the ADD region appear to 
be involved with increased psychomotor impairment while mutations in the C-terminus are 
frequently associated with genital abnormalities (Gibbons, Wada, Fisher, et al., 2008). 
 
XNP is also speculated to interact with genes that are involved in the process of sex 
determination (Neri and Opitz, 1999). Ion, Telvi, Chaussain et al. (1996) reported on an XNP 
mutation (frameshift mutation, generating a premature stop codon) in a French family in which 
the affected males presented with features suggestive of ATR-X syndrome (severe MR, 
dysmorphic features but without ATH), partial ocular albinism and with male-to-female sex 
reversal (46,XY female). 
 
1.5.5 ATR-X syndrome 
Alpha-thalassaemia/mental retardation syndrome (OMIM#301040, OMIM website, 2009) was 
first reported by Wilkie, Buckle, Harris et al. (1990a) and Wilkie, Zeitlin, Lindenbaum (1990b). 
Two distinct syndromes, ATR-16 and ATR-X were defined. ATR-16 is a contiguous gene 
syndrome, in which there are large (1-2Mb) chromosomal rearrangements at 16p13.3 that 
delete many genes, including the -globin genes. In ATR-X syndrome, mutations in the XNP 
gene down regulate alpha ( ) gene expression rather than delete  genes and possibly also 
disrupt the expression of other genes (Gibbons et al., 1995a). Clinical features are more 
variable in ATR-16, whereas ATR-X cases show a very typical phenotype. 
 
Picketts et al. (1996) established that ATR-X downregulates -globin but not -globin, possibly 
due to the fact that - and -globin are on different chromosomes and interact differently with 
regulatory factors and chromatin. 
 
 
1.5.5.1 Clinical features of ATR-X syndrome 
Classical cases of ATR-X present clinically with severe to profound MR (95% of cases), 
characteristic facial dysmorphism, most easily recognized in early childhood (>90% of cases) - 
epicanthic folds, flat nasal bridge, small and triangular upturned nose, anteverted nostrils, a 
triangular mouth and protruding tongue. Other clinical features include muscle hypotonia, most 
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distinct in neonates and microcephaly. Urogenital malformations are present in 80% of cases - 
genitalia are usually abnormally small, undescended or dysgenetic testes to external female 
genitalia, with the affected individuals being defined as male pseudohermaphrodites 
(Mcpherson, Clemens, Gibbons et al., 1995), shawl-like or hypoplastic scrotum and small penis 
with hypospadias. Many affected individuals (90%) will have haematological signs of - 
thalassaemia (not from deletions of the  genes) (Gibbons, Brueton, Buckle, et al., 1995b; 
Gibbons and Higgs, 2000; Gibbons 2006). Other features include: skeletal abnormalities (90%), 
microcephaly (75%), short stature (65%), seizures (30%), cardiac defects (20%), renal/urinary 
abnormalities (15%) (Gibbons, 2006). Figure 1.8 shows the typical facial characteristics of 2 
unrelated boys with ATR-X syndrome. 
 
 
 
 
Figure 1.8 Two unrelated boys with ATR-X syndrome. 
Note the flat nasal bridge, small and triangular upturned nose, anteverted nostrils, a triangular mouth and 
protruding tongue. (Gibbons Laboratory website, 2008)  
 
 
 
1.5.5.2 Worldwide prevalence of ATR-X syndrome 
The prevalence of ATR-X in the general population is unknown. As of 2006, 168 patients have 
been reported. An estimate for the prevalence is <1-9/1,000,000 (Gibbons, 2006). In 2000, 
Wada, Kubota, Fukushima et al. reported on 9 patients (severe MR and typical facial 
appearance) from 8 independent Japanese families with ATR-X. Stevenson (GeneReviews 
website, 2009) indicates that there have been no reports on ATR-X occurring at high 
frequencies in any specific racial or ethnic group. Three patients with ATR-X syndrome were 
identified in our laboratory and confirmed on molecular investigations. The results obtained will 
be discussed in Chapter 7. 
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1.5.5.3 Detection of -thalassaemia 
Confirmation of a clinical diagnosis of ATR-X usually requires a routine haematological screen. 
The atypical form of -thalassaemia (ATH) is revealed by the presence of HbH inclusions (β-
globin tetramers) in a fresh blood sample (Figure 1.9). This is a technically difficult test to 
perform. 
 
 
 
   
Figure 1.9 HbH inclusion bodies (excess -chains) or „golf balls‟ (shown by arrow) in red blood 
cells in peripheral blood. 
The test uses light microscopy to detect red cells containing HbH inclusions after incubation, at room 
temperature, of venous blood with 1% brilliant cresyl blue for 4-24 hrs (Gibbons Laboratory website, 2008)  
 
 
 
 
It was thought that 90% of patients with ATR-X mutations have evidence of ATH (Gibbons et al., 
1995a). However, this is not always the case, as there have been a number of ATR-X families 
where the affected members have no signs of ATH (Villard et al., 1996b, 1996c). Patients with 
the same mutation may have very different degrees of ATH. The effect of ATR-X protein on -
globin gene expression may be modified by other genetic factors (Gibbons et al., 2000). The 
relationship between ATR-X mutations and ATH remains unclear (Gibbons, 2006).  
 
Haematologically, ATR-X patients are not as severely affected as the classic ATH and there is 
much variation in the haematological manifestations (Gibbons and Higgs, 2000). ATR-X female 
carriers are phenotypically asymptomatic and HbH inclusions are only found in ~25% of carriers 
(Gibbons et al., 1995a), possibly due to a totally skewed X-inactivation pattern of the mutant X 
chromosome seen in a variety of tissues. A possible direct correlation is postulated between X-
inactivation selection and mutation in the gene (Lossi et al., 1999). 
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1.5.5.4 Mutation testing for ATR-X syndrome 
Molecular genetic testing for ATR-X syndrome by sequence analysis of the XNP gene can 
detect disease-causing mutations in ~90% of affected individuals. Approximately 40-50% of 
known ATR-X mutations are in the region covering exons 7, 8 and the beginning of exon 9 
(Villard et al., 1999a) which prompted this study of mutation analysis in this region. The next 
most commonly affected region is the helicase domain in which 30% of mutations are clustered 
(Gibbons et al., 2008).  
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1.6 ARX AND ITS ASSOCIATION WITH XLMR 
The fourth gene which was investigated in this study is the ARX gene. Mutations in this gene 
are reported to be the second most cause of XLMR after fragile X MR syndrome (reviewed in 
Gecz, Cloosterman and Partington, 2006). This gene is discussed in detail below as well as its 
role in NS-XLMR and other syndromes.  
 
 
1.6.1 ARX gene 
The ARX gene (Aristaless-related homeobox gene) (OMIM*300382, OMIM website, 2009) is 
located at Xp22.13. It contains 5 exons, spanning 12.5 kb and encodes a 562-amino acid 
protein. The ARX gene is transcribed into an mRNA of about 2.8 kb, with an open reading frame 
of 1 686 bp (Stromme, Mangelsdorf, Shaw et al., 2002; Gronskov, Hjalgrim, Nielsen et al., 
2004). 
 
 
1.6.2 ARX protein 
The ARX protein belongs to the largest class of homeoproteins, namely the Prd (paired) class 
(Bienvenu, Poirier, Friocourt et al., 2002). The ARX protein has two important domains: the 
homeobox domain that directly binds DNA, and the C-terminal OARb or aristaless domain of 
unknown function. A conserved octapeptide domain is known to be involved with transcriptional 
repression and four polyalanine tracts, three of which are encoded in exon 2 and one in exon 4 
are thought to be involved with suppressing transcription (Gronskov et al., 2004).  Figure 1.10 
shows a schematic diagram of the ARX gene (Chiurazzi, Tabolacci and Neri, 2004) 
 
The ARX protein is only expressed in the fetal brain and testes during early development, while 
expression is detected in a wide variety of tissues in adults, including the brain (specifically the 
forebrain and the floor plate of the developing CNS), heart, liver and skeletal muscles (Suri, 
2005). The ARX protein was found to interact via its homeodomain with IPO13, a mediator of 
nuclear import (Shoubridge, Cloosterman, Parkinson-Lawerence et al., 2007). 
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Figure 1.10 Schematic representation of the genomic organization of the ARX gene and the 
corresponding protein domains 
(Chiurazzi, et al., 2004) 
 
 
 
1.6.3 ARX mutations in S-XLMR and NS-XLMR  
Mutations in the ARX gene have been identified in NS-XLMR and S-XLMR. Mutations in the 
ARX gene are associated with more than 10 different S-XLMR disorders including: West 
syndrome (also called X-linked infantile spasms, ISSX, characterised by infantile spasms, MR 
and hypsarrythmia) (Stromme et al., 2002),  Partington‟s syndrome (characterised by MR and 
dystonic hand movements) (Stromme et al., 2002),  MR associated with myoclonic epilepsy and 
spasticity (Scheffer, Wallace, Phillips et al., 2002; Stromme et al., 2002), X-linked lissencephaly 
and ambiguous genitalia (XLAG) syndrome (Kitamura, Yanazawa, Sugiyama et al., 2002) and 
Proud syndrome (which consist of XLMR, agenesis of the corpus callosum and abnormal 
genitalia) (Kato, Das, Petras et al., 2004).  
 
Mutations in NS-XLMR were described by Bienvenu et al., 2002. It is reported that almost 10% 
of the 81 large MRX (NS-XLMR) families have mutations in the ARX gene; far more frequent 
than mutations in other NS-XLMR genes. The frequency of mutations in the ARX gene is 
reported to be much lower (0% to 5%) in smaller families (2.2% in affected brother pairs and 
0.13% in sporadic males with MR) (reviewed in Ropers, 2006). 
 
A number of mutations have been identified in the ARX gene, including polyalanine tract 
expansions, insertions and deletions, missense and nonsense mutations leading to frameshifts 
and premature truncation (in the case of XLAG) (Gronskov et al., 2004; Poirier, Lacombe, 
Gilbert-Dussardier et al., 2006). Almost 90% of ARX mutations are situated in exon 2 within the 
Octapeptide 
domain 
Aristaless-related 
domain 
Polyalanine tails 
Paired-like Homeodomain 
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polyalanine domains and homeodomain. Other mutations have been described in exon 1 within 
the octapeptide domain (Poirie et al., 2006). 
 
Two recurrent mutations, both leading to expansions of the polyalanine tracts, have been 
reported, c.431-454 dup24 and c.333-334ins(GCG)7 (Bienvenu et al., 2002; Stromme et al., 
2002). A 24 bp duplication, c. 431-454 dup24, also referred to as c. 428-451 dup24 in exon 2, 
resulting in expansion of a polyalanine (PolyA) tract from 12 to 20 alanines was first identified in 
individuals with NS-XLMR (Claes, Gu, Legius et al., 1996). This recurrent in-frame duplication is 
reported to account for about 6.6% of XLMR families and is the most common mutation in ARX 
seen in the majority of the syndromic forms (Mandel and Chelly, 2004). It has been 
recommended that males with NS-XLMR and S-XLMR who have tested negative for the FMR1 
expansion be tested for the 24 bp duplication mutation in the ARX gene, especially in the 
presence of dystonic hand movements, spasticity and epilepsy (Suri, 2005; De Souza Gestinari-
Duarte, Santos-Reboucas and Pimentel, 2006; Nawara, Szczaluba, Poirier et al., 2006). 
 
Disorders associated with brain malformations (XLAG, severe hydrocephalus, Proud syndrome) 
are reported to result from protein truncation mutations and missense mutations in the 
homeobox, whereas the non malformation phenotypes (ISSX, Partington syndrome, NS-XLMR) 
are associated with missense mutations outside the homeobox and expansion of the PolyA 
tracts (Kitamura et al., 2002; Suri 2005). 
 
Phenotypic heterogeneity within families has been seen with the 24 bp duplication mutation. 
(Bienvenu et al., 2002; Stromme et al., 2002). Epilepsy is in fact one of the most common 
symptoms experienced in families with mutations within ARX (Friocourt, Poirier, Rakic et al., 
2006). 
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1.7 AIMS OF THE STUDY 
The aim of this study was to investigate the contribution of different XLMR genes, particularly 
the FMR1, FMR2, XNP and ARX genes associated with NS-XLMR to XLMR in the South 
African population. Further, the study was extended to investigate some families with XLMR 
including a large family positive for the XLMR condition, fragile X MR syndrome and 3 families 
with XNP mutations in subjects with a clinical phenotype of ATR-X syndrome. 
 
 
 
1.8 OBJECTIVES OF THE STUDY 
 
 
 
1.8.1 FRAGILE X MR SYNDROME 
To undertake a retrospective analysis of fragile X MR syndrome referrals to the Division of 
Human Genetics Molecular Laboratory, NHLS to: 
1) Determine the frequency of fragile X MR syndrome due to FMR1 expansions in South 
African males with MR of unknown cause 
2) To investigate the distribution of all FMR1 CGG allele sizes in a random cohort of MR 
males 
 
 
1.8.2 FRAXE SYNDROME 
1) To optimize the PCR assay for FRAXE syndrome on the ABI Genetic Analyzer 
2) To validate the PCR assay by investigating Mendelian inheritance and transmission in 
normal controls 
3) To determine the frequency of FRAXE in FMR1 expansion negative South African males 
with MR of unknown cause 
4) To implement FMR2 mutation analysis as a routine diagnostic test in MR males if 
indicated 
5) To investigate the distribution of FMR2 GCC allele sizes in a random cohort of MR 
males 
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1.8.3 XNP 
1) To determine the frequency of XNP mutations in FMR1 expansion negative South 
African males with MR of unknown cause 
2) To implement XNP mutation analysis as a routine DNA diagnostic test if indicated 
 
 
 
1.8.4 ARX 
1) To determine the frequency of the common 24 bp duplication mutation in FMR1 negative 
South African males with MR of unknown cause 
2) To implement ARX mutation analysis as a routine DNA diagnostic test if indicated 
 
 
 
1.8.5 FMR1 POSITIVE FAMILY STUDY 
1) To determine the FMR1 (CGG)n repeat length in the available members of a fragile X 
MR syndrome positive family 
2) To perform haplotype analysis in this family using flanking markers 
3) To determine the haplotypes associated with the expansion in this family 
 
 
 
 
1.8.6 ATR-X SYNDROME FAMILY STUDIES 
1) To undertake diagnostic, carrier and prenatal testing for ATR-X syndrome in three South 
African White families 
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CHAPTER TWO 
2 SUBJECTS, MATERIALS AND METHODS 
 
This chapter describes the subjects used in this study and the techniques and methods of 
detection used for screening MR subjects at the 4 NS-XLMR gene loci, FMR1, FMR2, XNP and 
ARX. The patients and their families investigated for fragile X MR syndrome and ATR-X 
syndrome are also described. The methods including haplotype analysis is presented. All 
samples used in the study were coded to maintain confidentiality. 
 
SUBJECTS 
 
2.1 SUBJECTS FOR FRAGILE X A MR SYNDROME RETROSPECTIVE ANALYSIS 
A retrospective analysis was performed on 1736 probands referred to the Division of Human 
Genetics, NHLS over a period of 17 years (1992 to 2009) for routine fragile X MR syndrome 
testing to determine the frequency of FMR1 expansions. A cohort of 126 institutionalized 
patients was also included in this analysis. The distribution of FMR1 alleles was determined by 
testing a selected cohort of 1184 male subjects. These are described below and summarised in 
Table 2.1. 
 
2.1.1 Referrals for fragile X MR syndrome testing (1992-2009) 
A total of 1803 unrelated probands of all ethnic groups in South Africa were referred for fragile X 
MR syndrome testing between 1992 and June 2009. Analysis was done only on 1736 probands 
as no result was obtained on the remaining 67 probands due to poor DNA quality, test 
cancellation, incorrect blood tubes received, etc. The 1736 probands included 783 White, 617 
Black, 194 Coloured and 142 Indian probands. The probands had a suspected diagnosis of 
fragile X MR syndrome and were referred for diagnostic testing. In some cases, extended family 
members (mothers of affected individuals, siblings etc.) were referred to determine their FMR1 
status. In total, 2144 subjects were tested for the FMR1 expansion which consisted of 1736 
probands (1471 males and 265 females), 394 extended family members and 14 prenatal 
samples (chorionic villus sampling (CVS) or amniocentesis). 
 
Each patient/family was given a “FRAX” code, e.g. FRAX200. Most referrals were from the 
Assessment and Learning Clinics at the Johannesburg Hospital (TMI), Coronation Hospital and 
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Alexandra Clinic as well as from general practitioners, paediatricians and the medical 
geneticists at the Genetic Counselling Clinics (NHLS, previously SAIMR, Chris Hani 
Baragwanath Hospital, Donald Gordon Medical Centre, Coronation Hospital) and genetic 
nurses. A few cases were referred from doctors in private practice. These patients presented 
with developmental delay, MR of varying degrees and of unknown cause, or clinical features 
suggestive of fragile X MR syndrome. 
 
 
2.1.2 Institutionalized patients 
These subjects included a total of 158 institutionalized Black male subjects collected prior to 
1997 from 2 institutions caring for MR individuals - The Millsite institution which cared for 
severely retarded individuals and the Takalani institution which sheltered moderately to mildly 
developmentally delayed individuals, who were able to care for themselves, as well as 
individuals who came to the institution daily and worked in a sheltered employment structure. 
The samples consisted of blood taken from a total of 158 Black, unrelated male patients, 86 
from Millsite and 72 from Takalani. From this cohort, FMR1 results were only obtained on 126 
individuals (62 Millsite and 64 Takalani) as the remaining samples were inadequate or of poor 
DNA quality. Permission to test these individuals was given by the legal guardian of each 
individual. 
 
 
2.1.3 FMR1 expansion negative males for allele distribution analysis 
A total of 1184 unrelated MR male subjects were analysed to determine the distribution of non 
expanded FMR1 alleles in the different ethnic populations in South Africa. These subjects were 
selected from the cohort as they had successful PCR results at the FMR1 locus. These subjects 
included 1067 unrelated MR male patients of all ethnic groups selected from the cohort of 
referred probands (described in Section 2.1.1) and 117 institutionalized Black male individuals 
(described in Section 2.1.2) with non expansions for FMR1 or FMR2. 
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Table 2.1 Summary of subjects used for FMR1 retrospective analysis. 
SUBJECTS WHITE BLACK COLOURED INDIAN 
TOTAL 
TESTED 
FMR1 EXPANSION FREQUENCY  
Probands1 tested for fragile X MR 
syndrome 
     
Male probands 636 536 173 126 1471 
Female probands 147 81 21 16 265 
Sub total of probands tested 783 617 194 142 1736 
% of total probands tested (N=1736) 45.1% 35.5% 11.2% 8.2%  
Institutionalized patients (males) 0 126 0 0 126 
GRAND TOTAL OF PROBANDS 
TESTED 
783 743 194 142 1862 
% OF TOTAL PROBANDS TESTED 
(N=1862) 
42.1% 
(783/1862) 
39.9% 
(743/1862) 
10.4% 
(194/1862) 
7.6% 
(142/1862) 
 
      
FMR1 ALLELE DISRIBUTION IN NON 
EXPANSION SUBJECTS 
 
Males tested for FMR1 alleles 506 367 122 72 1067 
Institutionalized patients 0 117 0 0 117 
TOTAL MALE SUBJECTS TESTED 506 484 122 72 1184 
% OF TOTAL MALE SUBJECTS 
TESTED (N=1184) 
42.7% 
(506/1184) 
40.9% 
(484/1184) 
10.3% 
(122/1184) 
6.1% 
(72/1184)  
 
 
 
                                                 
1
 Proband refers to the individual per family that was tested 
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2.2 SUBJECTS FOR FRAGILE X E SYNDROME SCREENING 
A total of 1194 MR male subjects were tested for the FMR2 expansion. These subjects were 
selected from the cohort as they had successful PCR results at the FMR2 locus. These included 
1069 FMR1 negative MR male patients and 125 institutionalized males. These are described 
below and summarised in Table 2.2 which also characterizes the ethnicities tested.  
 
 
2.2.1 FMR1 expansion negative MR male subjects 
A total of 1069 FMR1 expansion negative MR male subjects of all ethnic groups (507 White, 
368 Black, 122 Coloured, 72 Indian) were tested for the FMR2 expansion. These were random 
DNA samples obtained from consecutive patient referrals to the Division of Human Genetics, 
Molecular Laboratory, NHLS from 1997 to 2009 for routine fragile X MR syndrome diagnostic 
testing (described in Section 2.1.1) with MR and who tested negative for the FMR1 expansion 
mutation. 
 
 
2.2.2 FMR1 expansion negative institutionalized patients 
These samples consisted of blood taken from a total of 158 Black, unrelated male subjects 
(described in Section 2.1.2). From this cohort, FMR2 results were only obtained on 125 
individuals (58 Millsite and 67 Takalani) as the remaining samples were inadequate or of poor 
DNA quality. 
 
 
 
Table 2.2 Summary of subjects used for FMR2 screening 
SUBJECTS WHITE BLACK COLOURED INDIAN TOTAL TESTED 
FMR1 expansion negative 
MR males 
507 368 122 72 1069 
FMR1 expansion negative 
institutionalized males 
0 125 0 0 125 
TOTAL SUBJECTS 507 493 122 72 1194 
% OF TOTAL SUBJECTS 42.5% 
(507/1194) 
41.3% 
(493/1194) 
10.2% 
(122/1194) 
6.0% 
(72/1194)  
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2.2.3 FMR2  expansion positive control used 
No known case of FRAXE syndrome has been reported in South Africa and thus positive 
controls with known repeat sizes were not available locally for the study. A DNA sample from a 
male with an FMR2 expansion was provided by Dr Steve Abbs (DNA Diagnostic Laboratory, 
Genetics Centre, Guy‟s Hospital, London). After validating the FMR1/FMR2 multiplex PCR 
assay, samples that gave consistent fragment sizes on repeated PCR amplification screens at 
both the FMR1 and FMR2 loci were used as controls. 
 
 
2.2.4 Subjects used for validation of FMR2 in the multiplex PCR 
The PCR was validated using 3 different groups of subjects which are described below. 
 
 
 
2.2.4.1 Patients with an FMR1 expansion 
A total of ten fragile X MR syndrome patients with FMR1 full mutations (8 males and 2 females) 
were used to validate the FRAXE PCR assay. These subjects are expected to have a normal 
FMR2 allele. The FMR1 status of these subjects was confirmed previously on Southern blot 
analysis. 
 
 
2.2.4.2 FMR1 expansion negative mother-child pairs 
A total of ten FMR1 expansion negative mother-child pairs were tested to track the inheritance 
and sizing consistency of FMR2 alleles over two generations. The mothers are expected to 
have two normal FMR2 alleles and their children are expected to have either one normal FMR2 
allele if male or 2 normal FMR2 alleles if female. The FMR1 status of these subjects was 
confirmed previously on Southern blot analysis. 
 
 
 
2.2.4.3 FMR1 full mutation positive family (FRAXA family 2) 
The FMR1/FMR2 multiplex PCR assay was also validated by tracking FMR2 alleles in an FMR1 
expansion positive family, consisting of 19 members, 3 of whom were affected with fragile X MR 
syndrome. The family pedigree is illustrated in the FRAXE/FMR2 results Chapter 4, Figure 4.1. 
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2.3 SUBJECTS FOR XNP SCREENING 
DNA from a total of 210 MR male subjects was tested for XNP mutations. These consisted of 
100 FMR1 expansion negative MR White subjects randomly selected from the cohort of 
consecutive patient referrals to the Division of Human Genetics described in Section 2.1.1 and 
110 of the 158 Black institutionalized male patients (48 from Millsite and 62 from Takalani), 
described above in Section 2.1.2 on whom results were obtained as the remaining samples 
were inadequate or of poor DNA quality. 
 
 
 
 
2.4 SUBJECTS FOR ARX SCREENING 
DNA from a total of 868 MR male subjects was tested for ARX mutations. These consisted of 
737 FMR1 expansion negative MR subjects (299 White, 282 Black, 98 Coloured, 58 Indian) 
randomly selected from the cohort of consecutive patient referrals to the Division of Human 
Genetics described in Section 2.1.1 and 131 of the 158 Black institutionalized male patients (64 
from Millsite and 67 from Takalani), described above in Section 2.1.2 on whom results were 
obtained as the remaining samples were inadequate or of poor DNA quality. 
 
 
 
 
2.5 FRAGILE X MR SYNDROME FAMILY STUDY (FRAXA FAMILY 1) 
A large White South African family (Laboratory family code: FRAX 551) that tested positive for 
fragile X MR syndrome was investigated and their FMR1 repeat lengths were determined to 
track the inheritance of FMR1 alleles in the family. Probands who tested positive for the FMR1 
expansion syndrome and extended family members whose mutation status was known from 
Southern blot analysis were studied. The family consisted of 24 members, including the 
probands. The family pedigree is shown in Figure 6.2. In an attempt to elucidate the FMR1 
status of the family members, an interesting finding was observed in two female siblings at the 
FMR1 locus. Haplotype analysis using intragenic markers, DXS548 and FRAXAC2 in the FMR1 
gene was used to track the disease chromosomes in the family. The markers used and the 
detection method are described in Section 2.12.7. 
 
 
   Chapter 2. Subjects, materials & methods 
44 
2.6 ATR-X SYNDROME FAMILY STUDIES 
A DNA investigation was undertaken on 3 individuals suspected of having ATR-X syndrome. 
These patients are described below. Consent (documented in the individual patient counselling 
files) was received from these families to use the photographs in this thesis. 
 
2.6.1 ATR-X Patient 1 (Laboratory Code: FRAX12) 
This White family presented to our Genetic Counselling Clinic with a family history suggestive of 
XLMR. The proband, patient 1, shown in the pedigree Figure 7.1 (II-5) presented with MR. He 
tested negative for FMR1 and FMR2 full expansion mutations. The parents of the proband, I-1 
and I-2 are healthy and have 2 healthy daughters. They have a healthy, non-identical male twin 
to patient 1. They had another son, II-2, who was severely mentally retarded and died of 
pneumonia at the age of 14 yrs. Figure 7.2.shows the clinical features of patient 1. 
 
 
 
2.6.2 ATR-X Patient 2 (Laboratory Code: FRAX549) 
This White family presented at the Genetic Counselling Clinic in Johannesburg with a severely 
delayed child. There was no family history of similarly affected children (see family pedigree in 
Figure 7.7). He tested negative for FMR1 and FMR2 full expansion mutations. Figure 7.8 shows 
the clinical features of Patient 2. 
 
 
 
2.6.3 ATR-X Patient 3 (Laboratory Code: ATRX-1 and FRAX1003) 
This is a White patient who presented at the Genetic Counselling Clinic in East London with 
global developmental delay and family history suggestive of XLMR. He tested negative for 
FMR1 and FMR2 full expansion mutations. The family pedigree and the clinical features are 
shown in Figure 7.12 and Figure 7.13 
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2.7 ETHICS APPROVAL 
Ethics approval for the use of diagnostic patient DNA samples (anonymised) for this study was 
obtained (Appendix A). The collection of blood samples from the institutionalized patients was 
initiated through Goldman‟s study (1997). An informed consent stating that samples could be 
used for research purposes was obtained for each of the institutionalized patients. The fragile X 
MR syndrome and ATR-X families were referred for diagnostic testing. Individual consent forms 
were obtained to include and present the family results in research and these are filed in each 
patient‟s file. The samples were all used in accordance with current regulation on the use of 
biological material.  
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MATERIALS AND METHODS 
The common methods used in the assays for FMR1, FMR2, XNP (ATRX) and ARX are 
presented in Sections 2.8, 2.9, 2.10 and 2.11 respectively and in Appendices C and D, followed 
by the detailed methodology used for each of the genes tested. All solutions used in this study 
can be found in Appendix B. 
 
 
2.8 DNA EXTRACTION 
There are a number of procedures available for extraction of nucleic acids, which are based on 
a variety of methods and principles. The majority of samples used in this study were extracted 
using a salting out procedure (Miller, Dykes and Polesky et al., 1988). The samples were 
extracted as part of the routine diagnostic procedure.  
 
A brief outline of the protocol is described. For a detailed protocol see Appendix C1. A 
commercial DNA extraction kit from Roche Diagnostics was used to extract DNA from samples 
where the initial volume of blood received was less than 1ml (see Appendix C2 for protocol). 
Whole blood (5-10ml in purple-top EDTA or yellow-top ACD vacutainer tubes) was used for the 
salting out method. The procedure involved washing and lysing the red blood cells with a 
detergent (sucrose Triton-X buffer). Through a series of washes and centrifugation steps, the 
red cell debris was removed and the white bloods cells (WBC) pelleted. Degradation of the 
proteins and the lipid bilayer of the WBC was achieved by an overnight incubation at 37 C with 
proteinase K, SDS and EDTA. The DNA was recovered with salt and absolute ethanol. The 
DNA was resuspended in an appropriate volume of Tris-EDTA (TE) buffer (usually 200 l to 
1000 l) and stored at 4 C until ready to use. 
 
 
2.9 DNA QUANTIFICATION 
The NanoDrop® ND-1000 spectrophotometer V3.3 is used to quantify DNA samples. The 
NanoDrop® ND-1000 is a 220-750 nm spectrophotometer based on fibre optic technology. One 
microlitre of DNA is dispensed onto the end of a receiving fibre optic cable. A second source 
fiber optic cable is brought into contact with the DNA, allowing the liquid to bridge the gap 
between the two fibre optic cables. This gap is controlled to both 1 mm and 0.2 mm paths. A 
pulsed xenon flash lamp provides the light source. A spectrometer with a CCD array analyzes 
the light passing through the sample and the data is displayed by specialised software. The 
absorbance at both 260nm (the wavelength at which DNA best absorbs light) and 280nm (the 
wavelength at which proteins best absorb light) are measured using the 1 mm and 0.2 mm path 
   Chapter 2. Subjects, materials & methods 
47 
lengths. The 260/280 ratio of sample absorbance represents the purity of DNA and RNA. A ratio 
of ~1.8 generally represents pure DNA. Any ratio lower than 1.8, indicates contaminants such 
as proteins and phenol, which absorb strongly at 280 nm. 
 
 
2.10 THE POLYMERASE CHAIN REACTION (PCR) 
The Polymerase Chain Reaction (PCR) (Mullis and Faloona, 1987) is a technique that involves 
the use of specific oligonucleotide primers (18 to 30 mer in length) that flank a DNA sequence of 
interest to amplify it. PCR was used to amplify FMR1 and FMR2 alleles, the hotspot region of 
the XNP gene and the ARX region containing the 24 bp duplication. A brief outline of this 
technique is presented in Appendix C3.  
 
 
2.11 AGAROSE GEL ELECTROPHORESIS (AGE) 
This technique is used to separate DNA molecules by base composition, size and conformation.  
AGE was used to verify the PCR product after amplifying the XNP hotspot region and the ARX 
gene. A brief outline of this technique is provided in Appendix C4.  
 
 
2.12 FRAGILE X TESTING PROCEDURE 
PCR analysis with primers was used to detect the size of the CGG/GCC repeat for FMR1 and 
FMR2. Southern blot analysis was used to determine the methylation status and to detect full 
expansions which were too large to be amplified by PCR analysis. The combination of FMR1 
and FMR2 in a multiplex PCR reaction and Southern blotting has a sensitivity of 99% for FMR1 
and FMR2 expansion detection. An overview of the strategy as used to test for FMR1 and 
FMR2 is shown in Figure 2.1, followed by a description of the methods used. 
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Figure 2.1 An overview of the procedure used for fragile X syndrome testing. 
The PCR is set up as a multiplex PCR reaction to detect FMR1 and FMR2 repeat and the flow diagram 
shows the steps followed for each locus. 
Allele detection on ABI 
Genetic Analyzer 
Male Female 
1 FMR1 or 
FMR2 allele 
 
2 alleles each of 
FMR1 and FMR2 
1 FMR1 and 1 
FMR2 allele 
No amplification of 
FMR1 or FMR2 
? FMR1 or FMR2 
Expansion 
No expansion ? Homozygous 
normal 
? Expansion 
carrier 
No further analysis 
Southern blot analysis 
Genomic DNA extraction 
DNA quantification 
(100ng/µl) 
Fragile X multiplex 
PCR assay 
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2.12.1 Methodology for FMR1/FMR2 multiplex PCR screen 
The PCR assay is a multiplex reaction, comprising of two primer sets (each labelled with a 
different fluorescent marker to distinguish the alleles at each locus), which simultaneously 
detects FMR1 and FMR2 alleles in a multiplex reaction.  
 
Genomic DNA was extracted (described in Section 2.8). Since the FMR1/FMR2 multiplex PCR 
assay is sensitive to DNA concentration, the extracted DNA was quantified to 100ng/ l, using 
spectrophotometric absorbance readings at a wavelength of 260nm (See Section 2.9). PCR 
across the CGG/GCC repeats was used as a first-line screen to determine the size of the 
normal and lower PM FMR1/FMR2 alleles. Alleles were detected on the ABI PRISMTM 377 or 
ABI 3130xl Genetic Analyzer.   
 
PCR does not amplify the FMR1 and FMR2 full expansions. Suspected expansions based on 
non-amplification (Figure 2.1) have to be confirmed on Southern blot analysis, which is able to 
detect normal, PMS and FMs reliably. PCR is problematic due to the high GC rich content which 
promotes formation of alternative and secondary DNA structures and the creation of polymerase 
pause sites which introduce errors during replication (Kang, Ohshima, Shimizu et al, 1995; cited 
in Khaniani, Kalitsis, Burgess et al., 2008). The FMR1 PCR optimised previously makes use of 
DMSO which is a co-solvent inhibiting secondary structure (Pomp and Medrano, 1991). 
 
For each locus, male patients with one normal-sized allele and female patients with two normal-
sized alleles were not analysed further as a diagnosis of fragile X syndrome or FRAXE 
syndrome due to an FMR1 or FMR2 expansion was excluded (see Figure 2.1). If non-
amplification was observed at any one locus in a male and if only one allele was observed in a 
female, Southern blot analysis was performed to identify a possible expansion of the repeat in 
the PM or FM range.  
 
PCR is capable of determining the exact CGG/GCC repeat number in the normal and lower PM 
range. This is an effective approach since a diagnosis is made in considerably less time than 
with Southern blotting. Southern-blot based detection does not provide a precise measure of the 
number of CGG/GCC repeats in either the FMR1 or FMR2 gene. The multiplex reaction controls 
for PCR failure at the FMR1 and FMR2 loci as each locus is used as an internal control for the 
other. The largest FMR1 allele detected by far with the PCR assay in this laboratory was 92 
CGG repeats, which was tested through the external quality assurance program from the 
College of American Pathologists. The largest FMR2 allele amplified was 33 GCC repeats. 
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2.12.2 Method for validating FMR2 in the multiplex PCR screen 
The FMR1 PCR validation was done previously as part of my Honours project (Essop, 1999). 
The FMR1/FMR2 multiplex PCR assay was validated at the FMR2 locus by performing 'blind' 
screens on 3 different groups of subjects, viz. patients with an FMR1 FM, mother-child pairs and 
a large FMR1 expansion positive family (FRAXA family 2), as described in Section 2.2.4. 
Consistent allele sizes observed on at least 2 PCR runs and the stable transmission of normal 
alleles across generations was used as the criteria for validation. 
 
Primer sequences for the FMR1/FMR2 multiplex PCR assay were provided by Dr Chris Mathew 
(Guy‟s Hospital, UK). The primers were synthesized locally by Roche Diagnostics. Each forward 
primer was labelled with a different ABI Prism fluorescent dye. Table 2.3 lists the primer 
sequences and the fluorescent dye used to label the primers.  
 
Table 2.3 Primers used in the FMR1/FMR2 multiplex PCR assay. 
 PRIMER SEQUENCE 
FRAXE 598 – F  5‟(FAM) –GCG AGG AAG CGG CGG CAG TGG CAC TGG G -3‟ 
FRAXE 603 –R 5‟ –CCT GTG AGT GTG TAA GTG TGT GAT GCT GCC G -3‟ 
FRAXA fxc – F 5‟(HEX) –GCT CAG CTC CGT TTC GGT TTC ACT TCC GGT –3‟ 
FRAXA fxf – R 5‟ – AGC CCC GCA CTT CCA CCA CCA GCT CCT CCA -3‟ 
(Wang, Green, Bobrow et al., 1995) 
 
 
2.12.3 FMR1/FMR2 multiplex PCR optimization 
The PCR optimisation for FMR2 proved to be rather challenging as the region is a G-C rich 
sequence due to the GCC triplet repeat. The presence of a high G+C content in the target DNA 
template presents difficulties for PCR amplification across GC rich triplet repeats. To obtain an 
accurate sizing of the GCC repeat, the conditions must be optimised sufficiently well. An 
accurate sizing is important and significant as it may give some indication of the stability of the 
repeat and hence the risk of expansion. This is subsequently helpful for appropriate genetic 
counselling. 
 
The incorporation of 7-deaza-guanosine triphosphate (deaza-dGTP), a nucleotide analogue, 
allows successful amplification of GC rich segments by destabilizing the secondary DNA 
structure (Innis, 1990; Wallace, 1996). A 3:1 ratio of deaza-dGTP:dGTP was used in the 
multiplex PCR assay. As deaza-dGTP interferes with EtBr intercalation, PCR products with high 
deaza-dGTP content do not stain efficiently with EtBr (Innis, 1990; Latimer and Lee, 1991) and 
were therefore not detected on an agarose gel prior to detection on the ABI Genetic Analyzer. 
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After a series of PCR optimization steps of different reaction conditions and PCR additives, the 
assay was optimized. A detailed worksheet for the PCR reaction is available in Appendix D1. 
The GCC repeats are determined using a formula based on primer length and distance. Allele 
sizes (bp) were rounded off to the nearest GCC repeat number (Appendix D1).  
 
2.12.4 Detection of FMR1/FMR2 alleles on ABI Genetic Analyzer 
Products were analyzed on the gel based ABI PRISMTM 377 Genetic Analyzer and more 
recently on the capillary based ABI 3130xl Genetic Analyzer (Applied Biosystems). PCR 
products were not detectable by EtBr staining. The labelled products emit fluorescence when 
excited by a laser. Each dye emits a fluorescent signal within a specific wavelength. The 
Genetic Analyzer uses the virtual filter sets to detect the dye that is within its wavelength range 
and displays a peak in the colour that it detects. 
 
On the ABI377 Genetic Analyzer, a polyacrylamide gel is cast, scanned, and prerun, and the 
GeneScan collection and analysis files are set up. The PCR products are mixed with a size 
standard, denatured, and loaded onto the prerun gel. After electrophoresis the collected data is 
transferred to a second Macintosh computer for analysis. A results file is generated and the PCR 
products are scored and verified. An overview of the procedure for automated genotyping of 
FMR1/FMR2 on the ABI377 Genetic Analyzer is shown in Figure 2.2. The protocol for 
microsatellite detection on the ABI3130xl Genetic Analyzer is described in Appendix C5. As the 
ABI377 Genetic Analyzer model has been discontinued, the PCR products are now detected on 
the ABI 3130xl Genetic Analyzer which does not require a gel to be cast. The 16-capillary 3130xl 
Genetic Analyzer (Applied Biosystems/Hitachi) allows simultaneous loading of 16 samples by 
electrokinetic injection (Huang, Quesada and Mathies, 1992). The capillaries are 0.1 mm in 
diameter and are filled with an electrolyte-type gel (performance optimized polymer - POP) that 
allows the separation of analytes based on their size to charge ratio. The DNA migrates through a 
process called multi-sheath flow. When the DNA migrates through the detection cell, light from a 
single laser source is split creating a dual beam that illuminates capillaries from both sides of the 
array. The fluorescent light emitted from each DNA fragment is collected, separated by wavelength 
and focused onto a charge-coupled device (CCD).  The data generated is transferred to a 
computer linked to the 3130xl Genetic Analyzer where the data is transformed into 
electropherograms by a program called Foundation Data Collection v3.0. A program called 
GeneMapper v4.0 is used to visualise and analyse microsatellite data. The protocol for 
microsatellite detection on the ABI3130xl Genetic Analyzer is described in Appendix C6.  
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Figure 2.2 Schematic diagram illustrating the procedure for automated genotyping of 
FMR1/FMR2 alleles on the ABI377 Genetic Analyzer. 
 
 
 
2.12.5 Expected FMR2 allele in males and females 
The number of alleles expected to amplify in the multiplex PCR assay in males and females are 
outlined below. A summary of the number of alleles expected from the FMR1/FMR2 multiplex 
PCR assay in individuals with different FMR2 genotypes is listed in Table 2.4. 
FMR1/FMR2 multiplex PCR 
Generate 
sample sheet 
Labelled PCR products 
Denature 
Detection on ABI 
Genetic Analyzer 
Assign gel 
file name 
Assign electrophoresis 
parameters 
Plate check 
Pre-run gel 
Analysis 
Save and file 
Genotyper 
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Cast polyacrylamide 
gel 
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Table 2.4 Summary of the number of FMR2 and FMR1 alleles observed using the multiplex 
FMR1/FMR2 multiplex PCR assay. 
FMR2 GENOTYPE 
FMR2 ALLELES 
OBSERVED ON PCR 
FMR1 ALLELES 
OBSERVED ON PCR 
MALE   
Normal (N) 1 1 
Carrier (E) 0 1 
Affected (EE) 0 1 
   
FEMALE   
Normal heterozygote (N/N) 2 1 or 2 
Normal homozygote (N/N) 1 1 or 2 
Carrier (N/E) 1 1 or 2 
Affected (N/EE) 1 1 or 2 
E/E 0 1 or 2 
EE/EE 0 1 or 2 
 
A normal male (N) is expected to generate one peak each at the FMR1 and FMR2 loci, 
representing one normal sized FMR2 GCC allele and one normal sized FMR1 CCG allele, as 
shown in Figure 2.3..  
 
 
A normal heterozygous female (N/N) is expected to generate two peaks each at the FMR1 and 
FMR2 loci, representing two normal sized FMR2 alleles and two normal sized FMR1 alleles, as 
shown in Figure 2.4. If only one allele is present at either locus, it could be interpreted either as 
a female homozygous for that allele, or the presence of second allele that is expanded, which 
could not be detected with the PCR assay. In normal heterozygous females there appears to be 
marked preferential amplification of the smaller allele relative to the larger allele. The greater the 
difference in size (in bp) observed between the two alleles, the greater the preferential 
amplification of the smaller sized allele.  
 
 
Non-amplification at either the FMR2 or FMR1 locus in a male implies a premutation (E) or a full 
mutation (EE), as the PCR technique cannot amplify such large fragment sizes as illustrated in 
Figure 2.5. These samples were further analysed by Southern blotting (described in section 
2.12.6).  
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Figure 2.3 Electropherogram of a male with an FMR2 allele in the normal range. 
The diagram shows one FMR2 allele of 332 bp, corresponding to 15 GCC repeats and one FMR1 allele of 
318 bp corresponding to a 33 CGG repeats, both within the normal range.  
 
 
 
Figure 2.4 Electropherogram of a female with two FMR2 alleles in the normal range.  
The diagram shows two FMR2 alleles of 332 bp (= 15 GCC repeats) and 335 bp (= 16 GCC repeats) in the 
normal range and two normal FMR1 alleles of 306 bp (= 29 CGG repeats) and 310 bp (= 30 CGG repeats) in 
the normal range. 
 
 
 
Figure 2.5 Electropherogram of a MALE displaying non amplification of the FMR2 allele, 
suggestive of an FMR2 expansion.  
The FAM-labelled (green) FMR1 allele is 306 bp, corresponding to 29 CGG repeats. The pattern shown at 
the FMR1 locus does not represent an allele but is a result of interference from the FMR2 repeat due to a 
matrix overlap. 
FMR2 (GCC) n 
FMR1 (CGG) n 
FMR2 (GCC) n 
FMR1 (CGG) n 
FMR2 (GCC) n 
FMR1 (CGG) n 
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2.12.6 Southern blotting 
Southern blotting is a technique that was developed by Southern in 1975. It is a commonly used 
method for the identification of specific DNA fragments that are complementary to a known DNA 
sequence.  Southern blot analysis was performed on male samples that failed to amplify on 
PCR analysis and on female samples with only one FMR2 or FMR1 allele detected.  
 
 
2.12.6.1 Restriction enzyme digestion of genomic DNA 
Genomic DNA (5-15ug) was digested with one or more restriction enzymes. A single digest 
using HindIII was performed for the detection of the FMR2 allele. A double digest was 
performed at 37 C for detection of the FMR1 allele, using a methylation sensitive enzyme, EclXI 
and EcoRI (Roche). The digest reaction was verified on a trial 0.8% gel to establish if complete 
digestion had occurred. The digested samples were loaded onto a 0.8% preparative Southern 
agarose gel and electrophoresed for ~24 hrs at 1.6 V/cm to resolve fragments sizes adequately. 
A photograph was taken of the Southern agarose gel. The digest reactions and worksheets for 
the FRAXE/FMR2 and FRAXA/FMR1 are shown in Appendix D2 and D3 respectively. 
 
 
2.12.6.2 Southern transfer 
The gel was denatured for ~30 min in an alkali solution and neutralised for a further 30 min in a 
neutralising solution (see Solutions in Appendix B). This was followed by soaking the gel in a 
solution of 20 x SSC for ~10 min. The blot was set up by placing the gel onto a wick draped in 
2xSSC. A Hybond nylon membrane (AEC-Amersham) was placed on top of the gel and filter 
papers and paper towels were stacked on top of this to allow for capillary action to move the 
DNA out of the gel and onto the membrane. This was allowed to blot for 2 nights after which the 
membrane was removed and baked for ~1 hr in an 80ºC oven to allow the DNA to fix to the 
membrane. 
 
 
2.12.6.3 Pre- and Post-hybridisation 
The membrane was pre-treated for ~1 hr with a pre-hybridisation solution (Church-Gilbert pre-
hybe buffer, Appendix B) which contained ready to use salmon sperm DNA (Roche). Twenty 
five nanograms of the probe was labelled with the radionuclide isotope 32PdCTP using the 
MegaprimeTM DNA Labelling Systems kit (from AEC-Amersham) according to manufacturer‟s 
instructions (refer to Appendix D4 for detailed labelling protocol). Hybridization was allowed to 
occur over 2 nights in a Hybaid rotisserie oven. Post hybridisation washes were performed with 
   Chapter 2. Subjects, materials & methods 
56 
2xSSC, 0.1%SDS for 10 min at room temperature (twice), 1xSSC, 0.1%SDS at 65 C for 20 min 
and three rinses at room temperature with 0.1xSSC. The blot was exposed to Hypersensitive X-
ray film (from AEC-Amersham) for at least 2 nights, after which the X-ray film was developed 
using an Axim developer.  
 
 
2.12.6.4 Probe preparation 
The insert (probe) is contained within a recombinant plasmid. The plasmid containing the probe 
had been transformed into dH5  competent cells using the method described by Chung, 
Niemala and Miller (1989). The culture media required for growth is LB broth containing the 
antibiotic ampicillin at standard concentrations (100 g/ml). The plasmid was extracted using the 
QIAGEN Plasmid Maxi Kit from QIAGEN (supplied by Southern Cross Biotechnology (Pty) Ltd - 
South Africa) as per manufacturer‟s instructions. The insert/probe was excised from the plasmid 
using a restriction endonuclease which flanks the insert. The probe was purified from a low-
melting-temperature agarose gel using QIAquick Gel Extraction Kit from QIAGEN as per 
manufacturer‟s instructions. 
 
 
a) FMR1 StB12.3 Probe preparation 
The membrane was probed with an α-32PdCTP labelled StB12.3 probe. The insert StB12.3 is 
contained within the recombinant pBluescript II KS plasmid. The plasmid containing the probe 
had been transformed into dH5  competent cells. The culture media required for growth is LB 
broth containing the antibiotic ampicillin at standard concentrations (100 g/ml). The plasmid 
was extracted using the QIAGEN Plasmid Maxi Kit from QIAGEN. The insert StB12.3 is 1.2 kb 
in size and was excised from the 2.9 kb plasmid using the restriction endonuclease PstI. 
StB12.3 detects a ~5.2 kb EcoRI fragment in Xq28 of the normal human X chromosome. Figure 
2.6 illustrates the restriction map of the FMR1 region. 
 
 
b) FMR2 OxE20 Probe preparation 
The membrane was hybridised with an α-32PdCTP labelled OxE20 probe using standard 
procedures (Rousseau et al., 1991).  The insert OxE20 probe was provided by Knight, SJL, 
Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, England. It is 
contained within the recombinant pBluescript plasmid. The plasmid containing the OxE20 probe 
had been transformed into dH5  competent cells. The culture media required for growth is LB 
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broth containing the antibiotic ampicillin at standard concentrations (100 g/ml). The insert 
OxE20 is ~800 bp in size and was excised from the plasmid using the restriction endonucleases 
EcoRI and EaGI (isoschizomer is EclXI). 
 
OxE20 detects a ~5.2 kb HindIII fragment in Xq28 of the normal human X chromosome 
(Biancalana et al., 1996). OxE20 lies ~600 bp distal to the GCC repeat and within the same 5.2 
kb HindIII fragment (Knight et al., 1994). A rare polymorphism of the HindIII site has been 
observed and this gives a fragment of ~6.4 kb which is unaltered through successive 
generations. A BamHI digest probed with OxE20 should enable the HindIII polymorphism to be 
delineated from a true FMR2 expansion (Knight et al., personal communication, 1994). 
Restriction mapping indicated that the OXE20 probe would not detect the mutation in EcoRI 
digests, since an EcoRI site separates the probe sequence from the GCC repeat (Biancalana et 
al., 1996). Figure 2.7 illustrates the restriction map of the FMR2 region. 
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Figure 2.6 This diagram represents a magnification of the 5‟ UTR of the FMR1 gene 
This gene is subjected to digestion by EcoRI and EclXI for Southern blot analyses. FMR segment includes 
both the CGG repeat (indicated by the orange inverted triangle), at the proximal portion of exon 1 and the 
CpG island (indicated by the red box) that is located 250 bp 5‟ to the CGG polymorphism. The ATG start site 
is downstream to the CGG polymorphism within exon 1. Restriction sites are indicated by vertical arrows. 
The StB12.3 probe hybridises to the distal portion of the CGG repeat, contained in the 2.8 kb fragment 
 
 
 
Figure 2.7 This diagram represents a magnification of the 5‟ UTR or promoter region of the 
FMR2 gene. 
The gene is subjected to digestion by HindIII for Southern blot analyses to detect the GCC expansion at 
FMR2. The exact location of the GCC repeat with respect to the transcription initiation site of the FMR2 gene 
is uncertain. Vertical arrows indicate restriction sites. The OxE20 probe hybridises adjacent to but on the 
same fragment as the GCC repeat, contained in the 5.2 kb fragment (modified from Knight et al, 1994). This 
FMR segment includes both the GCC repeat (indicated by the orange inverted triangle) and the CpG island 
(indicated by the red box). Restriction sites are indicated by vertical arrows. 
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2.12.7 Haplotype analysis in FMR1 expansion positive family (Family 1) 
Two intragenic markers, DXS548 and FRAXAC2, were used for haplotype construction in the 
FMR1 expansion positive family. The PCR protocol and detection method for each of these 
markers is described below. An overview of the procedure is shown in Figure 2.8. 
 
 
 
 
Figure 2.8 An overview of the procedure used for DXS548 and FRAXAC2 marker detection.
Genomic DNA 
PCR 
DXS548 
32P -dCTP 
FRAXAC2 
32 P -dATP 
Polyacrylamide gel 
electrophoresis 
192-210bp 147-161bp 
Expose to X-ray film 
Develop 
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2.12.7.1 DXS548 marker 
This is a polymorphic repeat marker, 150 kb centromeric to the CGG repeat (Riggins et al., 
1991). PCR was used to amplify the repeats and -32PdCTP radioactivity was incorporated into 
the PCR reaction to detect the repeat length and corresponding alleles on a vertical PAG with 
expected fragment sizes between 192 bp and 210 bp. Primer sequences for the DXS548 
marker were obtained from Verkerk et al., (1991). The PCR reaction and worksheet for the 
DXS548 PCR is shown in Appendix D5. 
 
 
2.12.7.2 FRAXAC2 marker 
The FRAXAC2 marker is an Alu-associated polymorphism located in intron 2 of the FMR1 gene, 
10 kb telomeric to the CGG repeat and contains three polymorphic (GT)x(AT)y(T)z subregions 
(Richards et al., 1991; Zhong, Dobkin and Brown et al., 1993). PCR was used to amplify the 
repeat and -32PdCTP radioactivity was incorporated into the PCR reaction to detect the alleles 
on a vertical PAG with expected fragment sizes between 147 bp and 161 bp. Primer FR (a) 
(also called PM151) was endlabelled prior to the PCR set up. This was performed using -
32PdATP as per protocol described by Sambrook, Fritsch, Maniatis et al. (1989). Primer 
sequences for the FRAXAC2 marker were obtained from Richards et al. (1991). Polynucleotide 
kinase was used to transfer -32PdATP to the 5‟ end of the primer. The endlabelling reaction and 
the PCR reaction are shown in Appendix D6. 
 
 
 
 
2.12.7.3 Methodology for DXS48 and FRAXAC2 marker detection 
Both the DXS548 and the FRAXAC2 markers are detected using vertical polyacrylamide gel 
electrophoresis. A mix of 3µl formamide loading dye and 2µl of the PCR product was made and 
denatured at 95 C for 2 min. The denatured sample was loaded on a 6% denaturing PAG and 
electrophoresed for 2-6 hrs at ~1500 V (20-25 mA). The gel was transferred from the glass 
plates onto filter paper (Whatman), covered with cling wrap and vacuum dried in a vacuum oven 
for ~30-60 min after which it was exposed to an X-ray film (Hyperfilm MP from Amersham) for 
~1 hr (FRAXAC2) to 24 hrs (DXS548). The X-ray film was developed using the X-ray developer 
machine (Axim). 
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2.13 XNP SCREENING 
Genomic DNA was extracted (see Section 2.8) and the 300 bp „hot-spot‟ region, where the 
majority of mutations are found (See Section 1.5.3) was sequenced using the ABI PRISMTM 377 
Genetic Analyzer to identify any pathogenic mutations described in Appendix C7. An overview 
of the screening protocol is shown in Figure 2.9. 
 
 
 
 
 
 
 
 
 
Figure 2.9 An overview of the procedure used for XNP mutation screening. 
Genomic DNA 
PCR 
Amplify exon 7 + flanking 
intronic boundaries 
Amplify 3‟ boundary of intron 7, exon 
8, intron 8 and 370bp of exon 9 
PCR (5‟Ci/5‟R primers) 
898bp product 
 
Check PCR product by 
agarose gel electrophoresis  
Analyze (DNA Star) 
Sequence (5‟Di primer)  
Check PCR product by 
agarose gel electrophoresis  
Sequence (5‟Ci primer)  Sequence (5‟R2 primer)  
PCR (5‟Di/5‟DRi primers) 
287bp product  
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2.13.1 XNP sequencing 
Two methods exist for rapid DNA sequencing, the chain termination method (Sanger, Nicklen 
and Coulson, 1977) and the chemical degradation method (Maxam and Gilbert, 1977) but the 
chain termination procedure is the method of choice for genome sequencing. This is a method 
in which the sequence of a ssDNA molecule is determined by enzymatic synthesis of 
complementary polynucleotide chains, these chains terminate at specific nucleotide positions. 
 
The PCR protocol for XNP sequencing was taken from Villard et al. (1999a). Two primer pairs 
were used to amplify and sequence the zinc finger coding region (hotspot) from the XNP 
transcript. For both primer pairs, PCR was performed on the GeneAmp 9700 cycler. Agarose 
gel electrophoresis with ethidium bromide (EtBr) fluorescence was used to verify the PCR 
products (see Section 2.11). A volume of 5 l PCR product was loaded on a 3% (for primer set 
5‟Di/5‟DRi) or 0.8% (for primer set 5‟Ci/5‟R) agarose gel. Unidirectional sequencing was 
performed for PCR product 1 using the forward primer 5‟Di and bidirectional sequencing was 
performed for PCR product 2 using primers 5‟Ci and 5„R2. This method of sequencing was 
found to be the most cost-effective option which allowed for sequencing of the entire region. A 
detailed worksheet for the PCR reaction and the amplified regions with primer sequences are 
shown in Appendix E1 and E2. 
 
DNA was sequenced using the dye terminator labelling method. With this method, each of the 
four dideoxy terminators (ddNTPs) is fluorescently labelled with a different fluorolabel. Thus the 
growing chain is simultaneously terminated and labelled with the dye that corresponds to that 
base. The reaction is carried out in a single tube and each reaction is loaded into just one lane 
of the polyacrylamide gel. The fluorescent detector can discriminate between the different labels 
and hence determine if each band represents an A, C, G, or T. The protocol for sequencing 
analysis on the ABI3130xl Genetic Analyzer is described in Appendix C8. 
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2.14 ARX GENE c. 431-454dup24 MUTATION SCREENING 
Genomic DNA was extracted (see Section 2.8) and the 24 bp duplication mutation in exon 2 of 
the ARX gene was screened using conventional agarose gel electrophoresis, followed by DNA 
sequencing if indicated. 
 
 
 
 
 
 
 
Figure 2.10 An overview of the procedure used for ARX mutation screening for the common 24 
bp duplication mutation (modified from Gronskov et al. 2004). 
Genomic DNA 
PCR 
(amplify exon 2) 
 
Check product  
(agarose gel electrophoresis) 
 
251bp  
24bp dup absent 
 
275bp 
24bp dup present 
 
Sequence 
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2.14.1 ARX PCR 
Primers amplifying the most common 24 bp duplication mutation in the ARX gene were obtained 
from Gronskov et al. (2004). The primer sequences were verified and validated using the In-
Silico PCR application from the UCSC genome browser website (2009). The primers amplified a 
fragment of 251 bp in an individual without the 24 bp duplication. The presence of the 
duplication resulted in an expected fragment size of 275 bp (see Figure 2.10).  
 
Gronskov et al. (2004) detected the amplified PCR fragment on the ABI310 Genetic Analyzer 
using a fluorescently labelled primer (ARX-2F). Due to the high GC-content of the ARX region, 
the primers (GC-content of 70%) and the existence of secondary structures, the laboratory was 
unable to optimize the assay using the method used by Gronskov et al (2004). Instead, a 
modified, simpler and cost effective approach was used in this study by using an unlabelled 
primer (ARX-2F) and agarose gel electrophoresis with ethidium bromide (EtBr) fluorescence to 
detect the amplified fragment. Any shift observed was sequenced using primer ARX-2F 
(Appendix F). The ARX-2R primer could not be used as the sequence was unreadable. A 
detailed worksheet for the PCR reaction showing primer sequences and the amplified region is 
available in Appendix F.  
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CHAPTER THREE 
3 FMR1 RESULTS AND DISCUSSION 
 
The Division of Human Genetics, Molecular Laboratory at the NHLS has over the past 13 years 
taken a keen interest in screening loci associated with XLMR with a view to incorporating 
common mutation testing into the routine diagnostic service. The FMR1 PCR assay was 
optimized as part of my Honours project (Essop, 1999) and is now routinely implemented as a 
first line diagnostic test for referrals for fragile X MR syndrome. 
 
 
3.1 RESULTS OF RETROSPECTIVE ANALYSIS OF FRAGILE X A MR SYNDROME 
REFERRALS 
A retrospective analysis was done on probands referred to the Division of Human Genetics for 
fragile X MR syndrome testing (described in Section 2.1) over a period of 14 years (1992 to 
June 2009). The results obtained from testing 1862 probands (1736 referred probands and 126 
institutionalized male subjects described in Section 2.2.2) are presented below.   
 
 
3.1.1 Frequency of full mutation in 1862 probands tested 
From a total of 1736 unrelated probands referred for routine fragile X MR syndrome testing, 108 
probands (6.2%) tested positive for the FMR1 full mutation (FM) (>200 CGG repeats). Of the 
126 institutionalized males tested, the FMR1 FM was detected in 9 subjects (7.1%). This gives a 
combined total of 117 positive probands identified in 1862 unrelated probands (6.3%). These 
consisted of 107 male (5.7%) and 10 female probands (0.5%) who were found to be positive for 
the FMR1 full mutation (FM).  
 
The cohort of subjects was classified into 4 different ethnic groups, White, Black, Coloured and 
Indian. The frequency of the FMR1 FM was determined in the total cohort of 1862 probands. 
The FMR1 FM was found in 46 (2.5%) Black, 38 (2.0%) White, 17 (0.9%) Coloured and 16 
(0.9%) Indian probands (summarised in Table 3.1). 
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The frequency of the FMR1 mutation was also determined within each ethnic group. From a 
total of 743 Black probands tested, 46 were found to have the FMR1 FM. This is a frequency of 
6.2% (46/743). Similarly, a frequency of 4.9% (38/783) was observed within the White probands 
tested, 8.8% (17/194) in the Coloured and 11.3% (16/142) in the Indian probands. 
 
 
3.1.2 Frequency of premutation and intermediate alleles in probands 
PMs (59-200 CGG repeats) accounted for 0.8% (14/1862) of total probands tested, ranging from 
0% to 1.4% in the different ethnic groups tested. A total frequency of 1.9% (34/1862) was observed 
for intermediate alleles (41-58 CGG repeats), ranging from 0.2% to 1.1% in the different ethnic 
groups tested (summarised in Table 3.1).  
 
 
3.1.3 Frequency of full and premutation in extended family members 
Of the 394 extended family members tested, a FM was found in 50 (25 males, 25 females) 
(12.7%) subjects and 54 (48 females, 6 males) were found to be PM and/or I carriers (13.7%). 
 
 
 
3.1.4 Outcomes of prenatal diagnostic testing 
A total of 14 prenatal tests (10 White, 4 Indian, 0 Black and 0 Coloured) were performed on 
CVS material or amniotic cells. Five of the 14 (36%) fetuses were found to have an FMR1 FM (4 
male fetuses with an EE and 1 female fetus with N/EE) and 9 fetuses (64%) were found to test 
negative for the FMR1 FM. 
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Table 3.1 Results obtained from screening subjects referred for fragile X MR syndrome testing 
 
FMR1 
GENOTYPE 
WHITE 
(n=783) 
BLACK 
(n=743) 
COLOURED 
(n=194) 
INDIAN 
(n=142) 
TOTAL NO. 
OF 
UNRELATED 
PROBANDS 
(n=1862) 
Full mutation (FM)       
Males EE 28 33 15 14 90 
Mosaic males 
E + EE 2 2 2 1 7 
EE + del 1 0 0 0 1 
Females N/EE 7 2 0 1 10 (0.5%) 
Total referred 
probands 
 38 37 17 16 108 
Institutionalized males EE 0 9 0 0 9 
GRAND TOTAL  38 46 17 16 117 
FREQUENCY OF FM IN 
ETHNIC GROUP 
 4.9% 
(38/783) 
6.2% 
(46/743) 
8.8% 
(17/194) 
11.3% 
(16/142) 
6.3% 
(117/1862) 
       
Premutation (PM)       
Males E 5 2 1 0 8 (0.4%) 
Females N/E 6 0 0 0 6 (0.3%) 
TOTAL  11 2 1 0 14 
% OF PM IN ETHNIC 
GROUP 
 1.4% 
(11/783) 
0.3% 
(2/743) 
0.5% 
(1/194) 
0% 
(0/142) 
0.8% 
(14/1862) 
       
Intermediate allele (I)       
Males I 14 5 3 3 25 (1.3%) 
Females N/I 6 3 0 0 9 (0.5%) 
TOTAL  20 8 3 3 34 
% OF I IN ETHNIC 
GROUP 
 2.6% 
(20/783) 
1.1% 
(8/743) 
1.6% 
(3/194) 
2.1% 
(3/142) 
1.9% 
(34/1862) 
       
Normal range       
Males N 586 494 152 108 1340 
Females N/N 128 76 21 15 240 
Institutionalised males N 0 117 0 0 117 
TOTAL  714 687 173 123 1697 
% OF N IN ETHNIC 
GROUP 
 91.2% 
(714/783) 
92.5% 
(687/743) 
89.2% 
(173/194) 
86.6% 
(123/142) 
91.1% 
(1697/1862) 
Probands referred for fragile X syndrome (1992 to June 2009), including institutionalized male subjects classified into 
their different ethnicities. 
CGG repeats sizes (GeneReviews website, 2009): 
EE (full expansion) = >200 
E (premutation) = 59-200 
I (intermediate/gray zone) = 41-58 
N (normal) = 5-40
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3.1.5 Results of distribution of alleles in FMR1 negative MR male subjects 
The distribution of FMR1 alleles detected in 1184 FMR1 expansion negative MR males 
(described in Sections 2.2.1 and 2.2.2) is shown in the histogram below in Figure 3.1. Figure 3.2 
illustrates the distribution of common FMR1 alleles in the different ethnic groups in this cohort.  
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Figure 3.1 Histogram showing the distribution of the FMR1 CGG repeat in 1184 MR males 
referred for fragile X MR syndrome testing. 
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Figure 3.2 Histogram showing the distribution of common FMR1 alleles in the 4 different ethnic 
groups and their frequencies within each ethnic group tested. 
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The distribution of the CGG repeat in 1184 FMR1 expansion negative MR subjects showed that 
the smallest FMR1 CGG repeat size detected was 11, while 75 was the largest allele detected 
on PCR analysis in this cohort (Figure 3.1). The most frequent repeat size observed in the total 
study cohort of 1184 FMR1 expansion negative MR males was 29 CGG repeats (32.6%), 
followed by 30 CGG repeat (27.2%) (Figure 3.1). Allele sizes 20, 23, 29, 30, 31 and 32 CGG 
repeats together accounted for the majority (82%) of alleles in the study population. The most 
common allele observed in the Black and Coloured population was 29 CGG repeats (41%) 
while 30 CGG repeats was common in the White population (31%) and Indian population (40%). 
The number of CGG alleles identified in each population group can be found in Appendix G. 
 
 
 
3.2 DISCUSSION OF RETROSPECTIVE ANALYSIS OF FRAGILE X A MR 
SYNDROME REFERRALS 
As part of an investigation on XLMR loci, this study undertook a retrospective review of all 
probands referred between 1992 to June 2009 to the Division of Human Genetics, NHLS for 
fragile X MR syndrome testing. This study is an extension of Goldman et al. (1997), with a focus 
on a larger cohort of probands in all South African ethnic populations. 
 
 
3.2.1 Frequency of full mutations 
The frequency of fragile X MR syndrome in MR cohorts varies worldwide with estimates 
reported to range from 0.5% to 5% and with the larger reliable studies reported to be between 
1% and 3% (Hofstee, Arinami and Hamaguchi, 1994; Mazurczak, Bocian, Milewski et al., 1996; 
Turner et al., 1996; Zhong, Ju, Xu et al., 1999; Biancalana et al., 2004).  
 
From a total cohort of 1862 probands tested for fragile X MR syndrome in this study, the FMR1 
full mutation was identified in 117 probands (5.7% male and 0.5% female probands). This 
represents a frequency of 6.3% (117/1862), which is higher than reported worldwide figures. A 
recent study undertaken in Iran showed that the frequency of FMR1 mutations was 6.3% 
(32/508 families) which is comparable to that found in our study (Pouya, Abedini, Mansoorian et 
al., 2009). 
 
The frequency of the FMR1 full mutation was further determined in each ethnic group. Fragile X 
MR syndrome was previously thought to be rare in the South African Black population. Goldman 
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et al. (1997) presented the first molecular evidence that fragile X MR syndrome occurs in the 
South African Black MR population with a frequency of 6.1% (9/148) and that it was severely 
underdiagnosed in the past due to ascertainment bias. This study reviewed a larger cohort of 
probands referred to the Division and a frequency of 6.2% (46/743) was observed in all Black 
subjects tested, which is comparable to that found in Goldman‟s study. It is noteworthy that this 
is higher than the frequency of 4.9% (38/783) observed within the White probands tested. This 
lends further support to the findings by Goldman et al. (1997) that fragile X MR syndrome is not 
rare in the SA Black population and that it may be a more common cause of MR than in Whites. 
 
The frequency of the full mutation in the Indian population was shown to occur at 11.3%, which 
is higher than the frequencies observed in the other ethnic groups (4.9% in Whites, 6.2% in 
Blacks and 8.8% in Coloureds). The majority of these Indian probands were referred from 
KwaZulu Natal, a region which has a large Indian population base. A possible explanation for 
this finding could be due to selection bias as testing is expensive and due to restrained health 
budgets, referrals may be limited to patients with a very high clinical suspicion of fragile X MR 
syndrome. Studies in the Indian population in the Indian subcontinent report on a frequency of 
approximately 7% for fragile X MR syndrome due to FMs (Chowdhury, Kabra, Sharma, et al., 
2006), lower than the frequency observed in this study but higher than worldwide figures. 
 
The frequency of the full mutation in the Coloured population was shown to occur at 8.8%, 
which is also higher than the frequency observed in the White and Black ethnic groups (4.9% in 
Whites, 6.2% in Blacks). This Coloured population in SA comprises of racially mixed individuals 
of African (Black), European (White) and Asian (Indian) origin.  
 
Cascade screening of extended family members detected an additional 50 subjects with the 
FMR1 FM (25 males, 25 females). As the FMR1 mutation is rarely a new mutation, cascade 
screening from the probands often detects other affected individuals in a family. 
 
 
 
3.2.2 Frequency of premutations and intermediate alleles 
The PM frequency in the total MR cohort detected in this study was 0.8% (14/1862) while the 
intermediate allele was observed at a frequency of 1.9% (34/1862). Both PMs and intermediate 
alleles were observed to occur at higher frequencies within the White MR population (1.4% and 
2.6% respectively) compared to the other MR populations tested in this study. Youings, Murray, 
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Dennis et al. (2000) was the first report to show a significant excess of intermediate alleles in 
special education needs‟ boys compared to normal controls.  
 
The PM is reported to occur in the general population at a frequency of 1 in 260 females (0.4%) 
and 1 in 800 (0.1%) males, evidently more common than fragile X MR syndrome (1 in 4000 
males) (Rousseau, Rouillard, Morel et al., 1995; Dombrowski, Levesque, Morel, et al., 2002; 
cited in Cornish, Turk and Hagerman, 2008). The frequency of PMs in the normal population 
was not determined as part of this study. A recent study in Israel performed on 40 000 women 
showed a PM carrier frequency of 1 in 154 and that there was no difference in the PM carrier 
frequency observed in women with or without a family history of MR. However, different ethnic 
groups are reported to have different prevalences, e.g. it is less common in Asian populations 
and more common in Mediterranean populations (reviewed in Brouwer et al., 2009b).  
 
Studies have shown the presence of neurobehavioural symptoms in children with PMs (Moore, 
Daly, Schmitz et al., 2004). A study by van Esch (2006) identified several boys who had PMs 
and presented with learning problems, developmental delay and/or autistic features. She 
identified four times more PMs in a cohort of MR boys younger than 16 years old who were 
referred for fragile X MR syndrome testing. This study did not review the age of the subjects 
tested and a comparison to van Esch‟s study can not be made. However, there have been a 
number of studies that have refuted the clinical significance of PMs (Mazzocco, Sonna, Teisl et 
al., 1997; Mornet, Chateau, Simon-Bouy, et al., 1998; Sherman, Marsteller, Abramowitz et al., 
2002). 
 
An average of 3 (394/117) extended family members per positive family was tested. Of the 394 
extended family members tested, 54 (48 females, 6 males) were PM and/or I carriers (13.7%). 
This group included mothers of affected subjects who are expected to be carriers of FMR1 
expansions. There is a need for increased cascade testing of families to identify at-risk 
members and for early diagnosis in affected members. 
 
 
 
 
 
 
   Chapter 3. FMR1 results and discussion 
72 
3.3 DISCUSSION OF DISTRIBUTION OF ALLELES IN FMR1 NEGATIVE MR MALE 
SUBJECTS 
The investigation of the normal allele distribution of the FMR1 CGG repeat in non expansion MR 
males was assessed. This is an extension of the study undertaken by Goldman et al. (1997). 
The allele distribution is comparable with other studies in which CGG repeat sizes of 28, 29 and 
30 (shown in Figure 3.1) were found to be most common in different populations (Fu et al. 1991; 
Snow, Doud, Hagerman et al., 1993; Reiss et al., 1994; Goldman et al., 1997). The allele 
distribution in the normal range in non FMR1 expansion males is not expected to be significantly 
different to the distribution in a random population as the normal allele is not associated with 
MR. 
 
 
3.3.1 Distribution of FMR1 alleles in different ethnic groups 
The cohort in this study was further classified into different ethnic groups. Goldman et al. (1997) 
investigated a cohort of South African individuals and showed that the commonest allele 
identified was 28 CGG repeats (32%) in Negroids (Blacks). In this study the most common allele 
observed in the Black population was 29 CGG repeats (40.5%), one repeat different to that 
observed by Goldman et al. (1997).  This minor difference could be due to less accurate sizing 
of CGG repeats previously as newer techniques have allowed for more accurate sizing. Further, 
a larger cohort of subjects was tested which gives a lower error rate. Hence this study is most 
likely to reflect the accurate size. It is worth noting that allele sizes scored using this PCR assay 
corroborate with the mean size of alleles as determined by the College of American Pathologists 
external quality assurance program which the laboratory participates in biannually. 
 
Goldman et al. (1997) reported on 30 CGG repeats as the common allele in the San and 
Caucasoids (34% and 39% respectively). In this study, the most common allele observed in the 
White population was 30 CGG repeats (31%) which correlates with the findings from the 
Goldman study. 
 
 
3.4 SUMMARY 
The frequency of fragile X MR syndrome in the referred SA MR population was retrospectively 
reviewed. A frequency of 6.3% was observed, which is consistent with previously reported 
figures in SA but higher than reported worldwide figures. The analysis of non expansion FMR1 
alleles in MR males shows a similar distribution between the different SA ethnic groups and 
compares well with other reported studies. This study reinforces the presence of fragile X MR 
   Chapter 3. FMR1 results and discussion 
73 
syndrome in the SA Black population. The frequency of fragile X MR syndrome observed in the 
Black population and the high frequency in the Indian and Coloured populations may be due to 
ascertainment bias. With a high pick-up rate of 6.3%, it reinforces and supports the already 
available diagnostic test offered. Further, it is a relatively simple test to perform and normal 
alleles are easily detected and the majority of the subjects are excluded on PCR analysis 
although homozygous normal females and males with an FMR1 expansion need to have 
Southern blot analysis done. 
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CHAPTER FOUR 
4 FRAXE/FMR2 RESULTS AND DISCUSSION 
 
This project investigated the frequency of the FMR2 expansion causing FRAXE syndrome, 
together with other XLMR genes, XNP and ARX in FMR1 negative South African males with MR 
of unknown cause. The FRAXE/FMR2 results are presented and discussed in this chapter.  
 
 
4.1 RESULTS OF VALIDATION OF FMR2 IN THE MULTIPLEX PCR ASSAY 
One of the main aims of this project was to assess the frequency of the FMR2 expansion 
mutation in MR males in the South African population. A multiplex PCR was developed, which 
could simultaneously detect FMR2 and FMR1 repeat sizes in the large numbers of routine 
referrals for fragile X MR syndrome to the Human Genetics Division at the NHLS. Each primer 
in the multiplex PCR reaction was labelled with a different fluorescent dye so that detection on 
the Genetic Analyzer was made possible. All samples were expected to produce a product from 
either the FMR1 or the FMR2 locus or both, thus controlling for failure of the PCR reaction. 
Peaks were generated and analysed with the GeneScan and GenotyperTM software (ABI/Perkin 
Elmer) described in Appendix C7.  
 
To validate the multiplex assay and in particular the FMR2 alleles, subjects with an FMR1 
expansion were tested. In addition, mother-child pairs were tested and an FMR1 expansion 
positive fragile X family was used to demonstrate stable transmission of FMR2 alleles across 
generations (FRAXA family 2). These results are presented below. The results obtained from 
screening FMR1 expansion negative referral patients and MR males from two institutions are 
also shown. 
 
4.1.1 Screening patients with an FMR1 expansion 
Ten patients with an FMR1 expansion (FM) were used to validate the consistency of 
amplification of FMR2 alleles in the multiplex PCR assay. The FMR2 allele is expected to 
amplify in patients with an FMR1 expansion. As expected, all 8 FMR1 expansion positive males 
showed non-amplification of the FMR1 allele and amplification of the FMR2 normal allele. The 2 
females with an FMR1 FM showed amplification of one FMR1 allele and two FMR2 alleles. 
These results are summarised in Table 4.1. 
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Table 4.1 Summary of FMR2 results obtained from testing 10 FMR1 expansion positive patients 
with the multiplex FMR1/FMR2 multiplex PCR assay.   
SAMPLE LAB CODE GENDER 
FMR1 
GENOTYPE 
FMR2 
(GCC)n 
1.  FRAX728 M EE 16 
2.  FRAX778 F 30/EE 19/20 
3.  FRAX809 M EE 15 
4.  FRAX88 M EE 17 
5.  FRAX832 F 30/E 15/18 
6.  FRAX854 M EE 10 
7.  FRAX866 M EE 15 
8.  FRAX966 M EE 18 
9.  FRAX974 M EE 19 
10.  FRAX993 M EE 17 
“EE” indicates a full mutation at the FMR1 locus 
 
4.1.2 Mother-child pairs 
Ten normal mother-child (male and female) pairs were also used to validate the PCR assay. 
The samples were amplified at the FMR2 and FMR1 loci and the alleles generated were tracked 
from mother to child. The child was expected to inherit one stable allele (unchanged) from the 
mother. The allele that was inherited from the mother to the child is highlighted in blue in Table 
4.2 which summarises the results obtained. 
 
 
 
Table 4.2 Summary of results obtained from testing mother-child pairs for FMR2 alleles using 
the multiplex FMR1/FMR2 multiplex PCR assay. 
The FMR2 allele passed on by the mother and inherited by the child is highlighted in blue 
 
 
SAMPLE 
LAB 
CODE 
FMR2 ALLELE(S) 
IN MOTHER 
FMR2 ALELLE(S) 
INHERITED BY CHILD 
GENDER OF CHILD 
1.  FRAX60
9 
15/? 15 M 
2.  FRAX63
4 
17/18 18/26 F 
3.  FRAX64
8 
16/21 17/21 F 
4.  FRAX76
6 
16/20 16 M 
5.  FRAX76
8 
18/29 18 M 
6.  FRAX83
2 
15/18 15 M 
7.  FRAX89
6 
15/20 15 M 
8.  FRAX61
4 
15/? 15/? F 
9.  FRAX65
3 
18/18 18 M 
10.  FRAX66
0 
13/15 15 M 
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Stable inheritance of alleles was observed in 100% of mother to child pairs. All transmissions of 
normal alleles were consistent with Mendelian inheritance. This consistency in allele inheritance 
was sufficient to validate the PCR assay. The PCR was repeated and the results were 100% 
reproducible. 
 
 
4.1.3 FMR1 expansion positive family (FRAXA family 2) 
To further validate the PCR assay, the transmission of FMR2 alleles across generations was 
assessed in a family. Nineteen members from an FMR1 expansion positive family were tested 
to track the FMR2 allele. The pedigree with the FMR2 allele amplified is shown in Figure 4.1. As 
expected, Mendelian inheritance of FMR2 alleles was observed in all 19 members of the family, 
further validating FMR2 in the multiplex PCR assay. The FMR1 allele was used as a linked 
marker which assisted in determining the phase of alleles. The FMR1 expansion in this family 
tracks with allele 18 at the FMR2 locus. 
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Figure 4.1 Pedigree of FMR1 expansion positive family (Family 2) tested for the FMR2 GCC 
repeat.  
 
The FMR2 allele was tracked in the family as part of the FMR1/FMR2 multiplex PCR validation process. The 
FMR1 genotype is indicated below each of the members tested. „N‟ represents a normal FMR1 allele, „E‟ an 
allele in the premutation range and „EE‟ a full expansion. The FMR2 GCC repeat size is indicated below 
each of the 19 members tested. 
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4.2 RESULTS OF SUBJECTS SCREENED FOR FMR2 
After validating and assessing the reliability and reproducibility of the FMR1/FMR2 PCR assay, 
1194 FMR1 negative MR patients (ranging from mild to severe) were screened for FRAXE 
syndrome. None of the subjects tested were found to have the FMR2 expansion mutation, 
confirming the rarity of FRAXE syndrome. There was a suspicion of an FMR2 expansion in 2 
patients from the cohort as the FMR2 allele failed to amplify after several attempts on PCR 
analysis in the mutiplex reaction. Southern blotting (discussed in Section 2.12.6) was performed 
and the results are presented below. The distribution of FMR2 non expanded alleles in the 1194 
MR male subjects screened is also described below. 
 
4.2.1 FMR2 Southern blot result 
Two samples from the cohort of institutionalised males repeatedly failed to amplify at the FMR2 
locus on PCR analysis, suggesting a possible FMR2 expansion since the FMR1 internal control 
had amplified at each attempt. Southern blotting was performed to clarify the result. In addition, 
three FMR1 negative MR males were found to have an allele of 33 FMR2 repeats in the gray 
range. Since the amplitude of the peaks was low on PCR relative to control samples, Southern 
blotting was performed to confirm this result. 
 
On Southern blot analysis, using the OXE20 probe, a normal male and female would be 
expected to show a 5.2 kb band, corresponding to X chromosomes with GCC repeats in the 
normal range. A carrier female is expected to show two fragments, corresponding to the normal 
5.2 kb fragment and one of increased molecular weight. A summary of expected fragments after 
Southern blotting is shown in Appendix D2. 
 
Southern blots of HindIII-digested genomic DNA from these 5 individuals all showed a normal 
fragment of 5.2 kb. The autoradiograph of the result is shown in Figure 4.2. The non 
amplification observed on PCR analysis in the two samples of institutionalized males could have 
resulted due to poor DNA quality or some factor preventing amplification at the FMR2 locus, 
since the FMR1 allele had amplified at each attempt. This confirms that the FMR2 GCC repeat 
expansion is not causative of the non amplification observed on PCR analysis in these subjects. 
A positive control should always be included in a PCR reaction and on Southern blotting. This 
also emphasizes the importance of a follow-up test using Southern blotting to confirm whether 
non-amplification is a result of an expansion. 
 
The FMR2 expansion positive male control sample (Section 2.2.3) did not amplify as expected 
on PCR analysis due to the presence of the large expanded GCC repeat. The expanded 
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fragment could not be sized accurately on the blot since the 1 kb commercial ladder was faintly 
visible on the X-ray film but was estimated to have >280-300 expanded GCC repeats. As shown 
in Figure 2.7, the OxE20 detects a ~5.2 kb HindIII fragment in Xq28 of the normal human X 
chromosome and a large amplified fragment of >5.2 kb.  
 
 
 
 
 
Figure 4.2 FMR2 autoradiograph produced by probing Southern blots from HindIII digests with 
the OxE20 probe. 
Lanes 1, 2 and 3 are males who were shown to have 33 FMR2 GCC repeats on PCR analysis. No 
expansion is seen on Southern blot analysis (except the sample in Lane 2 which had no result due to poor 
DNA quality). Lanes 4 and 5 are two males with normal FMR1 alleles and who failed to amplify the FMR2 
allele on PCR after several attempts. A normal-sized FMR2 fragment with no expansion is seen on Southern 
blot analysis thus excluding FRAXE syndrome. Lane 6 is a normal female (note the active X chromosome 
and the lyonized, inactive X chromosome are indistinguishable unless subjected to digestion with a 
methylation sensitive enzyme. Lane 7 is a positive control sample of a male with an FMR2 expansion 
Lane 8 is a 1 kb DNA commercial ladder. 
1 2 3 4 5 6 7 8 
FRAXE EXPANSION 
NORMAL 5.2kb ACTIVE 
X CHROMOSOME 
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4.2.2 FMR2 allele distribution in FMR1 expansion negative male subjects 
The distribution of normal alleles observed in the cohort of 1194 male patients (1069 FMR1 
expansion negative MR patients and 125 FMR1 expansion negative institutionalized patients) of 
all ethnic groups (described in Section 2.1) was determined. The total distribution of FMR2 allele 
sizes in the 1194 MR male study population ranged from 5 to 33. The modal number of 15 GCC 
repeats was observed in 500 males (41.9%). The second most common allele in the study 
population was 16 GCC repeats observed in 115 males (9.6%), followed by 14 repeats (9.4%). 
 
4.2.3 FMR2 allele distribution in ethnic groups tested 
The cohort of FMR1 expansion negative MR male subjects tested for FMR2 comprised all 
ethnic groups. The number of GCC alleles identified in each population group can be found in 
Appendix H. The distribution of FMR2 alleles identified in each ethnic group is shown in Figure 
4.3. The modal number of 15 FMR2 (GCC)n repeats is evident in each of the 4 different ethnic 
groups, observed at 34.1% (173/507) in Whites, 51.7% (255/493) in Blacks, 36.9% (45/122) in 
Coloureds and 37.5% (27/72) in Indians. The distribution of common FMR2 alleles identified in 
each ethnic group is shown in Figure 4.4. 
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Figure 4.3 Histogram showing the distribution of FMR2 GCC repeats in the total cohort of 1194 
FMR1 negative MR male patients tested, classified into 4 different ethnic groups. 
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Figure 4.4 Histogram showing the common FMR2 GCC repeats and its frequency within each 
ethnic group tested 
 
 
4.2.4 FMR2 allele distribution classified into different allele categories 
To determine the frequency of alleles in the FMR2 repeat ranges and assess whether it was 
significantly different between the different ethnic populations, allele sizes were grouped into 5 
categories, Normal rare (<11 repeats), Normal common (11-25 repeats), intermediate (26-30 
repeats), gray zone (31-60 repeats), premutation (61-200 repeats) and full mutation (>200 
repeats).  The distribution of FMR2 alleles grouped into these categories in the 1194 MR male 
subjects tested is shown in Table 4.3.  
 
 
Table 4.3 Distribution of FMR2 alleles in MR males, grouped into 5 different categories and 
further classified into different ethnic groups. 
CATEGORY 
FMR2 
REPEATS 
WHITE BLACK COLOURED INDIAN 
Normal rare <11 7 1.4% 20 4.1% 1 0.8% 1 1.4% 
Normal common 11-25 480 94.7% 466 94.5% 120 98.4% 71 98.6% 
Intermediate 26-30 19 3.7% 6 1.2% 0 0.0% 0 0.0% 
Gray zone 31-60 1 0.2% 1 0.2% 1 0.8% 0 0.0% 
Premutation 61-200 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Full mutation >200 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
TOTAL  507 100.0% 493 100.0% 122 100.0% 72 100.0% 
The majority of alleles in each of the ethnic groups were found in the 11-25 FMR2 repeat group, 
classified as the normal common group (94.7% in Whites, 94.5% in Blacks, 98.4% in Coloureds 
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and 98.6% in Indians). Statistical analysis was performed using Pearson‟s Chi-square (χ2) test 
to compare the distribution of the different categories between the different ethnic populations. 
A highly significant difference (p value = 0.0019) was observed when the category distribution of 
the White population was compared with the Black population. There was no significant 
difference observed between the category distribution of White vs. Coloured (p=0.1959), White 
vs. Indian (p=0.2296), Black vs. Coloured (p=0.1806), Black vs. Indian (p=0.311) and Coloured 
vs. Indian (p=0.6932). 
 
4.2.5 Distribution of FMR2 alleles in institutionalized subjects 
Holden, Julien-Inalsingh, Chalifoux et al. (1996a) undertook testing in institutionalized males in 
Ontario, Canada. A total of 397 individuals from 2 institutions (61.1% being severely to 
profoundly affected), all of whom were negative for the FMR1 expansion were tested for the 
FMR2 expansion. The distribution of FMR2 GCC repeat numbers ranged from 5-38 and one 
profoundly retarded male was found to have a deletion of about 40 bp. These results are shown 
in Table 4.4 and a comparison is made with the distribution found in the 125 institutionalized MR 
males (described in Section 2.2.2) tested in this study.  
 
Table 4.4 A comparison of FMR2 alleles in institutionalized MR male individuals. 
FMR2 ALLELE 
RANGE 
HOLDEN STUDY 
(1996a) 
THIS STUDY 
(INSTITIONALIZED MALES) 
5-9 0 1 (0.8%) 
10-14 28 (5.6%) 33 (26.4%) 
15-19 366 (73.8%) 82 (65.6%) 
20-24 74 (14.9%) 9 (7.2%) 
25-29 20 (4.0%) 0 
30-38 5 (1.0%) 0 
>38 0 0 
 
 
Statistical analysis using Fisher‟s exact test and Pearson‟s Chi-square test showed that there 
was a highly significant difference between the distributions of FMR2 alleles in the Holden study 
cohort and this study cohort of institutionalized MR males, with a p value of 2.176e-10 and 
1.629e-12 respectively.  
 
 
4.3 DISCUSSION OF VALIDATION OF THE FMR2 MULTIPLEX PCR ASSAY 
The PCR assay can be used as an initial screen to exclude an FMR2 expansion by 
demonstrating the presence of a single allele in the normal range in males or heterozygosity 
within the normal range in females. The limitation with this PCR assay is that it does not 
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distinguish between a female who is truly homozygous at the FMR2 locus and a carrier and 
affected female, who would have one normal sized allele and a second pre- or full mutation 
sized allele not amplified by PCR. 
 
Normal-full mutation FMR2 mosaics may give false negative results (Nolin, Glicksman, Houck et 
al., 1994). PCR is sensitive enough to preferentially amplify the normal alleles in mosaic males 
even though they may be present in a low percentage of cells. In order to eliminate the small 
possibility of mosaicism, it is essential to screen all samples with a family history of the disease 
or a very strong clinical suspicion by Southern blotting. The absence of PCR amplification 
should never be interpreted as confirming the presence of a full mutation, but confirmation by 
Southern blot analysis should always be carried out. This is also essential for the diagnosis of 
female carriers. 
 
 
4.4 DISCUSSION OF SUBJECTS SCREENED FOR FMR2 
This is the first study conducted on South African males with MR which provides information on 
the range of the FMR2 GCC repeat alleles identified.  
 
4.4.1 FRAXE syndrome prevalence 
A total of 1194 male subjects who tested negative for the FMR1 expansion were screened for 
FRAXE syndrome. None of these patients were found to have a large FMR2 expansion. The 
data obtained in this study suggest that either FRAXE syndrome is very rare or that it is 
associated with a phenotype not represented in the subjects tested. The latter is unlikely as the 
cohort of individuals tested comprised of patients who were originally referred for fragile X MR 
syndrome testing and presented with a range of intellectual or behavioural problems. Thus this 
population is expected to include a significant number of mild MR and would be representative 
as FMR2 is associated with mild MR (Gecz, 2000). 
  
This study is comparable to a number of studies (summarized in Table 4.5) in which FRAXE 
syndrome was found to be extremely rare. Gecz (2000) in his review mentions that FRAXE 
syndrome has an estimated population prevalence of 1 in 23 500. This frequency is based on 2 
large population based studies undertaken on special education needs cases in an attempt to 
estimate FMR2 full mutations. Crawford et al. (1999) found no FMR2 expansion among a cohort 
of White and African American subjects (in Atlanta, USA) and Youings et al. (2000) found 1 
FRAXE syndrome positive subject among 3731 MR boys. As a result, the authors suggested 
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that routine FRAXE screening was not warranted due to the rarity of the FMR2 expansion 
mutation.  
 
Other smaller studies undertaken worldwide in different ethnic populations also report on the 
rarity of FRAXE syndrome. A study undertaken in Germany by Holinski-Feder, Chahrokh-
Zadeh, Jedele et al. (1996) reports on FMR1 and FMR2 screening performed in 737 patients 
(451 MR males and 276 females who were either MR or 1st degree relatives of MR males). 
None of the patients tested positive for an FMR2 expansion. As a result of this finding and the 
low prevalence of FRAXE syndrome reported in the literature, the authors recommended 
against routine testing for FMR2 but suggested follow-up testing only in selected fragile X MR 
syndrome negative subjects. Routine FMR2 testing was subsequently discontinued in their 
laboratory. 
 
The FRAXE screen undertaken in Greece by Patsalis, Sismani, Hettinger et al. (1999) identified 
no FMR2 FM in 611 male subjects from a cohort of 866 individuals tested. This study further 
indicates that FRAXE syndrome is not a common aetiological factor among MR males, or FMR1 
expansion negative males. 
 
In 2002, Pandey, Phadke and Mittal et al. studied 146 Indian patients (118 males, 28 females) 
with unexplained MR. Three males tested positive for the FMR1 expansion and no patients 
were found to have the FMR2 expansion. Chowdhury et al. (2006) found no cases of FRAXE 
syndrome in 294 Indian subjects with idiopathic MR.  
 
Lesca, Biancalana, Brunel et al. (2003) reported on a French family with 3 MR individuals 
having the FMR2 expansion. Russo, Selicorni, Bedeschi et al. (1998) identified two Italian 
families (4 FRAXE patients with moderate MR) that had a FMR2 expansion. 
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Table 4.5 FRAXE syndrome screening studies and cases identified 
AUTHOR YEAR POPULATION SCREEN FOR 
GCC 
ALLELE 
RANGE 
NO. OF 
INDIV 
TESTED  
FMR2 
FM 
Wang 1993 UK FRAXA/FRAXE NA 525 1 
Allingham-
Hawkins 
1995 Canada FRAXE 7-35 300 None 
Chen 1995 Taiwan FRAXA/FRAXE NA 273 1 
Biancalana 1996 France FRAXE NA NA 3 
Holden 1996 USA FRAXE 5-38 397 None* 
Holinski-Feder 1996 Germany FRAXE NA 737 None 
Meadows 1996 USA FRAXE 3-35 462 None 
Murray 1996 UK FRAXA/FRAXE 4-39,87 760 None 
Zhong 1996 US, China, 
Finland 
FRAXE 4-39 665  None 
Brown 1997 USA FRAXA/FRAXE 3-42 953 None* 
Mazzocco 1997 USA FMR1/FMR2# NA 1014 None 
Mila 1997 Spain FMR1/FMR2# NA 222 1 
Chan 1998 China FRAXA/FRAXE NA 73 None 
Mazzocco 1998 USA FMR1/FMR2# 1-43, 66 534 None* 
Russo 1998 Italian    4 
Crawford 1999 USA FRAXA/FRAXE 7-54 4779 None 
Patsalis 1999 Greece and 
Cyprus 
FRAXA/FRAXE 7-30 866 
 
None 
Youings 2000  FRAXA/FRAXE  3731 1 
Pandey 2002 Indian FRAXA/FRAXE 13-21 146 None 
Lesca 2003 France FRAXA/FRAXE NA  3 
Chowdhury 2006 Indian FRAXA/FRAXE  294 None 
This study 2009 South Africa FRAXA/FRAXE 5-33 1194 None 
(modified from Gecz, 2000) 
*, small alleles indicating deletions within and /or around (GCC)n were found 
 including females 
 including known FMR1 full mutations 
FM, Full mutation 
NA, Data not available 
 
 
 
The results obtained indicate that FRAXE syndrome is rare in South Africa, consistent with 
worldwide reports and therefore not included in routine testing at the Division of Human 
Genetics, NHLS, Johannesburg. 
 
4.4.2 Distribution of normal FMR2 alleles 
A total of 1194 males with MR were screened for FRAXE syndrome and the FMR2 allele 
distribution was determined.  The most common allele observed was 15 GCC repeats, followed 
by 16 GCC repeats.  
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A study undertaken by Allingham-Hawkins and Ray (1995) reported on 7-35 as being the 
normal range, broader than originally reported by Knight et al. (1993) who reported distributions 
of 6-25 repeats. The study by Holden et al. (1996a) extended this range from 5-38 repeats.  
 
Gecz (2000) reports that the modal number of 16-18 repeats is found in most populations, with 
differences likely due to laboratory variation and minor ethnic differences. The modal number of 
15 observed in this study is a true allele and unlikely to be an underestimate. The slight 
variation could be attributed to ethnic differences as the majority of patients tested were SA 
Whites (43%) followed by SA Blacks (41%).  Studies by Sharma, Gupta and Thelma (2001) and 
Pandey et al. (2002) showed that 15 GCC repeats was the most frequent allele observed in 
their sample cohort, which is similar to that observed in this study. A study by Zhong et al. 
(1999) showed that 18 GCC repeats was common in the Chinese population. Youings et al. 
(2000) undertook a 5 year survey to test for FMR1 and FMR2 and found that FMR2 repeats of 
15, 16 or 18 are common. This was also reported by Murray et al. (1996) who tested 992 boys 
with unexplained learning difficulties.  
 
When comparing the distribution of alleles grouped into the different FMR2 categories, a 
significantly shifted distribution was observed between the institutionalized males from Holden 
et al. (1996a) and this study. A possible explanation could be due to the different ethnic groups 
tested. The institutionalized MR males are Black individuals while those from the Holden study 
were presumably predominantly White as they were from Ontario, Canada. This difference is 
not surprising as a highly significant difference was observed when the category distribution of 
the White MR population was compared with the Black population (Table 4.3.). 
 
When comparing the distribution of alleles grouped into different categories between each of the 
ethnic populations tested in this study, no significant difference was observed. However, when 
the category distribution of the White population was compared with the Black population, a 
highly significant difference was observed. This shifted distribution observed in our study has 
been previously observed with other triplet repeat expansion disorders such as DM. Goldman, 
Ramsay and Jenkins et al., (1995) reported on South African Negroids who have a CTG allelic 
distribution that is significantly different from that in Caucasoids. Significant differences were 
found in allele and haplotype distributions in the Caucasoid DM and non-DM chromosomes and 
Negroid non-DM chromosomes (Goldman, Krause, Ramsay et al., 1996). 
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4.4.3 Intermediate/gray alleles 
Three patients in this study were found to have an FMR2 repeat size of 33, which is in the gray 
range. A study undertaken in by Murray et al. (1996) in the MR population of boys from Wessex, 
England (760 individuals) showed that there was an excess of intermediate/premutation FMR2 
(31-199 repeats) alleles. They suggested that alleles greater than 30 FMR2 repeats, which 
accounted for 0.76% of their sample, were rare and should be regarded as potentially unstable. 
Further, they suggested that these repeats may play some role in MR. 
 
Crawford et al. (1999) tested a diverse population (4779 individuals) of Atlanta, USA. In contrast 
to the findings of Murray et al. (1996), they found no evidence for an excess of intermediate/PM 
alleles at the FMR2 locus. They disputed the association of intermediate alleles with MR and 
suggested that more studies with larger numbers are needed to resolve this. 
 
It would be recommended to study other related family members of the 3 patients with 
intermediate alleles to investigate the meiotic stability or instability of this allele. Unfortunately it 
was not possible as this was a retrospective study. 
 
 
 
4.5 SUMMARY 
The results obtained from the screening of MR males in South African indicate that FRAXE 
syndrome, caused by FMR2 repeat expansions, is not common in South Africa. As a result, 
diagnostic testing for FRAXE syndrome has not been implemented routinely in the Division of 
Human Genetics at the NHLS. It is however being used in the multiplex FMR1/FMR2 PCR 
assay as a control for PCR failure and an indicator for an FMR1 expansion. If the FMR2 allele 
fails to amplify on PCR analysis, further testing could be pursued. Its value is also demonstrated 
when used as a linked marker in tracking the FMR1 expansion in families. 
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CHAPTER FIVE 
5 XNP AND ARX RESULTS AND DISCUSSION 
 
This project was undertaken mainly to investigate the contribution of NS-XLMR genes in the MR 
population. In addition to the FMR2 gene, the contribution of 2 other genes, XNP and ARX to 
XLMR was investigated in this study. Mutation screening in these genes was undertaken in 
male subjects with MR who tested negative for the FMR1 expansion. The results are presented 
and discussed in this chapter. 
 
 
5.1 RESULTS OF MUTATION SCREENING OF THE XNP HOTSPOT REGION 
5.1.1 PCR and sequence analysis 
XNP is a large gene (35 exons) but most mutations causing ATR-X syndrome and XLMR are 
clustered in the zinc finger (ADD) domain (Villard et al., 1997), covering exons 7, 8 and the 
beginning of exon 9 in which ~40-50% of known XNP mutations have been identified (Villard et 
al., 1999a; Gibbons et al., 2008). 
 
Mutation screening was undertaken in the XNP gene in 210 MR male subjects (100 male 
referrals with MR and 110 Black institutionalized males who tested negative for the FMR1 
expansion (described in Sections 2.2.1 and 2.2.2). No variation or pathogenic mutation was 
found in the „hot-spot‟ region tested. A single nucleotide polymorphism (SNP), c.101786C>T 
(Reference SNP Id rs35268552) in intron 7 of the XNP gene was detected in 108 (51%) 
subjects. This is a reported SNP with the ancestral „C‟ allele reported to occur at a frequency of 
87.5% and the „T‟ allele at 12.5% in the Yoruba population, which is considered representative 
of an African population (dbSNP website, 2009). 
 
 
5.2 DISCUSSION OF MUTATION SCREENING OF THE XNP HOTSPOT REGION 
This study was prompted by the study undertaken by Villard et al. (1999a) who reported on 
mutation analysis of the XNP gene using direct sequencing of the 300 bp zinc finger coding 
region, spanning exons 7, 8, and 9. The authors identified 6 mutations (28%) in 21 MR male 
patients who had facial appearances typical of ATR-X but did not necessarily have urogenital 
abnormalities or HbH inclusions (see Section 1.5.5.1), features which are commonly found in 
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patients affected with ATR-X syndrome. They concluded that this method was suitable for 
screening males who have severe mental retardation associated with hypotonic facies. 
 
As the gene is large, systematic testing of the whole coding region was not practical. As a 
result, this study concentrated the mutation detection effort in the XNP hotspot region. No 
mutations were identified in 210 MR male subjects tested. These findings show that there is a 
low frequency of mutations in the hotspot region of the XNP gene in South African males with 
an unknown cause of MR. However, this may not be a true reflection of all the mutations 
present in other regions of the XNP gene as has been reported in the literature where a family 
with borderline to moderate MR and no obvious facial dysmorphisms was shown to have a 
missense mutation (c.5069C>T = p.T1621M. Numbering according to GenBank accession 
number U75653) in exon 18 of the XNP gene (Yntema, Poppelaars, Derksen et al., 2002b). The 
authors suggested screening for XNP mutations in males with all degrees of MR and not just 
patients with severe MR. The authors also suggested that patients with and without typical facial 
characteristics should be screened for XNP mutations. This would allow us to elucidate the 
function of the XNP protein and to identify possible genotype-phenotype correlations.  
 
It must be noted that most mutations in XNP have been identified in males who present typically 
with features of ATR-X syndrome, including profound developmental delay, facial dysmorphism, 
genital abnormalities, and  thalassaemia. This is supported by our family studies, presented in 
Chapter 7, where 3 families studied to date have mutations identified in the XNP gene.  The 210 
MR subjects screened in this study were not selected for these clinical criteria, which may 
further contribute to the lack of mutations identified in our cohort. Gibbons et al. (2008) reported 
that the proportion of XLMR that can be accounted for by XNP mutations has not been fully 
determined and that further studies are required. 
 
 
5.3 SUMMARY OF MUTATION SCREENING OF THE XNP HOTSPOT REGION 
The results obtained from screening MR males for mutations in the XNP hot-spot region show 
that this gene is not a significant contributor to NS-XLMR in South African males. Large scale 
screening is not cost effective in clinical practice. Routine diagnostic testing for mutations in the 
hotspot region in MR males with an unknown cause has thus not been implemented in the 
Division of Human Genetics, NHLS. When this study commenced in 2001, the general feeling 
was that few genes would contribute to a large amount of NS-XLMR cases. With the 
identification of many genes through the subsequent years, this assumption has been 
disproved.  However, it is important to test patients with clinical features of ATR-X syndrome. 
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5.4 RESULTS OF ARX GENE 24 bp DUPLICATION SCREENING 
5.4.1 PCR and sequence analysis 
A total of 868 subjects (described in Section 2.4) were screened for the common ARX mutation, 
c.431-454dup24. One White patient (ARX patient 1) was found to have the common 24 bp 
duplication mutation and one Black patient (ARX patient 2) from the cohort appeared to have a 
deletion in this region. Due to technical challenges with sequencing this region as a result of the 
high GC content, the exact breakpoints of the deletion could not be determined. Figure 5.1 
shows the duplication and deletion on an agarose gel. Figure 5.2 illustrates the corresponding 
sequencing result for ARX patient 1 showing the region duplicated. 
 
Due to the high GC-content of the ARX region, the primers (GC-content of 70%) and the 
existence of secondary structures, PCR optimisation proved rather challenging. This appeared 
to be a common problem experienced by many authors who reported on the poor amplification 
and sequencing of this region (Stromme et al., 2002; Stepp, Cason, Finnis et al., 2005; de 
Souza Gestinari-Duarte et al., 2006). The PCR assay was optimized using the recommended 
Failsafe buffer J (from Epicentre Technologies) used by Gronskov et al. (2004). A screening 
approach using agarose gel electrophoresis was performed and the presence of the duplication 
was confirmed on sequencing analysis.  
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Figure 5.1 A 3% agarose gel showing the 24 bp duplication mutation and the deletion mutation 
identified in the ARX gene. 
The normal fragment (N) is 251 bp and the duplicated fragment can be seen as the shifted band, 
representing a 275bp fragment (M). The deleted fragment is approximately 220bp 
 
 
 
 
Figure 5.2 Sequencing electropherogram of the (c.431-454 dup) 24bp duplication mutation 
identified in ARX patient 1. 
The duplication results in an expansion of a polyalanine tract at amino acid position 144-155 from 12 to 20 
alanines. 
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5.5 DISCUSSION OF ARX GENE 24 bp DUPLICATION SCREENING 
A total of 868 individuals (described in Section 2.4) were screened for the common ARX 24 bp 
duplication mutation, c.431-454dup24. Only one White patient (ARX patient 1) from this cohort 
was found to have the common 24 bp duplication mutation. This gives a frequency of 0.12% for 
the duplication mutation. The patient is reported to present with global developmental delay, 
hypotonia, mild dysmorphism and a family history of MR from the maternal side. A Black patient 
(ARX patient 2) appeared to have a deletion in the amplified region. He was reported to present 
with autistic features, developmental language delay, behaviour stereotypes and impaired social 
interaction and functioning. There was no family history of note. A follow up was not made as 
these 2 patients were distant referrals and were not assessed clinically at the Genetic 
Counselling Clinic in Johannesburg. 
 
This study undertook to investigate whether the common 24 bp duplication mutation in the ARX 
gene is a common cause of MR in our population as ARX mutations have been reported to be 
the most frequent cause of XLMR patients after fragile X MR syndrome, although the true 
prevalence remains to be establised (Gecz et al., 2006). Many authors have recommended 
testing males with NS-XLMR and S-XLMR who have tested negative for fragile X MR syndrome 
for the 24 bp duplication mutation, especially in the presence of dystonic hand movements, 
spasticity and epilepsy (Suri, 2005; de Souza Gestinari-Duarte et al., 2006; Nawara et al., 
2006). Partington, Turner, Boyle et al. (2004) estimated the frequency of the duplication 
mutation to be 1 in 12 000 males, or approximately one-third the rate of FMR1 mutations. Poirier 
et al. (2006) concluded that ARX mutations are found in 9.5% of XLMR families and 2.2% of 
affected brother pairs. 
 
In contrast, Gronskov et al. (2004) showed that the recurrent mutations in ARX appear to be 
less frequent than previously thought in NS-XLMR cases in Denmark. They recommended that 
screening is not warranted in a child with MR without any family history. This finding was further 
supported by a study undertaken by Rujirabanjerd, Tongsippunyoo, Sripo et al. (2007) who 
undertook ARX mutation screening of the ARX gene in Thai paediatric patients with delayed 
development. 
 
Ropers in his review (2006) mentions that the frequency of mutations in the ARX gene was 
much lower (0% to 5%) in smaller families (2.2% in affected brother pairs and 0.13% in sporadic 
males with MR). Our findings support these studies as we have shown that the frequency of this 
24 bp duplication is 0.12% and not as common in our population of MR males as has been 
observed in other populations. This low frequency may be as a result of sample selection bias. 
Rujirabanjerd et al. (2007) indicated that this low frequency seen may be explained by the 
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different ethnic backgrounds in the world which may have different mutations rates. Our sample 
cohort consisted of 34.4% (299) Whites, 47.6% Blacks (413), 11.3% Coloureds (98) and 6.7% 
Indians (58). The duplication mutation was identified in a White patient and the deletion 
mutation in a Black patient. These numbers are too small to make any significant conclusion on 
the frequency in any particular ethnic group. 
 
 
 
5.6 SUMMARY OF ARX GENE 24 bp DUPLICATION SCREENING 
The results obtained from screening the ARX gene for the common 24 bp duplication mutation 
show that the mutation is rare in South African males with MR of unknown cause. It must be 
emphasized that this is a small study and one cannot draw conclusions about the frequency of 
ARX in NS-XLMR, given the genetic heterogeneity of this condition. Routine diagnostic testing 
for this mutation in MR males will not be implemented in the Division of Human Genetics, NHLS.  
However, males with S-XLMR who have tested negative for fragile X MR syndrome and who 
present with dystonic hand movements, spasticity and epilepsy or a strong family history, in line 
with other studies, may be considered for testing. 
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CHAPTER SIX 
6 FRAGILE X MR SYNDROME FAMILY STUDIES 
 
 
 
6.1 FRAGILE X MR SYNDROME POSITIVE FAMILY (FRAXA FAMILY 1) RESULTS 
A large family positive for the FMR1 expansion, consisting of 24 members was investigated. 
The pedigree is illustrated in Figure 6.1 together with results of FMR1 expansion testing and 
haplotype analysis. As an incidental finding during a routine investigation for fragile X syndrome, 
an interesting result was found. Two siblings were found to have two expanded FMR1 alleles in 
the intermediate and premutation range respectively. The segregation of this expansion in the 
family was examined using haplotype analysis. As this is the first South African report of 
females with 2 expanded FMR1 alleles and the fifth family reported thus far in the world 
(Mazzocco and Holden, 1996), it has been presented in this study.  
 
6.1.1 PCR and Southern blot results 
The alleles generated from the PCR reaction in the two sisters who were found to be 
homozygous for the FMR1 expansion are shown in Figure 6.2. The first female (III-10) was 
found to be a compound heterozygote for 2 FMR1 alleles in the intermediate/gray range, 51 and 
57 repeats respectively. Her sibling (III-12) was found to have one allele in the intermediate 
range and one in the premutation range 51 and 69 repeats respectively 
 
The parents of these female siblings were both found to be carriers of FMR1 expansions in the 
intermediate/gray range. The father (II-5) carries an allele of 51 repeats and their mother is a 
carrier of 57 repeats. Both siblings inherited the 51 repeat from their father which did not 
expand, as expected in a male transmission. The 57 repeat from their mother was inherited 
stably in III-10 but was shown to have expanded to 69 repeats in III-12 and subsequently 
expanded to a full mutation in III-12‟s son, IV-12. 
 
Although III-10 inherited the 57 repeat from her mother stably, the repeat was shown to be 
unstable in the next generation as it had expanded to 67 repeats in her daughter, IV-6. Her 
other three children, IV-7, IV-8 and IV-9 were shown to have inherited the 51 repeat which had 
expanded to 52 repeats. Southern blot analysis was performed which confirmed the PCR 
results. Figure 6.3 shows the autoradiograph obtained after the blotting procedure. 
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Figure 6.1 Family pedigree of FMR1 expansion positive family (FRAXA family 2) tested for FMR1 expansion and at 2 intragenic markers, FRAXAC2 and DXS548. 
Haplotype analysis was performed to track the expansion in the family. The FMR1 CGG allele and haplotype results are indicated below each of the members tested. A dash (-) indicates an unsuccessful result or not tested for. 
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Figure 6.2 FMR1 alleles on PCR showing two females compound heterozygous for FMR1 
expansions.  
III-12 has alleles of 51/69 repeats and III-10 has alleles of 51/57 repeats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Southern blot autoradiograph of FMR1 expansion positive family 1 produced by 
probing Southern blots from EcoRI and EclXI digests with the StB12.3 probe. 
N (normal) =  5-40 
I (intermediate/gray zone) = 41-58 
E (premutation)  = 59-200 
EE (full expansion)  = >200 CGG repeats
III-12 
III-10 
  Chapter 6. Fragile X MR family studies 
97 
6.1.2 Haplotype results 
Further investigations were undertaken using haplotype analysis to examine the segregation of 
this expansion. Two intragenic markers, DXS548 and FRAXAC2, previously optimised by 
Goldman (1997) in the Division of Human Genetics Laboratory, NHLS, were used to track the 
disease chromosome in the family. The results from the polyacrylamide gels are shown in 
Figure 6.4 and Figure 6.5 and the haplotypes are shown in the pedigree in Figure 6.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Autoradiograph of the DXS548 marker in FMR1 expansion positive family 1.  
The PCR fragment was run on a 6% denaturing polyacrylamide gel and exposed to an X-ray film for 24 hrs. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 Autoradiograph of the FRAXAC2 marker in FMR1 expansion positive family 1.  
The PCR fragment was run on a 6% denaturing polyacrylamide gel and exposed to an X-ray film for ~1 hr. 
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The FMR1 full expansion (EE) tracks with allele 196 bp of the DXS548 marker and allele 149 bp 
of the FRAXAC2 marker as seen in the affected proband IV-12. The X chromosome with the 
FMR1 intermediate allele tracks with allele 206 bp of the DXS548 marker and allele 153 bp of 
the FRAXAC2 marker and appears to be stably inherited in the family.  
 
 
6.2 FMR1 EXPANSION POSITIVE FAMILY (FRAXA FAMILY 1) DISCUSSION 
This family was referred for fragile X MR syndrome testing and 2 siblings were found to be 
compound heterozygous for FMR1 expansions.  III-10 was found to have 51/57 CGG repeats 
and her sibling, III-12 was found to have 51/69 CGG repeats. This is the first such case 
described in South Africa and the fifth family in the world which has been described (Mazzocco 
and Holden, 1996).  
 
Li, Malarchok, Martinez et al. (1995) reported on a female homozygous for the PM with no MR 
or physical features typical of fragile X MR syndrome. Mila, Castellvi-Bel, Gine et al. (1996a) 
reported on a moderately MR female (IQ 53) with characteristic facial appearance and a short 
attention span with a PM and a FM. An extended family screen detected 33 normal individuals, 
14 carriers of a PM (1 male, 13 females) and 18 individuals with a FM (8 males, 10 females). 
 
Mazocco and Holden (1996) reported on 3 adult sisters who were compound heterozygotes for 
FMR1 PMs. Their study aimed to examine whether the sisters manifested a neuropsychological 
phenotype that was similar to that reported for women affected by fragile X MR syndrome. They 
concluded that the profiles observed in the 3 females were consistent with reports that the 
FMR1 PM does not affect cognitive performance. 
 
Linden, Tassone, Gane et al., (1999) reported on a 15 year old female with fragile X MR 
syndrome with an FMR1 FM of 363 repeats and a PM of 103 repeats. She was shown to have 
inherited FMR1 repeats of 146 and 98 from her mother and father respectively. The female 
presented with mild to borderline MR and her behavioural characteristics were typical of females 
with fragile X MR syndrome. 
 
This study examined the FMR1 CGG repeat length in a large family. Clinical data were not 
available but we would expect the 2 sisters not to present with MR. As would be expected, it 
was established on further investigation that the parents of these female siblings were carriers 
of the FMR1 expansion in the intermediate/gray range. 
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The expansion of the 57 repeat in III-10 to a PM allele of 67 repeats in her daughter IV-6 has 
implications for this female as she has a 5.3% risk of having children affected with fragile X MR 
syndrome (see Table 6.1) and an odds ratio of 6.9 of developing POF (Table 6.2). She also has 
an increased risk for FXTAS, although the precise risk has not yet been defined but it is lower 
than that reported for males (Hagerman and Hagerman, 2004; Biancalana, Toft, Le Ber et al., 
2005). 
 
Her other 2 sons, IV-7 and IV-9 and her daughter IV-8 were shown to have inherited the 51 
repeat which had expanded to 52 CGG repeats. The clinical significance of carrying an allele in 
this intermediate size range is unclear. There is an increased risk of expansion compared to 
normal alleles, but expansion into the full mutation range is very rare (Morris et al., 1995).  The 
number of “pure” CGG repeats without interrupting AGG repeats is a good predictor of repeat 
instability, especially in intermediate alleles at the upper end. This was not determined in these 
individuals. Eichler et al. (1994) reported on longer pure repeats, especially those with more 
than 35 uninterrupted CGG repeats to become more unstable.  
 
The smallest repeat known to expand to a full mutation in a single generation was 59 repeats 
(Nolin et al., 2003). The odds ratio of POF in IV-8 is estimated to be 2.5 (Table 6.2) although 
there appears to be no consensus for estimating an absolute risk for POF. 
 
 
 
Table 6.1 Risks for expansion from a maternal premutation to a full mutation when transmitted 
to offspring. 
NUMBER OF 
MATERNAL 
PREMUTATION CGG 
REPEATS 
TOTAL MATERNAL 
TRANSMISSIONS 
EXPANSIONS TO FULL 
MUTATIONS (%) 
55-59 27 1 (3.7%) 
60-69 113 6 (5.3%) 
70-79 90 28 (31.1%) 
80-89 140 81 (57.8%) 
90-99 111 89 (80.1%) 
100-109 70 70 (100%) 
110-119 54 53 (98.1%) 
120-129 36 35 (97.2%) 
130-139 18 17 (94.4%) 
140-200 19 19 (100%) 
(GeneReviews website, accessed online September 2009). 
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Table 6.2 Odds ratio for POF by intermediate and premutation size. 
INTERMEDIATE/PREMUTATION 
SIZE IN CGG REPEATS 
ODDS RATIO FOR POF 
41-58 2.5 
59-79 6.9 
80-99 25.1 
>100 16.4 
(GeneReviews website, accessed online September 2009). 
  
 
PM carriers are reported to have increased FMR1 mRNA levels in leucocytes and this toxic 
RNA gain-of-function mechanism has been proposed for the pathogenesis of FXTAS and may 
also be a cause of POF (reviewed in Brouwer et al., 2009b). Female PM carriers are less likely 
to develop FXTAS and tend to present with a less severe phenotype compared to males with a 
PM, most probably due to the presence of a normal FMR1 allele. Both female siblings in this 
study (III-10 and III-12) were found to be compound heterozygous for the FMR1 expansion with 
no normal FMR1 transcript, it is unknown if this increases the risk of FXTAS and POF. 
 
Anticipation is demonstrated to occur in this family as seen in IV-12 who has inherited the larger 
PM which has expanded to a full mutation. In compound heterozygous females, it is expected 
that the larger allele is more unstable than the smaller allele. 
 
Haplotype analysis was performed at the FMR1 locus and the high-risk X chromosome was 
determined. Haplotype studies performed previously by Goldman et al. (1997) showed that 2 
haplotypes 194-154 DXS548-FRAXAC2 and 204-153 DXS548-FRAXAC2 accounted for 61% of 
Caucasoid disease chromosomes. The haplotype in the study family is 196-149 DXS548-
FRAXAC2 and is not one of the common haplotypes observed in Caucasoid populations. 
 
 
 
6.3 SUMMARY 
A large family positive for an FMR1 expansion causing fragile X MR syndrome was investigated 
and 2 females were found to be compound heterozygotes for 2 FMR1 alleles. Extended family 
members were tested and their FRAXA status was determined. As a result of this investigation, 
females at risk for POF and FXTAS have been identified. The risk is uncertain in compound 
heterozygotes, but could be increased. Unexpected results in family analysis can sometimes 
alter the risk. 
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CHAPTER SEVEN 
7 ATR-X SYNDROME FAMILY STUDIES 
 
In addition to screening the XNP mutation hotspot in MR males, extensive molecular 
investigations were undertaken on three patients suspected clinically to have ATR-X syndrome 
and extended family members. The results obtained from these investigations are presented 
below followed by a discussion of these cases. For the naming of the mutations, mRNA 
accession no. NM_000489.3 and protein accession no. NP_000480.2 were used (36 exons with 
exon 7 spliced out). The cDNA number of +1 corresponds to the A of the ATG translation 
initiation codon in the reference sequence. 
 
 
7.1 ATR-X PATIENT 1 RESULTS 
Figure 7.1 illustrates the family pedigree of patient 1. Patient 1 (II-5) reportedly had a phenotype 
similar to MR brother, II-2 who had died. Patient 1 was developmentally delayed with features 
consistent with ATR-X syndrome. He had marked short stature, was microcephalic and entered 
puberty at 20 yrs of age. He had a long face, a big jaw, a cows-lick to the frontal hairline, 
bilateral epicanthic folds and had a soft palate cleft. He had inverted nipples, fine digits and flat 
feet. He had bruxism and drools. His physical appearance is shown in Figure 7.2. 
Haematological analysis performed at Johannesburg Hospital, special haematology laboratory 
showed a haemoglobin of 14.0g/dL (N=14.3-18.3), a RCC of 4.87x1012/L (N=4.89-6.11), MCV of 
89.1fL (N=79.1-89.9), MCH 29.2pg (N=27.0-32.0), a haematocrit of 0.434 (N=043-0.55). “Golf 
balls” (HbH inclusions) were seen on the incubated reticulocyte preparation which was done at 
the Johannesburg Haematology Laboratory and confirmed in the UK (Dr Richard Gibbons 
Laboratory, University of Oxford), in keeping with the clinical diagnosis of ATR-X syndrome.  
 
 
7.1.1 Screening the XNP hotspot region 
DNA from patient 1 was sent to France (Dr L Villard, INSERM, Marseille, France) to sequence 
the hotspot region in the XNP gene. Molecular testing was undertaken concurrently in our 
laboratory. No mutation was identified in the hotspot region of XNP in exons 7, 8 and 9. 
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Figure 7.1 Family pedigree of patient 1 (II-5) affected with ATR-X syndrome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Patient 1 showing clinical features of ATR-X syndrome. 
The photograph on the right shows the normal twin of the patient. 
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7.1.2 Testing for fragile X MR syndrome 
Patient 1 was tested for fragile X MR syndrome and shown to have 30 FMR1 CGG repeats on 
PCR analysis thus excluding a diagnosis of fragile X MR syndrome. 
 
7.1.3 Prenatal investigation 1 using linked marker analysis (Fetus 1, CVS 2001) 
Prenatal diagnosis was requested for the sister of ATR-X patient 1 (II-1). Since the ATR-X 
causing mutation had not been identified at the time, linked marker analysis was undertaken on 
the family in 2001 at the Kennedy-Galton Centre in England to determine the carrier status of II-
1. She was found to carry the high-risk X chromosome and her sister II-3 was shown to carry 
the low-risk X chromosome. Chorionic villus sampling (CVS) was performed and the fetus, III-I 
was shown to be female on PCR testing at the SRY and amelogenin-Y (AMEL-Y) Y-
chromosome specific loci. Further testing for ATR-X was therefore not indicated for the fetus. 
The fetus was however found to have Down syndrome and the pregnancy was subsequently 
terminated. 
 
 
7.1.4 Mutation identification 
Mutation analysis on a research basis was subsequently carried out in the UK (Dr Richard 
Gibbons Laboratory, University of Oxford) on ATR-X patient 1 (II-5). The mutation in the family 
was identified as a novel missense mutation, c.5328C>G (p.F1776L) in exon 22 of the XNP 
gene, in the C-terminal region corresponding to the helicase domain (Figure 7.3). The mutation 
was confirmed by restriction enzyme (RE) analysis using MnlI and direct carrier testing in the 
patient‟s sisters, II-1 and II-3 was performed using the RE assay in order to confirm the results 
obtained by linked marker analysis. The mother of the index case was confirmed to be a carrier. 
Further, II-1 was confirmed to be a carrier and II-3 was confirmed not to carry the causative 
mutation, consistent with the linked marker results. This is shown in Figure 7.5. The primer 
sequences to detect the family mutation were obtained from Dr Gibbons (UK). Diagnostic 
testing by sequence analysis was performed to confirm the mutation in Patient I and his mother 
(I-2) (Figure 7.4). 
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ttggtaattcacttgtagatcagacttataaccatgtttattctatacttagcttgatattctttctttatagcttaattctaatgcatgtgtttttgaca
tgagcatttcattggggaatttttctaagtctttttaacgattgttaatgttgttaatgaataatgtcttctctcttagATCATTGTATGG
TTAATTTTATCAAGGAAAATTTACTTGGATCCATTAAGGAGTTCAGGAATAGATTTATAAATC
CAATTCAAAATGGTCAGTGTGCAGATTCTACCATGGTAGATGTCAGAGTGATGAAAAAACG
TGCTCACATTCTCTATGAGATGTTAGCTGGATGTGTTCAGgtacaaatatgttccatagtaataaaatattctt
acttttttatataacaatcccaacatattttctgagcttaaagtttaataattttgtgttttctttcccgctctttcagtagatagttttacagttata
tctccttgcgttgtcttaaaaaatttctgctgcattcaacttttaaa 
Figure 7.3 Sequence of exon 20 of the XNP gene showing the site of the novel c.5328C>G 
(p.F1776L) mutation identified in Patient 1 affected with ATR-X syndrome.  
The base which is mutated is highlighted in red and the primers are highlighted in blue. The lowercase 
letters represent the intronic region and the uppercase letters represents the exon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 Sequence analysis in Patient 1 affected with ATR-X syndrome and his mother 
compared to a negative control sample.  
The mutation identified in the patient is a novel missense mutation, c.5328C>G (p.F1776L) in exon 20 of the 
XNP gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5 Agarose gel picture showing PCR products from patient 1 and extended family 
members digested with MnlI enzyme to detect the 5328C>G (F1776L) mutation.  
The enzyme creates a restriction site in the presence of the mutation as seen in lanes (5), (7) and (9). Lanes 
(2), (4), (6), (8), (10) and (12) show PCR products that were not restricted with MnlI. Patient I (II-5) was set 
up twice, using 2 different concentrations of DNA template, as shown in lanes (5) and (7). 
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7.1.5 Prenatal investigation 2 (Fetus 2, CVS 2002) 
A second prenatal investigation for II-1 was performed in 2002 in the Molecular Genetics 
Laboratory, NHLS by me. Further, the RE assay using MnlI was used to confirm the prenatal 
investigation.  
 
Prenatal testing was undertaken on CVS material. The fetus, III-2 was found to be male on PCR 
analysis at the SRY and AMEL-Y Y-chromosome specific loci and thus ATR-X syndrome testing 
was indicated. The fetus tested negative for the c.5328C>G (p.F1776L) mutation on RE 
analysis. The result from this investigation is shown in Figure 7.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6 Agarose gel picture showing the result from the second prenatal investigation workup 
undertaken on CVS material obtained from the sister (II-1) of Patient 1 who was found to be a 
carrier of the c.5328C>G (p.F1776L) mutation.  
Genomic DNA was digested with MnlI enzyme. 
 
 
7.1.6 Prenatal investigation 3 (Fetus 3 CVS 2005) 
A third prenatal investigation for II-1 was performed in 2005 in the Molecular Genetics 
Laboratory, NHLS under my supervision. Prenatal testing was undertaken on CVS material. The 
fetus, III-3 was found to be male on PCR analysis at the SRY and AMEL-Y Y-chromosome 
specific loci and thus ATR-X syndrome testing was indicated. The fetus tested negative for the 
c.5328C>G (p.F1776L) mutation on RE analysis. 
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7.2 ATR-X PATIENT 2 RESULTS 
This patient presented with extreme hypotonia at birth, a persistently weak cry, hypoglycaemia, 
severe global delay, failure of speech development, microcephaly (HOC = 46 cm), brisk reflexes 
and mild dysmorphism comprising: spiky, thick hair, low-set rotated ears, protruding tongue, 
high-riding testes, mild mid-facial hypoplasia, carp-shaped mouth. Figure 7.7 shows the family 
pedigree and Figure 7.8 shows the clinical features of Patient 2. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7 Family pedigree of patient 2 (II-1) affected with ATR-X syndrome. 
 
 
 
Figure 7.8 ATR-X Patient 2 showing clinical features of ATR-X syndrome. 
 
1 2
1
ATR-X FAMILY 2
MUTATION : c.4868T>C (p.L1623S)
2
PATIENT 2
c.4868T>C +ve
I
II
c.4868T>C +ve
Minor. 
Not  tested
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7.2.1 Testing for fragile X MR syndrome 
This patient was tested for fragile X MR syndrome and shown to have 46 FMR1 CGG repeats 
on PCR analysis. This is in the intermediate range and is not thought to be causative of the 
features in the patient (see Section 1.4.2.2). 
 
7.2.2 Screening the XNP hotspot region 
XNP screening of the 300 bp hotspot region was undertaken in the Molecular Genetics 
Laboratory, NHLS and a mutation was not identified. Mutation analysis undertaken in the UK 
(Dr Richard Gibbons Laboratory, University of Oxford) identified a point mutation, reported as 
c.4868T>C (p.L1623S) in exon 19 of the XNP gene (see Figure 7.9). This was a novel mutation 
and was confirmed to be in a highly conserved region in the helicase domain of the gene and 
was thus likely to be pathogenic. The mutation was subsequently confirmed in the Molecular 
Genetics Laboratory, NHLS on sequencing analysis as shown in Figure 7.10. 
 
 
 
tgatacatcatctagttgaactttggcattttactatctctttccctgtgccttgcctggtttggaaattctggccgtttattgtttaagcaaaaca
aagctataatattgtaagattgcttaatttattaaatttttttgtggatatttaaacgaaggtgacaatctgttttcttatagGTGGTAAGTT
TTCTTCATACAGTTCTTTTGTGTGACAAACTGGATTTCAGCACGGCGTTAGTGGTTTGTCCT
CTTAATACTGCTTTGAATTGGATGAATGAATTTGAGAAGTGGCAAGAGGGATTAAAAGATGA
TGAGAAGCTTGAGgtaacttattttaaatgttttctattattaaaatagtcacatgaaattcatatagtaaactatttttaattttttttaatt
tttaatgttttttaaccagtgatgcatatttcagtgggaatatttaatattcacatgtttttagtagctacttaaaaaaatctttatttccccacaaa
a 
Figure 7.9 Sequence of exon 19 of the XNP gene showing the site of the c.4868T>C (p.L1623S) 
mutation identified in Patient 2 (II-1). 
The base which is mutated is highlighted in red. The lowercase letters represent the intronic region and the 
uppercase letters represents the exon.
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Figure 7.10 Sequence analysis in patient 2 affected with ATR-X syndrome compared to a 
negative control sample.  
The mutation identified in the patient is c.4868T>C (p.L1623S) in exon19 of the XNP gene. The reverse 
sequence shows an A to G transition. 
 
 
 
7.2.3 Carrier testing in mother of patient 2 
DNA analysis was undertaken in the Molecular Genetics Laboratory, NHLS under my 
supervision in the patient‟s mother I-2, and she was shown to be a carrier of the mutation. The 
result from sequencing analysis performed in the mother can be seen in Figure 7.11. The sister 
(II-2) of patient 2 was not tested as she is a minor. Carrier testing will be offered to her in the 
future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11 Sequence analysis in the mother of patient 2 affected with ATR-X syndrome.  
The mother was confirmed to be a carrier of the c.4868T>C (p.L1623S) mutation in exon19 of the XNP gene 
as seen in the forward sequence and confirmed in the reverse sequence. 
NEGATIVE  CONTROL – Forward sequence
c.4868T> C
NEGATIVE  CONTROL – Reverse sequence
PATIENT 2 – Forward sequence PATIENT 2 – Reverse sequence
c.4868A>G
MOTHER (I-2) OF PATIENT 2
A C G G C G T N A G T G G T T A C C A C T N A C G C C G
Forward sequence in Mother I-2 Reverse sequence in Mother I-2
c.4868T>C carrier c.4868A>G carrier 
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7.3 ATR-X PATIENT 3 RESULTS 
This patient presented with marked hypotonia at birth and on clinical examination was shown to 
have brachycephaly, upsweep („cowlick‟) of the anterior hairline, bilateral epicanthic folds, 
conjunctivitis of the right eye and undescended left testes and shawl scrotum, clinical features 
compatible with ATR-X syndrome. On neurological examination he was found to be quite 
hyperactive and made frequent hand flapping movements. Figure 7.13 shows the clinical 
features of Patient 3. A possibility of an XLMR syndrome was considered as there was some 
history of two other males on the maternal side of the family with developmental delay (Figure 
7.12). The mother‟s brother, II-5 is reported to have had Down syndrome but not confirmed and 
died at age 24 years. Her mother has 2 sisters – one has a son (II-7) with developmental delay 
and the other has a daughter who had a son (III-2) with developmental delay who is now 
deceased. The developmental delay was apparently put down to rubella in one case and birth 
asphyxia in the other. There is no other significant family history.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.12 Family pedigree of patient 3 (III-1) affected with ATR-X syndrome. 
 
 
 
PATIENT 3
c.736C>T +ve
? Down 
syndrome
Developmental 
delay
1 2 3 4
1 2 3 4 6 7
1 2
5
I
II
III
ATR-X FAMILY 3 
MUTATION p.R246C (c.736C>T)
Developmental 
delay
c.736C>T +ve
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Figure 7.13 ATR-X Patient 3 showing clinical features of ATR-X syndrome. 
 
7.3.1 Testing for fragile X MR syndrome 
In view of the XLMR history, this patient was tested for fragile X MR syndrome. He was shown 
to have 29 FMR1 CGG repeats and 15 FMR2 GCC repeats thus excluding a diagnosis of fragile 
X MR syndrome and FRAXE syndrome. 
 
 
7.3.2 Screening the XNP hotspot region 
As he was suspected clinically of having ATR-X syndrome, DNA testing was undertaken in the 
Molecular Genetics Laboratory, NHLS under my supervision. Mutation screening in the XNP 
300 bp hotspot region was undertaken by sequencing analysis (Figure 7.14) and a common 
missense mutation, c.736C>T (p.R246C) changing an arginine to a cysteine, was identified in 
exon 10 in the zinc finger domain. The sequencing electropherogram is shown in Figure 7.15. 
 
acatatcttttcagtttcctgaaagaagggaataatgttttaatctttaaaacatttcagGTGGTGTGCGGAAGGTGGAAAC
TTGATTTGTTGTGACTTTTGCCATAATGCTTTCTGCAAGAAATGCATTCTACGCAACCTTGG
TCGAAAGGAGTTGTCCACAATAATGGATGAAAACAACCAATGGTATTGCTACATTTGTCACC
CAGAGCCTTTGTTGGACTTGGTCACTGCATGTAA 
Figure 7.14 Sequence of exon 10 of the XNP gene showing the site of the c.736C>T (p.R246C) 
mutation identified in Patient 3. 
The base which is mutated is highlighted in red. The lowercase letters represent the intronic region and the 
uppercase letters represents the exon.
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Figure 7.15 Sequence analysis in patient 3 affected with ATR-X syndrome compared to a 
negative control sample.  
The mutation identified in the patient is c.736C>T (p.R246C) in exon 10, the zinc finger domain of the XNP 
gene. 
 
 
7.3.3 Carrier testing in mother of patient 3 
DNA analysis undertaken in the patient‟s mother II-3 showed her to be a carrier of the mutation. 
The result from sequencing analysis performed in the mother can be seen in Figure 7.16.  The 
family pedigree is shown in Figure 7.12. As there are male relatives affected with intellectual 
disability, the possibility exists they may have, or had, ATR-X. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.16 Sequence analysis in the mother of patient 3.   
The mother was confirmed to be a carrier of the c.736C>T (p.R246C) in the zinc finger domain of the XNP 
gene. 
A T T C T A T G C A A C C
PATIENT 3
A T T C T A C G C A A C C
NEGATIVE CONTROL
p.R246C (c.736C>T) POSITIVE p.R246C (c.736C>T) NEGATIVE
MOTHER (I-2) OF PATIENT 3  
A T T C T A N G C A A C C
p.R246C (c.736C>T) CARRIER 
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7.4 DISCUSSION OF ATR-X FAMILY STUDIES 
Three families were investigated for ATR-X syndrome and a mutation in the XNP gene was 
identified in each family. A mutation was found in all 3 patients with a clinical suspicion of the 
condition. This allowed for accurate carrier and prenatal testing in these families using direct 
mutation analysis. All the mothers were found to be carriers and in one family, 2 extended family 
members were also confirmed to be carriers. There is a high chance of finding a mutation in 
clinically suspected patients as has been shown in the 3 patients discussed in this study. In all 3 
cases, the mutation was not de novo. This has important family implications. 
 
 
7.4.1 Diagnostic strategy for ATR-X syndrome 
Due to its large size, comprehensive mutation analysis of the XNP gene is time-consuming and 
expensive. Gibbons (Gibbons Laboratory website, 2008) proposed the following methods for 
diagnostic testing of ATR-X syndrome: 
 Detection of -thalassaemia (presence of HbH inclusions). This is a technically difficult 
test to perform, especially in laboratories unfamiliar with HbH inclusions. There are many 
false positive and false negative results. 
 Sequence analysis of the XNP gene 
 Mutation detection in the zinc finger domain (exons 7, 8 and proximal area of exon 9) 
and helicase region (exons 17-20) by sequencing analysis can detect disease-
causing mutations in ~90% of affected individuals. Approximately 50-60% of known 
ATR-X mutations are clustered in the zinc finger domain region and 30% of 
mutations are located in the helicase domain 
 Screening exons 35 and 36 in patients with severe genital abnormalities 
 Testing for the c.109C>T (p.R37X) mutation in families with individuals who have 
mild to moderate MR 
 Protein studies to determine the level of ATRX protein 
 X-inactivation studies to determine the carrier status of at-risk women if a mutation is not 
identified 
 
The strategy for mutation detected suggested above is a sensible and cost-saving approach 
and is only of value when there is accurate clinical direction as XNP mutations are rare in 
undefined MR cases. The Division of Human Genetics, Molecular Laboratory can perform 
mutation testing in the XNP hotspot region. If no mutation is identified, further screening is available 
in the UK.  The patients in this study were clinically suggestive of ATR-X syndrome and initially 
screened for mutations in the ADD region. One patient (Patient 3) was found to have the 
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common c.736C>T, p.R246C mutation which accounts for 20% of XNP mutations identified 
(Gibbons et al., 2008). The other 2 patients (Patients 1 and 2) had a mutation in the next most 
commonly affected region, exons 17-20 of the helicase region. Gibbons et al. (2008) reported 
on more than 200 mutation positive individuals in 182 families with 113 different mutations. The 
majority of disease-causing mutations are single base changes, most of which are missense 
mutations. 
 
ATR-X syndrome is an X-linked recessive disorder. Not all mothers of affected individuals are 
carriers of the mutation. New mutations are extremely frequent and no data are available on the 
frequency of de novo gene mutations in ATR-X syndrome (Stevenson et al., 2000). In sporadic 
cases resulting from de novo mutations, the mother is expected to have an 85% risk of being a 
carrier (Bachoo and Gibbons, 1999; Gibbons et al., 2008). If mutations are not detected in 
peripheral blood leucocytes, germline mosaicism cannot be excluded. The mothers of the 
patients investigated in this study were all found to be carriers of ATR-X syndrome. This has 
important implications for the family as females who are confirmed to be carriers have a 25% 
risk of having an affected child with every pregnancy. If the mutation is known, there is an 
opportunity for carrier detection and prenatal diagnosis. 
 
 
 
7.5 SUMMARY OF ATR-X FAMILY STUDIES 
In collaboration with the UK lab, the causative mutation in the ATR-X families has been 
identified. As a result of this, carrier testing to siblings and other at-risk family members and 
accurate prenatal testing has been offered to one family. Since the workups were undertaken 
locally, the cost of the test was considerably reduced and a result was available sooner than 
would be expected if undertaken overseas. Clinically suspected ATR-X can be referred to the 
Division of Human Genetics, Molecular Laboratory and will be investigated in collaboration with the 
UK laboratory, with mutation testing in the XNP hotspot region performed locally and if negative, 
mutation screening of the XNP gene performed in the UK.  
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CHAPTER EIGHT 
8 FINAL DISCUSSION AND CONCLUSION 
 
 
8.1 FINDINGS FROM THIS STUDY 
This study focused on 4 XLMR genes, FMR1, FMR2, XNP, and ARX and their contribution to 
MR in the South African population. The results obtained have shown the FMR1 XLMR gene, 
which was reported previously to be significant was confirmed in this study and is therefore an 
important gene to screen in patients presenting with MR. The FMR2, XNP and ARX genes 
investigated were shown not to contribute significantly to XLMR in the South African population 
and therefore will not be incorporated into the routine diagnostic testing for MR in the Division of 
Human Genetics, NHLS, Johannesburg. Previous studies undertaken in the Division on genes 
involved in XLMR also showed that the HOPA gene, a dodecamer duplication is not a major 
cause of MR and not a significant aetiological factor in XLMR (Friez et al., 2000).  
 
When this study commenced in 2001, the general feeling was that mutations in a few genes 
would contribute to a large amount of NS-XLMR cases and screening for the FMR2 and the 
XNP gene in males with MR of unknown cause was considered a viable approach. The 
approach taken in this study was to screen mutation hotspots as a first target for screening MR 
in patients. However through the subsequent years, many genes have been identified, none of 
which has been reported to contribute substantially to NS-XLMR. The number of XLMR genes 
involved is estimated to be >100 and present data show that the diagnostic contribution of each 
of the genes involved in XLMR is a maximum of 0.5% (Yntema et al., 2002a; Gronskov et al., 
2004; Mandel and Chelly, 2004; reviewed in Gecz et al., 2009). This low probability of finding a 
mutation in an XLMR gene in MR male patients makes routine screening of XLMR genes in MR 
males very expensive and of little value. Thus it is difficult to generate a specific protocol for 
screening MR males to identify the underlying cause. It seems sensible and cost effective to 
only test those genes that are more frequently causally involved in MR, such as the FMR1 gene.  
 
The testing approach used for the diagnosis of fragile X MR syndrome since 1994 at the 
Division of Human Genetics (NHLS) was Southern blotting. Prior to this, the diagnostic test was 
based exclusively on cytogenetic detection of the FRAXA fragile site. As of 2000, the PCR 
assay was implemented as an initial screen for the routine diagnosis of fragile X MR syndrome. 
This has improved and refined the diagnostic testing for fragile X MR syndrome by accurately 
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determining the FMR1 CGG repeat size, which was not possible with Southern blotting. The 
current approach used to test for fragile X MR syndrome at the Division of Human Genetics 
(NHLS) is first line PCR screening. Southern blotting is done to confirm all expansions. 
Together, Southern blot assays and the PCR-based assay complement each other to provide 
reliable results for routine analysis of specimens referred for fragile X MR syndrome testing. The 
PCR assay is reliable, relatively cheap, and an efficient test for a primary screen for fragile X 
MR syndrome. Cytogenetic detection of FRAXA is not reliable alone as a diagnostic test for 
fragile X MR syndrome and should no longer be done. However, routine cytogenetic analysis 
should complement the DNA test to rule out any other chromosomal abnormalities, a practice 
which occurs routinely in the Division of Human Genetics, NHLS, Johannesburg. 
 
 
8.2 LIMITATIONS OF STUDY 
There are a number of limitations to this study. The poor clinical definition in the routine 
referrals, many with minimal clinical information limits further investigation. Also, the study has 
spanned a considerable period of time over which basic principles to mutation screening have 
changed. With the availability of newer techniques and testing approaches, the current study 
would not be undertaken. An obvious limitation to such a study is the cost and time with 
performing large screens. Data handling is important and one has to be cautious with analysis 
and interpretation. 
 
 
8.3 CURRENT DIAGNOSTIC APPROACH 
Now with so many other genes implicated in XLMR, there is no simple diagnostic approach and 
test. Not only is it costly but inefficient and laborious. Ropers and Hamel (2005) in their review 
emphasize the huge costs of current methods and their unreliability to justify mutation screening 
of all known NS-XLMR genes for routine diagnostic testing. Diagnostic testing approaches will 
have to be improved upon and the utilization of newer molecular tools and techniques has to be 
cheaper and more robust if it is to be incorporated into clinical practice. Currently the technology 
is focused on cost-effective, efficient, and reliable methods. The uses of genomic microarray 
technology or related methods that assay gene function have revolutionized the study of human 
copy number variation (CNV) in patients with unexplained MR. It appears to have become the 
current method of choice in routine clinical practice and is likely to eventually replace DNA-
based mutation screening. However, this comes with technical challenges of its own, precluding 
widespread implementation of this analysis, e.g. CNVs will not detect point mutations. Currently 
17 CNVs have been reported on the X chromosome (Koolen et al., 2009). 
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Ropers (2006) proposes the development of re-sequencing chips to simultaneously screen 
many genes for mutations in one assay and their laboratory (Max-Planck Institute for Molecular 
Genetics, Germany) has developed a chip for diagnostic purposes in NS-XLMR families.  
 
Recently through the efforts of the IGOLD project, large-scale systematic resequencing using 
Sanger sequencing was undertaken on the coding exons, covering approximately 1 Mb of the 
X-chromosome and 720 genes, in 208 families with XLMR. As a result of this study, 12 new 
XLMR genes were identified using high-throughput sequence analysis (Tarpey, Smith, 
Pleasance et al., 2009). Further testing using array CGH is being used to identify whole exon 
deletions and duplications in the 16% of the cohort that did not have any significant sequence 
variant detected on the high-throughput sequence analysis. The authors proposed this method 
as a future strategy for identifying disease-causing variants although cautioned on the 
interpretation of the data and the need for more careful analysis. Interestingly, more than 1% of 
truncating variants which is the predominant disease-causing class of mutations in XLMR genes 
were found to be non pathogenic. One of the other major challenges faced with this type of 
strategy is distinguishing rare sequence variants from pathogenic mutations (Raymond, 
Whibley, Stratton et al., 2009).  
 
The contribution of ARMR also has to be considered. The use of high-resolution array CGH and 
MLPA has allowed genome wide screening for submicroscopic deletions and duplications in 
patients with MR of unknown cause. This is currently being offered as a routine diagnostic test 
in many laboratories. Our laboratory is currently assessing the clinical utility of MLPA testing. 
The limitation with this technique however is that point mutations are not detected. 
 
A cheaper but effective alternative screening approach has to be taken in this country due to the 
limited resources available. There is a need for rapid, cost-effective methods for detection of 
mutations in XLMR genes and with the new generation of sequencing technology, this seems 
possible. A strict clinical screening approach has to be taken and collaborative ventures need to 
be set up with laboratories overseas. Frints et al. (2002) suggested that a correct sub 
classification into S-XLMR and NS-XLMR should be the first differential diagnostic step in MR 
males, with or without other clinical/neurological findings, or dysmorphic features, normal 
karyotype and normal FMR1 repeat length. It is important to use the clinical information to direct 
the S-XLMR type. The possibility of using linkage sets in an environment with limited resources 
should be considered. 
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In those undiagnosed cases with a positive familial history, Genetic counselling can be 
provided. Individuals with a known or a suspected history of XLMR or MR of unknown cause are 
strongly encouraged to seek genetic counselling. The NHLS offers a comprehensive 
counselling service through the Genetic Counselling Clinics attached to the Division of Human 
Genetics. A confirmed diagnosis leads to improved support for newly diagnosed patients and 
allows identification of all carriers in the family. Prenatal diagnosis can be offered to 'at-risk' 
individuals and allow couples to make informed choices about their future. 
 
 
 
8.4 FUTURE PROSPECTS 
The genetic causes of XLMR are heterogeneous and despite the great collaborative efforts that 
have allowed the elucidation of many genes involved in these conditions, it remains complex 
and challenging to identify a causative mutation in an individual or family. Sustained efforts are 
required to identify the remaining genes in XLMR. As additional genes involved in the 
development of intellectual and cognitive functions are identified, a more reliable molecular 
diagnosis for MR in general and XLMR specifically can be provided. This will not only improve 
our understanding of the molecular and cellular bases underlying cognitive impairment, but also 
improve our understanding, management, counselling, prevention and ultimately perhaps even 
treatment of MR. 
 
Further studies can be proposed. An interesting study would be to determine the frequency of 
the FMR1 premutations in the normal South African population. There is controversy around 
whether or not premutation males and females have subtle behavioural or learning difficulties. A 
number of studies have refuted the clinical significance of PMs (Mazzocco, Sonna, Teisl et al., 
1997; Mornet, Chateau, Simon-Bouy, et al., 1998; Sherman, Marsteller, Abramowitz et al., 
2002). It may be an interesting study to undertake in the South African population. 
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9 APPENDICES 
 
APPENDIX A:  ETHICS CLEARANCE CERTIFICATE 
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APPENDIX B:  SOLUTIONS 
 
 
 Alconex solution (1%) to clean vertical plates for ABI377 Genetic Analyzer 
1g alconex crystals dissolved in 100ml ddH2O 
 
 Ammonium persulphate (10% APS) for ABI377 Genetic Analyzer Gel mix 
1g APS dissolved in 10ml ddH2O 
Store away from light at 4°C 
 
 Chloroform : Isoamylalcohol (24:1) 
960ml Chloroform + 40ml Isoamylalcohol  
Store in glass bottle at room temperature  
 
 Deionized formamide 
Mix 50ml of formamide and 5g of AG501 X8 ion-exchange resin. 
Ensure that the pH is >7.0 
Allow the beads to settle to the bottom of the beaker. 
Remove the supernatant (formamide) 
Dispense into 1ml aliquots and store for up to 3 months at -15 C to -25 C 
 
 Denaturing solution for Southern Blotting 
87.66g of 1.5M NaCl2 
20g of 0.5M NaOH 
Ensure that pH of solution is basic.  
Make up to 1L with ddH2O and store at room temperature 
 
 Dextran-Formamide loading dye (ABI377 Genetic Analyzer loading dye) (20mg/ml) 
20mg blue dextran 
1ml deionized formamide 
Aliquot 1ml into 1.5ml eppendorfs and store at 4 C 
 
 Deoxyribonucleic triphosphate (dNTP) 10x working stock solution (1.25 mM) 
125 l each of 10 mM Na-salt dATP, dGTP, dTTP and dCTP 
Add 500 l ddH2O to make up to 1ml 
Make 100 l aliquots and store at -20 C. Avoid excessive freezing and thawing. Final 
concentration in PCR reaction is 0.125 mM (125 M). 
 
 Ethidium Bromide (EtBr) (10mg/ml) 
Commercially available from Sigma as an aqueous solution (10mg/ml) 
Caution: EtBr is a powerful mutagen. Always wear gloves while handling gels or solutions 
containing the dye. 
 
 Ethylenediamine tetra-acetic acid (EDTA) (0.5M) for DNA extraction  
93.06g EDTA disodium salt crystals (Note : MW=372.24g/l) 
pH to 8.0 with 5M NaOH to allow crystals to dissolve completely 
Make up to 500ml with ddH2O. Autoclave and store at room temperature 
 
 Ethanol (70%) for DNA extraction 
70ml 100% Ethanol + 30ml water 
Store at room temperature 
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 Ficoll-bromophenol blue loading dye (100ml) 
50g of 50% sucrose crystals 
0.1ml 0.5M EDTA (pH 7.0) 
0.1g 0.1% bromophenol blue dye 
10g 10% ficoll powder 
Make up to 100ml with ddH2O. Aliquot into 1.5ml eppendorf tubes. Store at 4 C 
 
 1 kb Molecular Weight DNA marker (GIBCO BRL; 1 g/ l) 
250 l ladder (0.25 g/ l stock) 
125 l bromophenol loading dye 
2.1ml 1xTE 
Load 10 l onto each gel 
 
 MgCl2 (1M) for DNA extraction 
20.33g MgCl2  
Make up to 100ml with dH2O 
Autoclave. Store at room temperature. Note: MW=203.31g/l 
 
 Neutralising solution (pH 7.2) for Southern blotting 
87.6g of 1.5M NaCl2 
60.6g of 0.5M Tris Base 
0.292g of 0.01M EDTA 
~42ml HCl2 (Adjust with more HCl2 until pH = 7.2). Store at room temperature 
 
 4.3% Polyacrylamide gel (100ml) for ABI377 Genetic Analyzer  
10.6 ml of 40% Acrylamide : Bisacrylamide (19:1) 
20ml of 10xTBE 
36g Urea 
Water to make up to 100ml  
Stir until urea has dissolved and contents are translucent. Filter to remove any solid 
particles, which may fluoresce. Store at 4 C in a dark bottle for up to two weeks. 
 
 
Polyacrylamide Gel Mix for ABI377 Genetic Analyzer 36cm Plate 12cm Plate 
4.3% Polyacrylamide gel            40ml    20ml  
APS                  200 l    100 l  
Temed                  24 l    12 l Temed 
 
 Prehybridisation buffer (modified Church and Gilbert) (250ml) 
12.78g Na2HPO4 
9.75g NaH2PO4.2H2O 
17.5g SDS 
5ml of 0.5M EDTA 
Water to make up to 250ml  
pH to 7.2. Filter sterilize. Store at room temperature. Heat at 65°C to dissolve crystals.  
Use ~30 ml / 200 cm2 blot 
 
 Proteinase-K Mix (500 l) for 16 DNA extractions (2mg/ml) 
850 l of 10% SDS 
34 l of 0.5M EDTA 
1700 l of 10mg/ml proteinase-K 
ddH2O to make up to volume. Use 500 l per sample.  
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 Saline Solution (0.9%) (Isotonic) for DNA extraction 
4.5g NaCl2 
Make up to 500ml with dH2O 
Autoclave. Store at room temperature 
 
 Saturated NaCl for DNA extraction  
Add 40g NaCl2 to 100ml sterile ddH2O until absolutely saturated. Prior to use agitate 
solution and allow NaCl2 to precipitate out. Store at room temperature 
 
 SephadexTM G-50 fine (5% solution) (SIGMA) for removing unincorporated nucleotides 
Add 5g Sephadex powder to 100ml 1x TE buffer (pH 8.0). Leave solution overnight before 
use. Store at room temperature 
 
 Sodium citrate solution (SSC) (20x) 
350.7g of 0.15M NaCl2 
176.5g of 0.15M) Trisodium citrate 
Make up to 2L with ddH2O. No need to autoclave. Store at room temperature 
 
 Sodium dodecyl sulphate (SDS) (10%) for DNA extraction 
Add 100g SDS powder to 1L autoclaved ddH2O 
NB! Weigh out powder in fume hood. Store at room temperature 
 
 Sucrose-Triton X Lysing Buffer for DNA extraction  
10ml 1M Tris-HCl (pH8.0) 
5ml of 1M MgCl2    
10ml Triton-X 100 
Make up to 1L with distilled water. Autoclave 
Add 109.5g sucrose just before use. Stir until dissolved and keep solution chilled at 4 C 
 
 TEMED (N,N,N’,N’-tetramethylenediamine) 
Commercially available from Stratagene. Store at 4 C in the dark.  
 
 Tris Borate EDTA (TBE) (10x) 
109.02g Tris Base 
55.64g Boric acid 
7.44g NaEDTA 
pH solution to 8.3 with HCl and make up to 1L with distilled water. Dilute tenfold before use. 
Store at room temperature 
 
 Tris-EDTA (TE) Buffer (1x) for DNA extraction  
10ml of 1M Tris-HCl pH8.0 
2ml of 0.5M EDTA 
pH with HCl. Make up to 1L with ddH2O. Autoclave and store at room temperature 
 
 T20E5 for DNA extraction 
20ml of 1M Tris-HCl pH8 
10ml of 0.5M EDTA 
pH to 8.0 
Make up to 1L with ddH2O. Store at room temperature  
 
 Tris-HCl pH 8.0 (1M) for DNA extraction 
121.1g Tris base  
pH with 1M HCl 
Make up to 1L with ddH2O. Autoclave and store at room temperature
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APPENDIX C:  TECHNIQUES 
 
APPENDIX C1 - Salting out procedure for extracting DNA 
from human nucleated cells 
Miller, Dykes and Polesky et al., 1988 
 
DAY 1 
 
1) Collect 5-10ml blood into ACD or EDTA vacutainer tubes 
2) Decant no more than 10ml of whole blood into a 50ml polypropanol tube, i.e. 2 
ACD‟s/EDTA‟s per tube.  For volumes below 10ml the solution volumes are halved. 
Freeze at -20 C until ready to extract then thaw 
3) Fill each tube to the 45/50ml mark with Sucrose-Triton-X Lysing Buffer, which should be 
kept cold during the procedure 
4) Invert the tube several times to mix 
5) Centrifuge for 10 minutes at 1000g at 4 C  (+2300rpm) to pellet cells 
6) Discard the supernatant fluid 
7) Wash the pellet in 20-25ml Sucrose-Triton-X Lysing Buffer 
8) Leave on ice for 5 minutes 
9) Centrifuge for 5 minutes at1000g at 4 C  (+2300rpm) 
10) Discard supernatant fluid 
11) Add 3ml T20E5, 0.2ml (200 l) 10% SDS and 0.5ml (500 l) Proteinase-K mix 
12) Mix well by inversion. 
13) Incubate at 42  to 50 C overnight (no need to agitate). 
 
 
 
DAY 2 
 
14) Add 1ml saturated NaCl 
15) Agitate vigorously for 15 seconds by inversion 
16) Leave at -20 C for 5 minutes 
17) Centrifuge for 30 minutes at 4 C (2500rpm) 
18) A white pellet should be visible, which consists of protein pecipitated by salt. If no pellet 
is visible centrifuge again 
19) Transfer the supernatant fluid containing the DNA to a new 50ml polypropanol tube. 
20) Add 2 volumes of absolute ethanol kept at room temperature 
21) Agitate gently and spool, fish or precipitate DNA. If precipitating, do not centrifuge for too 
long to avoid salts and proteins precipitating out as well 
22) Wash the DNA in 70% ice-cold ethanol 
23) Air dry the DNA. 
24) Resuspend the DNA in an appropriate volume of 1XTE Buffer (~200 l-1000 l)
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APPENDIX C2 – DNA extraction protocol using the High Pure 
PCR Template Preparation Kit from Roche Diagnostics 
 
Protocol for isolating DNA from 200 μl mammalian blood, buffy coat, or cultured 
mammalian cells (pack insert available at www.roche-applied-science.com) 
 
Note: Before starting the purification, warm the Elution Buffer to +70°C. 
 
High Pure PCR Template Preparation Kit workflow 
 
1) To a nuclease-free 1.5 ml microcentrifuge tube: 
 Add 200μl of sample material 
 Add 200μl Binding Buffer 
 Add 40μl Proteinase K (reconstituted) 
 Mix immediately and incubate at +70°C for 10 min 
2) Add 100μl Isopropanol and mix well 
3) Insert one High Pure Filter Tube into one Collection Tube 
 Pipette the sample into the upper buffer reservoir of the Filter Tube 
 Insert the entire High Pure Filter Tube assembly into a standard table-top centrifuge 
 Centrifuge 1 min at 8,000 × g 
4) After centrifugation 
 Remove the Filter Tube from the Collection Tube; discard the flow through and the 
Collection Tube 
 Combine the Filter Tube with a new Collection Tube 
 Add 500μl Inhibitor Removal Buffer to the upper reservoir of the Filter Tube 
 Centrifuge 1 min at 8,000 × g 
5) Remove the Filter Tube from the Collection Tube; discard the flow through and the Remove 
Collection Tube 
 Combine the Filter Tube with a new Collection Tube 
 Add 500μl Wash Buffer to the upper reservoir of the Filter Tube 
 Centrifuge 1 min at 8,000 × g and discard the flow through 
6) Remove the Filter Tube from the Collection Tube; discard the flow through and the 
Collection Tube 
 Combine the Filter Tube with a new Collection Tube 
 Add 500 μl Wash Buffer to the upper reservoir of the Filter Tube 
 Centrifuge 1 min at 8,000 × g and discard the flow through 
7) After discarding the flow through: 
 Centrifuge the entire High Pure assembly for an additional 10 s at full speed 
The extra centrifugation time ensures removal of residual Wash Buffer 
 Discard the Collection Tube 
8) To elute the DNA: 
 Insert the Filter Tube into a clean, sterile 1.5 ml microcentrifuge tube 
 Add 200 μl pre-warmed Elution Buffer to the upper reservoir of the Filter Tube 
 Centrifuge the tube assembly for 1 min at 8,000 × g 
9) The microcentrifuge tube contains the eluted, purified DNA, which can be used directly or 
stored at +2 to +8°C or +15 to +25°C for later analysis. For details on adding an optional 
RNase digestion, see related procedures in the pack insert 
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APPENDIX C3 – The polymerase chain reaction (PCR) 
 
The Polymerase Chain Reaction (PCR) (Mullis and Faloona, 1987) is a technique that involves 
the use of specific oligonucleotide primers (18 to 30 mer in length) that flank a DNA sequence of 
interest to amplify it. The PCR procedure involves denaturing the template DNA at a high 
temperature in the presence of the primers, dNTPs (dATP, dGTP, dCTP, dTTP), and a heat 
stable DNA polymerase (Taq polymerase) with its corresponding buffer. The primers are then 
allowed to anneal to their target sequence by decreasing the temperature. This is followed by 
an extension of the primers, with the help of the DNA polymerase and nucleotides. The cycle of 
denaturation, annealing and extension is repeated to produce a large number of copies of the 
DNA region of interest. An exponential increase in product yield is obtained, which can be 
viewed under UV light on an agarose gel or using an automated Genetic Analyzer e.g. the 
ABI377 or ABI3130xl electrophoresis instruments. 
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APPENDIX C4 – Agarose gel electrophoresis (AGE) 
 
This technique is used to separate DNA molecules by base composition, size and conformation.  
Ethidium bromide (EtBr), (10mg/ml), a fluorescent dye that intercalates between the DNA 
bases) makes it possible to visualise the product under ultraviolet (UV) light. 
 
A vertical gel-casting tray was cleaned with 70% ethanol and an appropriate comb was 
positioned in the gel former. A 3% agarose gel was made by adding 3g agarose to 100ml 1x 
TBE buffer. This was heated in a microwave until all the particles were completely in solution 
(~400ml per 20 x 20 cm gel tray was used). The gel solution was allowed to cool before adding 
~12 l EtBr (10mg/ml) solution to the gel. The cooled gel was swirled gently to mix and poured 
carefully into the former. The gel was allowed to set for at least 1 hour and stored at 4 C until 
ready to use.  
 
5 l of PCR product was mixed with 5 l ficoll dye and loaded on the gel. The agarose gel was 
run for ~30 min to 1 hr at 120 V in 1xTBE running buffer. 
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APPENDIX C5 – Microsatellite detection using the ABI377 
Genetic Analyzer 
 
The procedure below was followed for GeneScan analysis of FMR2 and FMR1 alleles, as well 
as the preparation of a sequencer gel for detection of XNP sequencing products on the ABI377 
Genetic Analyzer.  
 
 
Plate Cleaning 
A set of 12 cm (36 cm for sequencing) glass plates were washed with a 1% Alconox  
(Labretoria) solution by gently rubbing the surface of the plates to remove any particles (dust, 
acrylamide, powder) that may fluoresce. A 'well-to-read' length (the distance the fragment 
migrates before being detected by the laser) of 12 cm was found to be sufficient for a good 
separation of FMR2 alleles. The longer 36 cm plates are required for a good resolution of 
sequencing products. The plates were placed upright in a rack and allowed to drip-dry for at 
least 30 min. No siliconizing treatment was necessary. 
 
 
Preparation of the gel-pouring apparatus and gel casting 
The 0.2 mm spacers were aligned into position and the plates were assembled in the gel 
apparatus and clamped. The gel-pouring device with an attached syringe was clamped securely 
to the gel frame. A 4.3% PAG mix (see Appendix B) was prepared. A volume of 100 l APS, 
which acts as a polymerizing agent, was added to the gel mix and the polymerization was 
catalyzed by the addition of 12 l TEMED solution. The acrylamide mix was poured gently into 
the syringe and the plates were tapped to ensure that the gel front was running evenly and that 
no bubbles were formed. A casting comb was inserted, taking care not to trap any air bubbles. 
The gel was left for at least 1 hr to polymerize. 
 
 
Preparing the gel for loading 
The gel pouring device and the comb were removed and the area flushed with ddH2O. The 
plates were cleaned with tissue paper moistened in ddH2O, ensuring that the area scanned by 
the laser is free of all debris. The bottom buffer chamber was attached and the frame containing 
the gel was placed into the Genetics Analyzer.  The ABI PRISMTM 377 collection software was 
selected. A new sample sheet was generated and saved.  
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A new GeneScan run was set up. The GeneScan software converts fluorescent signals to 
different coloured peak intensities by comparing the signals detected with Matrix standards. 
Matrix standards are obtained by loading the Genetic Analyzer with each of the different 
fluorochromes. The electrophoresis parameters for the gel were chosen. A run module, GS 
12A-2400 was selected. This corresponds to a gel separation distance, or a 'well-to-read' 
distance of 12 cm, using a virtual filter set A with a scan rate of 2400/ hr. A GeneScan pre-run 
module, PR GS 12A-2400 was chosen to match the run module. A matrix file was selected. This 
adjusts for the spectral overlap between the fluorescent dyes used on the ABI PRISMTM 377 
Genetic Analyzer. The operator, run time and the virtual filter set corresponding to the dyes 
being used was defined. The sample sheet was imported into the GeneScan run.  
 
 
Polyacrylamide gel electrophoresis 
A plate check was done to determine gel quality prior to adding the running buffer and loading 
since this allowed easy removal of the plates if they needed to be re-cleaned. The buffer 
chambers were assembled and 1x TBE running buffer was poured into the top (~500ml) and 
bottom (~1l) buffer chambers until the levels just reached those indicated on the chamber.  A 
pre-run for ~10 min was done to allow the gel to reach the required temperature and voltage 
output of 51 C and 3.00kV.  
 
The samples were prepared whilst the gel was pre-running. A mix of 1 l PCR product, 0.3 l 
Rox-500 (an internal size standard) and 2.2 l dextran formamide loading dye was prepared. 
The samples were placed on a 95 C heating block for ~2 min and cooled on ice to quench the 
reannealing of the single stranded (ss) DNA. The pre-run was stopped and the wells were 
flushed with the running buffer, using a disposable syringe and hypodermic needle. 1.7 l of the 
denatured samples was loaded into every odd lane, since alternate loading alleviates 
contamination arising from leakage of wells. The pre-run was resumed for ~10 min, after which 
the even lanes were loaded and the run was started on the Genetic Analyzer. The gel was run 
for at least 2 hours at a voltage of 3.00kV, ~15mA current, 200W electrophoresis power and a 
laser power of 40.0mW. The progress of the gel was intermittently viewed by monitoring the gel 
image and following the migration of the ROX standard. 
 
On completion of the run, the gel was removed from the frame and the running buffer in the top 
and bottom chambers was siphoned out. The gel was discarded and the plates and 
attachments used were thoroughly cleaned. The sample sheet was transferred into the run 
folder, which was then transferred to the Macintosh computer used to analyse the raw data.  
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GeneScan analysis 
The data were analyzed using the software programmes such as GeneScanTM (ABI/Perkin 
Elmer) and GenotyperTM (ABI/Perkin Elmer). The GeneScan software automatically sizes and 
quantitates DNA fragments by using the internal size standard to create a size calibration curve 
for each lane. The PCR product size is compared with this calibration curve. The size standard 
also serves as a positive control for scanner analysis, especially if the PCR amplification has 
failed. A gel file was created, which allowed the results to be analyzed. The gel image was 
regenerated and the gel contrast was adjusted to visualize the gel better. Each lane was 
tracked manually to mark the channel that exhibits the strongest fluorescent signal. The tracked 
lanes were extracted and a sample file for each lane was created. The peaks of the GeneScan 
500 size standard (or Rox 500, which is displayed as a red, fluorescent dye) were defined. Size 
standards are DNA fragments of known sizes labelled with ABI prism dyes (in this case, Rox). 
GeneScan 500 is a size standard with different peaks, corresponding to different sizes of the 
fragments in the size standard. This marker is useful for sizing fragments between 35 and 500 
base pairs. The ROX ABI Prism dye is detected as a red colour using the virtual filter set A. 
 
The software used this information, plus other analysis parameters such as the size calling 
method, analysis range of the gel, minimum peak height (a minimum of 50 was chosen and 
adjusted accordingly) and the colour of the fluorescent molecule to define all unknown 
fragments. The sample files were examined by displaying the fragments as peaks on an 
electropherogram. The gel results were analyzed and saved. 
 
 
Genotyper analysis 
The data that were analyzed with GeneScan were imported into GenotyperTM software 
(ABI/Perkin Elmer). This software converts size and quantitative data produced by GeneScan 
into genotypes by assigning fragment sizes to the peaks. The alleles were sized by selecting 
the correct colour of the fluorescent dyes, followed by running a macro. The macro is a 
programme that is designed specifically for the mutation being analyzed. A range in which 
peaks are detected is specified in the macro. 
 
 
Interpretation of results 
Each FMR2 peak was analysed and scored as an allele after analysing and verifying the 
controls. All peaks were scored as reliable alleles if a characteristic pattern was noted. Any peak 
that did not have the characteristic shape (Figure 2.5) of an allele was disregarded. FMR1 
alleles were required to have an amplitude >1000. This ensured reliability determined from the 
  Appendix C5 
129 
previous validation performed. The results were saved and printed. These sizes are converted 
to the number of GCC repeats using a formula based on primer length and distance. Since the 
FMR2 primer is labelled with a blue fluorescent dye (5‟FAM) a blue peak is observed and 
similarly a green peak is observed (HEX) for the FMR1 allele. 
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APPENDIX C6 – Microsatellite detection using the ABI3130xl 
Genetic Analyzer 
 
 
The following protocol is designed to demonstrate the procedure of microsatellite detection on the 
ABI 3130xl genetic analyser. (ABI instruction manual) 
 
OVERVIEW OF TECHNIQUE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An overview of the procedure for automated genotyping of microsatellites 
 
PCR using fluorescently labelled primers and agarose gel electrophoresis 
1) One of the PCR primers must be fluorescently labelled 
2) Perform PCR using specific protocol. 
3) Verify PCR products on agarose gel to identify if the PCR has worked, was not 
contaminated and to identify whether the sample needs to be diluted before running on the 
3130xl. 
 
 
Sample sheet for the ABI3130xl genetic analyser 
1) Create a plate record  
a. GA Instruments  ga3130xl  Plate Manager  
b. Click on the NEW icon 
c. Choose Microsatellite as type of plate 
d. A new window will open. Fill in the following information: 
e. Name   name the plate (the saved name is case sensitive manner) 
f. Description (optional) 
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g. Application  GeneMapper-ABI_3130XL (or GeneMapper-Generic) 
h. Plate type  96-well 
i. Owner name molecular 
j. Operator name your name 
k. Click OK 
2) Add the sample names. NB!: 
a. The 96-well plate is divided into 12 columns (1-12 across) and 8 rows (A-G down) 
and so that each well has a unique number, e.g. G5  
b. One run consists of 16 samples (columns 1&2, 3&4, 5&6, 7&8, 9&10 or 11&12) 
c. One sample sheet can be created for more than one run. The runs will only be 
processed one at a time  
d. A sample sheet can start anywhere on the plate (e.g. columns 5&6) but a full run 
must be filled with HiDi so all 16 capillaries have liquid passing through them.  
e. Make sure that sample identification is clear e.g. patient name, disease testing for, 
name of microsatellite or linked marker 
3) Select the following parameters in the sample sheet: 
a. Comment:  (optional) 
b. Priority:  100 
c. Sample type:  Sample 
d. Size Standard: GS500(-250) 
e. Panel:   own panel 
f. Analysis method: Microsatellite Default or own analysis method 
g. SNP set: 
h. Study: 
i. User-Defined 1: 
j. User-Defined 2: 
k. User-Defined 3: 
l. Results Group 1: Molecular_Diagnostics (GeneMapper-ABI_3130XL)  
m. Molecular-Genetics_Diagnostics (GeneMapper-Generic) 
n. Instrument Protocol 1: microsatellites 
4) Save and close the sample sheet 
 
 
Prepare the samples for analysis 
1) Add 1-2 l of PCR product (depending on how strong/weak the product is) to 8-9 l Hi-DiTM 
Formamide (highly deionised formamide) mixed with Rox 500 size standard (for 16 
samples – 1 run – use 146 l HiDi and 7 l Rox 500). 
2) Denature the plate at 95ºC for 2 minutes 
3) Place on ice until ready to load into the machine 
 
 
Preparing the Microsatellite Run 
1) Verify whether there is sufficient polymer, buffer and water 
a. If the polymer needs to be changed: follow the steps of the Polymer change wizard 
b. The buffer and water needs to be changed every 3 days or every 12 runs 
2) Place the 96-well plate into the machine 
a. Press the TRAY button on the 3130xl genetic analyser 
b. When the tray has moved to the front of the machine, open the door 
c. Place the 96-well plate onto the correct sample tray (either tray A or B) 
3) Link the correct plate to the correct tray position 
a. GA Instruments  ga3130xl  3130XL  Run Scheduler  Plate View 
b. Find all plates with the status “pending” (click the “Find all” icon) 
c. Link the correct plate to the Autosampler positions (tray A or B) (click the plate/file 
name, followed by the correct tray, the “in use” tray image icon will turn green) 
4) Verify that the runs schedules match the correct wells on the plate 
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a. GA Instruments  ga3130xl  3130XL  Run Scheduler  Run View 
b. Verify that each run scheduled matches the correct positions on the plate 
5) Verify if the spectral is correct for the fluorescent label used.  
a. GA Instruments  ga3130xl  3130XL  Spectral Viewer 
(do not move from this screen or the spectral will automatically change back to  
Spectral F. Just move on to Step 5). 
6) Initialise the run 
a. Click the green “play arrow” icon on the top tool bar of the Navigator window 
a. The run will start. The “instrument status” window will automatically open to give 
details on the run in progress. Otherwise go to GA Instruments  ga3130xl  
3130XL  Instrument Status  
 
 
 
Analysing the Microsatellite Results 
Use the GeneMapper v4.0 (Applied Biosystems) to analyse the raw data.  
Open the program by selecting the GeneMapper v4.0 icon on the desktop 
1) Log into the program 
a. User Name:  gm 
b. Password:  Password (case sensitive) 
2) Open a new project (if one isn‟t already open) 
a. File  New Project  choose Generic or Microsatellite (depending on what you 
used for your sample sheet) 
3) Add sample files to be analysed 
a. Select File  Add Samples to Project  
a. Select the folder containing the sample files (My Computer  Local Disk (E)  
Applied Biosystems  UDC  DataCollection  data  select your file 
b. Click the “Add to List” button 
c. Click the “Add and Analyse” button 
4) The SAVE PROJECT AS window opens. Name your project and click the “OK” button. 
Your project will now be analysed. The SQ column of analysed samples should contain a 
green square or a yellow triangle to pass analysis. If a red circle is present, highlight the 
sample row and click on the “Size Match Editor” button (the button with 3 red peaks on the 
top toolbar).  Once this comes up, adjust the sizes on the peaks if needed, to fit the size 
standard. If changes were made, highlight the samples with changed size standard and 
select Analysis  Analyse selected samples  OK 
5) To view results:  
a. Highlight the sample and click the “Display Plots” button (the button with the 
different coloured peaks on the top toolbar). 
b. Choose the colour of the fluorescent label (click off the other colour buttons) 
c. To zoom into the plot, move your cursor onto the axis so the magnifying glass ion 
appears. Click and drag the cursor over the area to be zoomed in. Double click on 
the axis to zoom out to full view. 
d. If a peak is not sized, click on the peak 
e. If it is highlighted, right click and select “Add allele call”  
f. If it is not highlighted, right click and select “Add peak”. Right click again and  select 
“Add allele call” 
6) To print display plots, File  Print  choose printer 
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APPENDIX C7 – Gel-based DNA sequencing using the 
ABI377 Genetic Analyzer 
 
The method for automated sequencing using the 377 Genetic Analyzer is described below  
 
Gel purification of PCR products 
It is essential that the PCR product be purified to obtain a pure sequencing template. The PCR 
product was electrophoresed on an agarose gel in 1x TBE buffer (120V, 85mA). The 
SAP:Exonuclease method was used to purify the PCR products. The NucleoSpin® Extract II 
Cleanup method is currently used. The NucleoSpin® Extract II Cleanup kit removes excess 
primers and contaminants such as salts from PCR reactions in preparation for cycle sequencing 
reactions. DNA can be purified from either TAE/TBE agarose gels or directly from PCR products. 
When verifying PCR products on an agarose gel, the gel was visualised with a Variable-intensity 
Transilluminator 312 Ultraviolet Model TVC-412A (Spectroline) and the band containing the 
fragment to be purified was cut out with a clean scalpel and allowed to melt in the buffer, NT.  
 
DNA purification was carried out as follows: the PCR product or molten gel containing the PCR 
product are loaded into the NucleoSpin® Extract II column in the presence of the NT buffer and 
centrifuged. DNA binds to a silica membrane within the column in the presence of chaotropic salts. 
Simple washing steps with ethanolic buffer, NT3, removed contaminants while the DNA fragments 
stayed bound to the silica membrane. A slightly alkaline buffer, NE facilitated the elution of DNA 
under low ionic strengths into a clean microcentrifuge tube (NucleoSpin® Extract II Cleanup kit 
manual). 
 
 
Cycle sequencing 
The ABI PRISMTM Dye Terminator Cycle Sequencing Ready Reaction Kits (v3.1) with AmpliTaq 
DNA polymerase, FS (from Applied Biosystems), combine the unique properties of this enzyme (it 
has no 5‟ to 3‟ nuclease activity) for dye terminator sequencing with reagents that are premixed. 
The terminator premix contains A-Dye terminator, C-dye terminator, G-dye terminator, T-dye 
terminator, dGTP, dATP, dCTP, dTTP, Tris-HCl (pH 9.0), MgCl2, thermal stable pyrophosphatase 
and AmpliTaq DNA polymerase, FS (ABI User Manual). 
 
A cycle sequencing PCR reaction was set up as suggested by the manufacturers. The reaction 
consisted of 5-8 l purified DNA (the quantity of product required for the sequencing reaction was 
also estimated from the intensity observed on the EtBr-stained agarose gel), 3.3pm/μl primer 
  Appendix C7 
134 
(either forward or reverse), 4 l of BigDye® terminator FS-kit (Applied Biosystems/Perkin Elmer) 
and ddH2O to make up to a total volume of 20 l. The PCR was carried out in the GeneAmp 
thermocycler with denaturing at 96 C for 30 sec, annealing at 50 C for 15 sec and extension at 
60 C for 4 min for 25 cycles.  
 
 
Qiagen DyeEx Cleanup for purification of PCR products 
The cycle sequencing reaction contains a large quantity of unincorporated dye-labelled terminators 
as well as labelled extension products that could interfere and contaminate the sequence. The 
removal of these contaminants requires the use of a spin column purification method. The DyeEx 
(Applied Biosystems) dye-terminator removal system removes unincorporated primers, deoxy- and 
dideoxynucleosides from cycle sequencing reactions. 
 
The procedure involves the use of a simple spin column containing a gel filtration system, made up 
of spheres with uniform pores allowing the separation of molecules according to molecular weight. 
The cycle sequencing products were added to the column. This was tapped gently to allow the gel 
material to settle to the bottom of the column. A volume of 800 l ddH2O was loaded onto the 
column. This was vortexed briefly to mix and left on the bench for at least 30 min to allow the resin 
to equilibrate and hydrate. The column was placed in a residual tube and allowed to drain. The 
column was spun for 2 min (3000xg) and thereafter the residual tube was discarded. A 
centrifugation step removes the storage buffer from the column and the cycle sequencing products 
are loaded.  
 
A second centrifugation step removes unincorporated dye terminators. Dye-terminator molecules 
are small enough to diffuse into the pores and are retained within the gel while DNA fragments are 
excluded and can therefore be recovered from the collection tube (Qiagen DyeEx dye-terminator 
system manual). About 20 l of the cycle sequenced PCR product was loaded on top of the 
column, which was placed into an eppendorf collection tube. The column was placed in the same 
orientation as it was for the first spin. This was important since the gel is at an angle in the column 
after the spin. The purified cycle sequencing products were collected after centrifuging the column 
for 2 min (3000xg). The sample was vacuum-dried for 40 min-1 hr using a Concentrator 5301 
vacuum drier (eppendorf). The dried samples were stored in a black bag at 4˚C. 
 
 
 
Polyacrylamide gel preparation for ABI377 Genetic Analyzer 
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The gel was prepared as described in Appendix C7. However, a 36 cm gel was used. The 
sequence sample was selected from the ABI Collection Software options and a new sample sheet 
was generated. A new Sequence run was chosen and all the essential analysis parameters were 
defined. A plate check and a pre-run were done as described in Appendix C5 (See Appendix C6 
for detection method using the ABI3130xl capillary Genetic Analyzer)  
 
 
Preparation of samples for loading 
The dried samples were resuspended in 3 l of dextran/formamide mix and denatured at 100 C for 
2 min and placed on ice.  
 
 
Gel electrophoresis 
The bands in the electrophoresis gel move past a laser which detects which ddNTP is present in 
each band. This information is passed on to the imaging system.  
 
 
Analysis of sequencer gel 
Two software programmes exist for sequence analysis: one is for data collection and one for data 
analysis as described in Appendix C5. The gel file was tracked and sample files were generated. 
 
 
Interpretation of sequencing results 
The electropherogram was printed and analysed. The sequence is represented by a series of 
peaks, one for each nucleotide position. A green peak represents an „A‟, blue „C‟, black „G‟ and red 
„T‟. The letters above the peaks are coloured to represent the appropriate bases. An N above a 
peak means that the software could not confirm that base (ABI User Manual).  
 
 
Sequence data analysis 
The DNAstar software program (DNASTAR, Inc.) was used to compare the sequence generated to 
a reference sequence obtained from the UCSC genome browser website (2007) using the SeqMan 
II ™ module of DNAstar. The sequences were aligned to the reference sequence and analysed 
and mismatches, if any, were highlighted. 
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APPENDIX C8– Capillary DNA sequencing using the 
ABI3130xl Genetic Analyzer 
 
 
The method for automated sequencing using the 3130xl Genetic Analyzer is described below 
(Applied Biosystems 3130/3130xl Genetic Analyzers: Getting started guide, 2004): 
 
1) Add 10 μl Hi-Di™ Formamide (Applied Biosystems) directly to the dried DNA samples and 
resuspend the DNA.  
2) Add 10 μl of each of these purified cycle sequencing products into a MicroAmp® 96-well 
reaction plate (Applied Biosystems). Since the Genetic Analyzer utilises 16 capillaries 
simultaneously, samples need to be loaded either in multiples of 16 or by adding 10 μl Hi-
Di™ Formamide to empty wells to make the sample number a multiple of 16 
3) Cover the MicroAmp® 96-well reaction plate with a MicroAmp® optical 96-well plate septa 
(Applied Biosystems) and centrifuge the plate using the CS 6R Centrifuge (Beckman). 
4) Insert the MicroAmp® 96-well reaction plate into the GeneAmp PCR System 9700 (Applied 
Biosystems) and allow the samples to denature for 2 min at 95 °C. Immediately place the 
MicroAmp® 96-well reaction plate on ice 
5) Press the “Tray” button on the Genetic Analyzer to allow the autosampler to move to the 
front. Load the MicroAmp® 96-well reaction plate into a plate retainer and insert the plate 
retainer onto the plate base of the autosampler 
6) Press the “Tray” button once again to allow the autosampler to move towards the back of 
the machine 
7) Verify whether the buffer and water reservoirs are filled. If not fill the reservoirs with the 
respective solutions. Verify whether there are any bubbles present in the Genetic Analyzer 
machinery 
8) Open Foundation Data Collection version 3.0 (Applied Biosystems) on the computer linked 
to the Genetic Analyzer. Prepare a sample sheet. The instrument protocol, 
KB_3130_POP7_BDTv3.mob is used to analyse the samples. 
9) The sample sheet is linked to the relevant plate and the green play button is pressed to 
start sequencing 
10) A program called Sequencing Analysis v5.2 (Applied Biosystems) is used to analyse the 
data generated by Foundation Data Collection v3.0. Select the samples to be analysed, 
click on “Add selected samples” and press the green play button to analyse the data. Each 
sample can be accessed individually, edited and printed. 
  Appendix D1 
137 
APPENDIX D:  FRAGILE X MR SYNDROME 
 
APPENDIX D1 – Worksheet for FMR1/FMR2 multiplex PCR  
 
Modified from Crawford et al., 1999 
PCR COMPONENTS STOCK FINAL CONC VOLUME X MIX 
DNA 100ng  1 l  
dNTPs mix 10X 1X 0.75 l  
7-deaza dGTP 10X 1X 0.75 l   
Expand Long Template Buffer 1 (with 
17.5 mM MgCl2) 
10X 1X 1.5 l  
DMSO 100% 10% 1.5 l   
MgCl2 25mM 0.25mM 0.15 l   
FRAXA fxf primer 10pmol/ l 5pm 0.5 l   
FRAXA fxc primer *(HEX labelled) 10pmol/ l 5pm 0.5 l   
FRAXE 603 10pmol/ l 2pm 0.2 l   
FRAXE 598 *(FAM labelled) 10pmol/ l 2pm 0.2 l   
Expand Long Template Enzyme (Roche) 3.5U/ l 1.05U 0.3 l  
Water   7.65 l  
TOTAL VOLUME   15 l  
 
dNTPs MIX LOT/BATCH NO STOCK 1 L 100 L MIX 
dATP  100mM 0.05 l 5 l 
dCTP  100mM 0.05 l 5 l 
dTTP  100mM 0.05 l 5 l 
Water   0.35 l 35 l 
 
PCR CONDITIONS: Thermocycler:GeneAmp9700        File: frax: elt 
95 C – 10 minutes  1 cycle 
95 C – 2.5 sec 
65 C – 1 min  
72 C – 2.5 min 
 
5 cycles 
95 C – 1.5 sec 
55 C – 1 min  
72 C – 2.5 min 
 
25 cycles 
72 C – 5 minute 1 cycle 
 
FMR1 (CGG)n = (FMR1 product  221 bp)   3      FMR1 = GREEN 
FMR2 (GCC)n = (FMR2 product  288 bp)   3   FMR2 =  BLUE 
Add 2.3 l dextran formamide dye + 0.2 l ROX 500 size standard to 1 l of undiluted sample and 
load on ABI377 Genetic Analyzer 
NO. SAMPLE GENDER 
DNA 
CONC 
FAMILY NO 
(CODE) 
FMR1 
(CGG)n 
FMR2 
(GCC)n 
1       
2       
3       
4       
5       
6       
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FMR1 AND FMR2 FRAGMENT SIZES WITH THEIR CORRESPONDING CGG/GCC 
REPEAT NUMBERS 
 
FMR1 (CGG)n  =  (FMR1 PCR PRODUCT – 221 bp)   3 
FMR2 (GCC)n  =  (FMR2 PCR PRODUCT – 288 bp)   3 
FMR1 (bp) (CGG)n FMR2 (bp)  FMR1 (bp) (GCC)n FMR2 (bp) 
(HEX = 
GREEN) 
(FAM = 
BLUE)  
(HEX = 
GREEN) 
(FAM = 
BLUE) 
224 1 291  326 35 393 
227 2 294  329 36 396 
230 3 297  332 37 399 
233 4 300  335 38 402 
236 5 303  338 39 405 
239 6 306  341 40 408 
242 7 309  344 41 411 
245 8 312  347 42 414 
248 9 315  350 43 417 
251 10 318  353 44 420 
254 11 321  356 45 423 
257 12 324  359 46 426 
260 13 327  362 47 429 
263 14 330  365 48 432 
266 15 333  368 49 435 
269 16 336  371 50 438 
272 17 339  374 51 441 
275 18 342  377 52 444 
278 19 345  380 53 447 
281 20 348  383 54 450 
284 21 351  386 55 453 
287 22 354  389 56 456 
290 23 357  392 57 459 
293 24 360  395 58 462 
296 25 363  398 59 465 
299 26 366  401 60 468 
302 27 369  404 61 471 
305 28 372  407 62 474 
308 29 375  410 63 477 
311 30 378  413 64 480 
314 31 381  416 65 483 
317 32 384  419 66 486 
320 33 387  422 67 489 
323 34 390  425 68 492 
326 35 393  428 69 495 
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APPENDIX D2 – FRAXE/FMR2 Southern blot working sheet 
 
DATE:          
BLOT NO:         
 
NO. NAME 
FAMILY 
NO. 
DNA AMT 
PCR 
RESULT 
BLOT 
RESULT 
COMMENTS 
1       
2       
3       
4       
5       
6       
7       
8       
9       
10       
11       
12       
13       
14       
15       
 
DIGEST: (37 C overnight) 
 
 
 
 
 
 
 
 
Run digest on a 0.8% agarose gel (HGT) over 1 night  
Label OXE20 probe with Megaprime kit 
Hybridise over 2 nights at 65 C in the rotisserie oven 
 
Post-hybe washes: 2 X SSC, 0.1% SDS 2 X 10min @ room temp 
       1 X SSC, 0.1% SDS 1 X 30min @ 65 C 
       0.1 X SSC     3 X rinses 
 
Expose blot to X-ray film for ~3-10 days 
 
Expected fragment sizes corresponding to the FMR2 GCC repeat ranges after hybridisation of 
the OxE20 probe to DNA digested with HindIII on Southern blot analysis: 
PHENOTYPE (GCC)n FRAGMENT DETECTED 
BY OXE20 PROBE (kb) 
Normal male (N) 6-25 ~ 5.2 kb 
Normal female (N/N) 6-25 ~ 5.2 kb 
Premutation carrier male (E) >30 5.2 kb + 
Premutation carrier female (N/E) >30 5.2 kb + 
Full mutation male (EE) >200 5.2 kb ++ 
Full mutation female (N/EE) >200 5.2 kb ++ 
 STOCK 1 X MIX FINAL CONC 
Genomic DNA  10µl 5-10µg 
Spermidine 0.1M 1µl  
HindIII (Roche) 10 units/µl 3µl 30 units 
Buffer B 10 x 5µl 1x 
Water  31µl  
TOTAL  50µl / reaction 50µl / reaction 
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APPENDIX D3 – FMR1 Southern blot working sheet 
 
DATE:         
BLOT NO:          
 
NO. NAME 
FAMILY 
NO. 
DNA 
AMT 
PCR 
RESULT 
BLOT 
RESULT 
COMMENTS 
1       
2       
3       
4       
5       
6       
7       
8       
9       
10       
11       
12       
13       
14       
15       
16       
17       
18       
19       
20       
 
 
DIGEST: (37 C overnight) 
 STOCK 1X MIX FINAL CONC 
Genomic DNA    5-10µg 
Spermidine  0.1M 1 l  
Buffer B 10X 5 l (1X) 1X 
EclX I (Roche) 10units/ l 3 l  30units 
ddH2O      l  
TOTAL   47 l  
 
Add EcoR I (30u = 3 l/reaction) next day. Digest at 37 C for ~6 hrs. 
Run digest on a 0.8% agarose gel (HGT) over 1 night  
 
Label StB12.3 probe with Megaprime kit 
Hybridise over 2 nights at 65 C in the rotisserie oven 
 
Post-hybe washes: 2 X SSC, 0.1% SDS 2 X 10 min @ room temp 
       1 X SSC, 0.1% SDS 1 X 30 min @ 65 C 
       0.1 X SSC     3 X rinses 
 
Expose blot to X-ray film for ~3-10 days
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APPENDIX D4 – Procedure for labelling probe for Southern 
blotting 
 
PROBE LABELLING REACTION USING THE MEGA-PRIME LABELLING REACTION KIT 
(AMERSHAM BIOSCIENCES). 
The Megaprime systems allow DNA from a variety of sources to be labelled in vitro to high 
specific activity with 32P and other radionuclides. 
 
Labelling reaction mix 
COMPONENTS 1 X REACTION 
Probe DNA 5μl - 15μl (depending on DNA concentration) 
Primer 5μl 
ddH2O adjust as needed 
Mix 1 26μl 
Incubate reaction at 95°C in the heating block for 5 min 
Place on ice to avoid renaturation. Make hole in the lid of the eppendorf tube (To prevent the lid 
from popping and spilling radioactivity) 
 
Add the following reagents to mix 1: 
COMPONENTS 1 X REACTION 
*dATP, dGTP and dTTP 12μl (4μl each) 
*Reaction buffer (10x concentrated buffer) 5μl 
α32PdCTP 5μl 
* DNA polymerase 1 Klenow fragment (1 unit/μl) 2μl 
Final reaction volume 50μl 
Reaction buffer containing Tris/HCl pH7.5, 2-mercaptoethanol and MgCl2 
DNA polymerase 1 Klenow fragment cloned in 100 mM potassium phosphate pH6.5, 10 mM 2-
mercaptoethanol and 50% glycerol 
*supplied in Mega-prime labelling kit 
 
 
Incubate the reaction @ 37°C for 20 – 30 min.  
Stop the reaction with 5μl of warm 0.2M EDTA. 
Add 50μl 1XTE buffer (pre-warmed at 37°C) to make up to 100μl volume. 
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SPIN COLUMN PREPARATION 
Items required: 1ml syringe, Glass wool, 1 falcon tube, 1.5ml eppendorf tube 
     Sephadex G50 saturated in TE buffer and 1X TE buffer 
 
 Remove plunger from the syringe and plug the bottom of syringe with the glass wool up to 
0.1ml mark. Fill syringe with Sephadex 
 Place labelled syringe with plug in a 15ml falcon tube and centrifuge @ (2700rpm) for 5 min 
to compact the Sephadex beads 
 Discard TE buffer collected at the bottom of the falcon tube 
 Top up syringe with Sephadex and centrifuge for 5 min. 
 Repeat top up process of Sephadex until the column is packed to approx 0.9ml.  
 If needed, store at 4 C, covered with cling wrap to minimise evaporation until ready to use. 
 
 
 
PROBE PURIFICATION (FOR THE REMOVAL OF UNINCORPORATED NUCLEOTIDES) 
 Cut the lid off an eppendorf tube and place it in the falcon tube under the column 
 Load the probe-mix onto the column and centrifuge @ (2700rpm) for 5 min  
 Load another 100ul pre-warmed 1XTE buffer into the column and centrifuge @ (2700rpm) 
for 5 min 
 Verify the amount of probe eluted. If less than 200μl, add another 100μl 1X TE buffer and 
spin again. 
 Retrieve the eppendorf containing the purified labelled probe  
 Transfer the labelled probe into another eppendorf (punch a hole in lid) 
 Add 1XTE buffer to purified labelled probe to make up to 1ml 
 Denature 1ml of  labelled probe @ 95°C for 5 min in the heating block 
 Put on ice for 7 min 
 Pour the pre-hybridization solution (from the Hybaid bottle with the membrane in it in the 
65°C oven) into a new 50ml NUNC tube and add the denatured probe to the buffer 
 Pour back the Prehyb solution and the labelled probe into the bottle and hybridize for 2 to 3 
nights at 65°C in the Hybaid rotisserie oven. 
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APPENDIX D5 – DXS548 PCR working sheet 
 
DATE:           
 
PCR REACTION: 
PCR Components Volume Final conc X Mix 
Genomic DNA 1-3µl (100ng-
600ng) 
  
dNTPs mix 2.5 l 0.125Mm  
Taq polymerase buffer 2.5 l 1x  
Primer 83 or Dx (a) (20pm/ l) 0.5 l (10pm) 10pm  
Primer 84  or Dx (b) (20pm/ l) 0.5 l (10pm) 10pm  
Taq polymerase enzyme 0.2 l (1 unit) 1U  
Water 9.8 l   
TOTAL 16 l   
Add 1/40diln 32P -dCTP 5 l 0.125uCi  
TOTAL 21 l   
 
 
PCR CONDITIONS:   HYBAID file  
DENATURATION ANNEALING EXTENSION CYCLES 
94 C, 30 sec 57 C, 15 sec  30 
72 C, 10 min   1 
15 C   HOLD 
 
Size: approx 192 bp- 210 bp 
Load product on a long 6% polyacrylamide gel. Run light blue dye 30 cm from well  
Expose O/N 
 
 
 
NO. SAMPLE CODE RESULT 
    
    
    
    
    
    
    
    
 
 
  Appendix D6 
144 
APPENDIX D6 – FRAXAC2 PCR working sheet 
 
DATE:          
 
ENDLABELLING REACTION: 
Components Volume X Mix 
Primer: PM151 or FR (a) 2.5 l (50pm)  
Buffer 2 l  
Water 11.5 l (1U)  
Kinase enzyme (10u/ l) 2 l (20U)  
32 P -dATP 2 l  
TOTAL 20 l  
Incubate the reaction at 37 C for 1 hour. 
Use 0.5ul, 1ul or 2ul of the labelled primer per PCR reaction (0.5 l usually works best) 
 
PCR REACTION: 
PCR Components Volume Final conc X Mix 
Genomic DNA 1-3µl (100ng-600ng)   
dNTPS mix 1.5 l 0.125mM  
Taq  polymerase buffer 1.5 l 1x  
Primer PM151*-or FR(a) end 
labelled 
0.5 l * 10pm  
Primer PM152 or FR(b) 
(20pm/ul) 
0.5 l 10pm  
Taq polymerase enzyme 0.2 l 1U  
Water 10.8 l   
TOTAL 15 l   
 
 
PCR CONDITIONS:     CETUS PCR cycler 
DENATURATION ANNEALING EXTENSION CYCLES 
94 C, 4 min   1 
94 C, 1 min 65 C, 1min 72 C, 1min 30 
72 C, 10 min   1 
15 C   HOLD 
 
PCR product size range: ~147 bp to 161 bp 
Load PCR product on a long 6% polyacrylamide gel. Run light blue dye 32 cm from well  
Expose for 1 hr 
 
 
NO. SAMPLE CODE RESULT 
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APPENDIX E:  XNP PCR WORKING SHEETS 
 
APPENDIX E1 – Di, DRi Primer pair 1 
 
DATE:          
  
PCR COMPONENTS STOCK VOLUME FINAL CONC 
DNA 200-500ng 1 l  
Taq Buffer (Roche) (with 17.5mM 
MgCl2) 
10X 2.5 l 1x 
dNTPs 10X (=250 M) 2.5 l 0.25 M 
5'Di primer 10pm/ l 0.5 l 0.2pm 
5'DRi primer  10pm/ l 0.5 l 0.2pm 
Taq polymerase (Roche) 3.5U/ l 0.2 l (1 unit) 0.03U 
Water  17.8 l  
TOTAL VOLUME  25 l / reaction  
 
 
PCR CONDITIONS: GeneAmp File: xnp 
94 C – 50 sec 
58 C – 50 sec 
72 C – 1 minute 
 
32 cycles 
15 C – hold temperature  
 
PCR fragment 1 using primers 5‟Di and 5‟DRi (Villard et al., 1999b) = 287 bp 
Primers used for sequencing: 5‟Di 
 
 
ggattatgaggtatttcatgtctaatacaaaagttacaaaatgctgactaaagtaagtatctttttctgtgtataaatgtgtgaataatagcc
actcctttctcctagAAGATGGGCTTCATGGGATTGTGAGCTGCACTGCTTGTGGACAACAGGTCA
ATCATTTTCAAAAAGATTCCATTTATAGACACCCTTCATTGCAAGTTCTTATTTGTAAGgtatgta
atgatctgttgatatttcataccgtaaatatttgaatgcttaccatataccaggcctttgag 
 
 
Load 5 l PCR product on 3% agarose gel to verify the product size 
 
NO. SAMPLE CODE RESULT 
    
    
    
    
    
    
    
    
    
    
5’Di 
5’DRi 
  Appendix E2 
146 
APPENDIX E2 – 5’Ci, 5’R Primer pair 2 
 
DATE:          
 
PCR COMPONENTS STOCK VOLUME FINAL CONC 
DNA 200-500ng 1 l  
Taq Buffer (Roche) (with 17.5mM 
MgCl2) 
10X 2.5 l 1x 
dNTPs 10X (=250 M) 2.5 l 0.25 M 
5'Ci primer 10pm/ l 0.5 l 0.2pm 
5'R primer  10pm/ l 0.5 l 0.2pm 
Taq polymerase (Roche) 3.5U/ l 0.2 l (1 unit) 0.03U 
Water  17.8 l  
TOTAL VOLUME  25 l / reaction  
 
 
PCR CONDITIONS: GeneAmp File: xnp 
94 C – 50 sec 
58 C – 50 sec 
72 C – 1 minute 
 
32 cycles 
15 C – hold temperature  
 
PCR fragment 2 using primers 5‟Ci and 5‟R (Villard et al., 1999b) = 898 bp 
Primers used for sequencing: 5‟Ci and 5‟R2 
 
 
cagtgtcctggagattttccccagtgtttttaattacttaaaaaaataaagtttttgtcctttatgaatgttatcaattttgaattaaatttccccttc
ctcttttcttttaatagAATTGCTTTAAGTATTACATGAGTGATGATATTAGCCGTGACTCAGATGGAAT
GGATGAACAATGTAGgtaggtaatatagatgagctaacattcagtgtttcctacttttgggaggaattgttacataatcatttatg
aggtttgtctttcatagtatcgtcattgatgtctttaatgaaaggttgttcttttccataaaaccctggatttatgtctagtttaagtttctaataaag
agtaagcagatgacctaaattaccactaaaattactggcagtaaaatttaaattgcattataacaaagagattaaaatgagttttgttgg
gaataatgtttatttttatttttttacatatcttttcagtttcctgaaagaagggaataatgttttaatctttaaaacatttcagGTGGTGTGC
GGAAGGTGGAAACTTGATTTGTTGTGACTTTTGCCATAATGCTTTCTGCAAGAAATGCATTC
TACGCAACCTTGGTCGAAAGGAGTTGTCCACAATAATGGATGAAAACAACCAATGGTATTG
CTACATTTGTCACCCAGAGCCTTTGTTGGACTTGGTCACTGCATGTAACAGCGTATTTGAG
AATTTAGAACAGTTGTTGCAGCAAAATAAGAAGAAGATAAAAGTTGACAGTGAAAAGAGTAA
TAAAGTATATGAACATACATCCAGATTTTCTCCAAAGAAGACTAGTTCAAATTGTAATGGAG
AAGAAAAGAAATTAGATGATTCCTGTTCTGGCTCTGTAACCTACTCTTATTCCGCAC 
 
 
Load 5 l PCR product on 0.8% agarose gel to verify the product size 
NO. SAMPLE CODE RESULT 
    
    
    
    
    
    
    
    
5’Ci 
5’R2 
5’R 
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APPENDIX F: ARX 24 bp DUPLICATION PCR WORKSHEET 
 
Sequence analysis of Exon 2 
DATE:          
 
PCR COMPONENTS STOCK CONC 1X MIX X MIX 
DNA 200 ng/ l 0.5 l - 
Failsafe PCR 2X PreMix J 2X 5 l (1X) l 
Primer ARX-2F 20pmol/ l 0.5 l (10pm) l 
Primer ARX-2R 20pmol/ l 0.5 l (10pm) l 
ddH2O - 3.4 l l 
Expand Long Template Enzyme 3.5U/ l 0.1 l (0.35 U) l 
TOTAL  10 l 9.5 l /rxn 
Include a control sample for each PCR run. Refer to PCR SOP (CGEN/CMGT00012). 
 
PCR CONDITIONS: Thermocycler: GeneAmp9700 Program: arx (~2.5 hour run) 
95 C – 5 minutes  1 cycle 
95 C – 1 minute 
64 C – 1 minute  
72 C – 1 minute 
 
30 cycles 
72 C – 5 minute 1 cycle 
15 C – hold temperature  
 
Primers ARX-2F (also called 2563-F) and ARX-2R (also called 2794-R) (Gronskov et al., 2004) 
PCR fragment = 251 bp.  
Mutation c.431-454dup (24 bp) = 275 bp 
 
The sequence in bold represents the region duplicated in the presence of the common 24 bp 
duplication mutation in exon 2 of the ARX gene. 
 
 
CCCAAGCTGCGGCGCCTGTACGGCCCGGGCGGGGGCCGCCTCCTTCAGGGTGCGGCAG
CGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCAGCGGCCGCCACGGCCACGGCGGGT
CCACGCGGGGAGGCCCCTCCGCCGCCACCGCCAACCGCGCGGCCCGGGGAACGGCCG
GACGGCGCAGGGGCCGCCGCGGCAGCCGCGGCCGCGGCCGCCGCGGCCTGGGACACG
CTCAAGATCAGCCAGGCGCCGCA                  
 
Load 2 l PCR product on a 3% agarose gel to verify the product size 
NO. SAMPLE CODE RESULT 
    
    
    
    
    
    
    
    
 
ARX-2F 
ARX-2R 
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APPENDIX G: FMR1 ALLELES IN 1184 NON EXPANSION MR 
MALES 
 
 
CATEGORIZED BY ETHNICITY 
FMR1 
(CGG)n 
WHITE 
(N=506) 
BLACK 
(N=484) 
COLOURED 
(N=122) 
INDIAN 
(N=72) 
GRAND 
TOTAL 
11 0 0.0% 1 0.2% 0 0.0% 0 0.0% 1 
17 1 0.2% 0 0.0% 0 0.0% 0 0.0% 1 
18 3 0.6% 1 0.2% 0 0.0% 0 0.0% 4 
19 3 0.6% 0 0.0% 0 0.0% 1 1.4% 4 
20 34 6.7% 2 0.4% 3 2.5% 0 0.0% 39 
21 3 0.6% 2 0.4% 1 0.8% 0 0.0% 6 
22 8 1.6% 11 2.3% 1 0.8% 2 2.8% 22 
23 28 5.5% 19 3.9% 3 2.5% 0 0.0% 50 
24 17 3.4% 9 1.9% 4 3.3% 1 1.4% 31 
25 2 0.4% 1 0.2% 2 1.6% 1 1.4% 6 
26 1 0.2% 3 0.6% 0 0.0% 0 0.0% 4 
27 0 0.0% 0 0.0% 1 0.8% 1 1.4% 2 
28 9 1.8% 11 2.3% 3 2.5% 0 0.0% 23 
29 120 23.7% 196 40.5% 50 41.0% 20 27.8% 386 
30 157 31.0% 109 22.5% 30 24.6% 29 40.3% 325 
31 44 8.7% 77 15.9% 13 10.7% 3 4.2% 137 
32 19 3.8% 17 3.5% 3 2.5% 2 2.8% 41 
33 13 2.6% 2 0.4% 1 0.8% 1 1.4% 17 
34 4 0.8% 2 0.4% 2 1.6% 2 2.8% 10 
35 4 0.8% 2 0.4% 1 0.8% 1 1.4% 8 
36 3 0.6% 3 0.6% 0 0.0% 0 0.0% 6 
37 3 0.6% 0 0.0% 0 0.0% 2 2.8% 5 
38 3 0.6% 3 0.6% 0 0.0% 0 0.0% 6 
39 8 1.6% 4 0.8% 1 0.8% 1 1.4% 14 
40 1 0.2% 1 0.2% 1 0.8% 2 2.8% 5 
41 5 1.0% 5 1.0% 1 0.8% 3 4.2% 14 
42 3 0.6% 0 0.0% 0 0.0% 0 0.0% 3 
43 2 0.4% 0 0.0% 0 0.0% 0 0.0% 2 
44 1 0.2% 0 0.0% 0 0.0% 0 0.0% 1 
45 2 0.4% 0 0.0% 0 0.0% 0 0.0% 2 
46 1 0.2% 0 0.0% 0 0.0% 0 0.0% 1 
49 2 0.4% 1 0.2% 0 0.0% 0 0.0% 3 
50 2 0.4% 1 0.2% 0 0.0% 0 0.0% 3 
52 0 0.0% 1 0.2% 0 0.0% 0 0.0% 1 
75 0 0.0% 0 0.0% 1 0.8% 0 0.0% 1 
TOTAL 506 100.0% 484 100.0% 122 100.0% 72 100.0% 1184 
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APPENDIX H: FMR2 ALLELES IN 1194 FMR1 EXPANSION 
NEGATIVE MR MALES 
 
CATEGORIZED BY ETHNICITY 
FMR2 
(GCC)n 
WHITE (N=507) BLACK (N=492) 
COLOURED 
(N=123) 
INDIAN (N=72) GRAND TOTAL 
5 0 0.0% 2 0.4% 0 0.0% 0 0.0% 2 
6 1 0.2% 1 0.2% 0 0.0% 0 0.0% 2 
7 1 0.2% 16 3.2% 0 0.0% 1 1.4% 18 
8 1 0.2% 0 0.0% 1 0.8% 0 0.0% 2 
9 4 0.8% 1 0.2% 0 0.0% 0 0.0% 5 
11 0 0.0% 0 0.0% 1 0.8% 0 0.0% 1 
12 10 2.0% 5 1.0% 2 1.6% 2 2.8% 19 
13 19 3.7% 29 5.9% 10 8.2% 1 1.4% 59 
14 43 8.5% 61 12.4% 3 2.5% 5 6.9% 112 
15 173 34.1% 255 51.7% 45 36.9% 27 37.5% 500 
16 54 10.7% 40 8.1% 13 10.7% 8 11.1% 115 
17 29 5.7% 31 6.3% 8 6.6% 3 4.2% 71 
18 55 10.8% 13 2.6% 14 11.5% 10 13.9% 92 
19 25 4.9% 0 0.0% 8 6.6% 4 5.6% 37 
20 18 3.6% 12 2.4% 10 8.2% 4 5.6% 44 
21 6 1.2% 9 1.8% 3 2.5% 2 2.8% 20 
22 8 1.6% 7 1.4% 1 0.8% 0 0.0% 16 
23 18 3.6% 1 0.2% 2 1.6% 3 4.2% 24 
24 11 2.2% 1 0.2% 0 0.0% 1 1.4% 13 
25 11 2.2% 2 0.4% 0 0.0% 1 1.4% 14 
26 11 2.2% 2 0.4% 0 0.0% 0 0.0% 13 
27 2 0.4% 2 0.4% 0 0.0% 0 0.0% 4 
28 3 0.6% 1 0.2% 0 0.0% 0 0.0% 4 
29 3 0.6% 1 0.2% 0 0.0% 0 0.0% 4 
33 1 0.2% 1 0.2% 1 0.8% 0 0.0% 3 
TOTAL 507 100.0% 493 100.0% 122 100.0% 72 100.0% 1194 
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